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ABSTRACT 
Psoriasis is a chronic autoimmune skin disease characterised by hyperplasia of 
epidermal keratinocytes and the accumulation of activated immune cells at sites 
of the disease. The disease is associated with aberrant activation of 
phagocytes, T-lymphocytes and the production of pro-inflammatory cytokines 
and chemokines. This thesis examines the therapeutic efficacy and 
mechanisms of action of the ginger species Halia Bara, or Zingiber officinale 
Roscoe var. rubrum (ZOR), on key immunopathogenic mechanisms relevant to 
psoriasis.  
 
In-depth experiments first determined the effect of a ZOR extract in chloroform 
(HB02) and its fractions on nitric oxide (NO) and prostaglandin E2 (PGE2) 
production. The results of these experiments showed that HB02 and its 
fractions efficiently inhibited NO and PGE2 production by activated 
macrophages. Extensive fractionation and characterisation experiments 
succeeded in identifying two compounds 6-shogaol (6S) and 1-dehydro-6-
gingerdione (GD) with potent inhibitory effects on NO and PGE2. These effects 
were comparable to dexamethasone and indomethacin.  
 
Studies on the effects of HB02, its fractions and compounds showed inhibitory 
effects on the level of mRNA for iNOS, TNFα, IL-12p40 and IL-23p19 in pre-
treatment experiments of macrophages. Studies of cell migration showed that 
the fractions and compounds from ZOR inhibited the migration of  
polymorphonuclear neutrophils (PMNs) through human vascular endothelial 
cells (HUVEC) by influencing CD11b expression and CD62L shedding.             
Further studies showed that the ZOR samples also inhibited the activation of 
  
IV 
CD8+ cytotoxic T-lymphocytes and reduced CD25 and CD69 expression. 
Furthermore, an in vitro model of epidermal inflammation showed that ZOR 
directly inhibits keratinocyte proliferation and the production of IL-20 and IL-8, 
both key psoriasis-promoting cytokines. 
 
The studies reported in this thesis provide experimental evidence for potent 
anti-inflammatory properties of ZOR and for potential mechanisms of action in 
ameliorating psoriasis. 
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1 Psoriasis: Immunological aspects 
1.1 The Immune system  
 
The immune system is highly evolved to protect one from infectious organisms. 
It is broadly organised into two compartments or arms, innate and adaptive, 
each consisting of cells, receptors and proteins that cooperate to deal with 
infectious pathogens and cancer. These arms of the immune system provide 
effective immunity during infections and is then followed by lasting immunity 
against the specific pathogen (immunological memory). An acute inflammatory 
response is a feature of the immune response following an infection and this 
aids in the recruitment of various effector components of that result in the killing 
of the infectious agent (bacteria, viruses or  parasites) while facilitating wound 
repair. However, persistent and prolonged chronic immune responses and 
inflammation are associated with the development of immune-mediated chronic 
diseases, such as rheumatoid arthritis (RA), Crohn’s disease and psoriasis.  
 
The innate immune system constitutes the first line of defence against a wide 
range of microorganisms during infections, providing immediate protection 
without requiring prior exposure. Components of the innate immune system 
express conserved receptors that recognise and interact with pathogen-
associated molecular patterns (PAMPs). Such conserved receptors include toll-
like receptors (TLR), mannose receptors and scavenger receptors. PAMPs are 
small molecules unique to a group of related microorganisms such as bacteria 
and virus, and not expressed by human cells. PAMPS are recognised on 
invading microorganisms by conserved receptors on innate immune cells and 
are then engulfed and destroyed at the site of infection by phagocytic cells such 
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as macrophages, monocytes, and polymorphonuclear leukocytes (PMN). In 
addition to recognition and destruction of infectious pathogens, cells of the 
innate immune system help to prime the adaptive immune system by 
processing and presenting pathogens to T- and B- lymphocytes at sites of 
infection and also in secondary lymphoid organs. Upon receptor binding with 
PAMPS, phagocytes react by releasing chemical mediators, known as 
cytokines and chemokines that collectively lead to inflammation. Other than the 
release of cytokines/chemokines, innate immune cells also help combat 
infectious pathogens by releasing inflammatory mediators such as nitric oxide 
(NO) and prostanoids. 
 
Cytokines are small cell-signalling molecules that are protein, peptides or 
glycoproteins, grouped into lymphokine, chemokines or interleukins depending 
on the originating cell and on their functions. They are produced by various cell 
types, particularly immune cells and cells of the nervous system in response to 
inflammation, infection and stress. Cytokines display redundancy in their 
functions. They are also multifunctional, involved in intercellular signalling, in 
systemic immune-modulation and in embryogenesis. Cytokines can act in both 
autocrine and paracrine manner and activate cascades of biological responses 
upon binding to their receptors. Cytokines can induce different biological 
responses depending on the cell type, activation status of the cell and previous 
or simultaneous exposure to other cytokines.  The different and, at times, 
paradoxical, biological effects of cytokines can be important in the pathogenesis 
of chronic diseases such as psoriasis as will be discussed in this thesis. 
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Another key molecule relevant to this study that plays important roles in 
immunity, inflammation and immune regulation is nitric oxide (NO). NO is a 
short-lived free radical with a range of physiological and pathological effects 
including vascular homeostasis, neurotransmission and immunity (1). NO is 
produced from L-arginine by nitric oxide synthase (NOS). There are three 
isoforms of NOS: endothelial NOS (eNOS), neuronal NOS (nNOS) and 
inducible NOS (iNOS). eNOS and nNOS are constitutively-produced and 
Ca2+/calmodulin-dependent. These two isoforms only synthesize small 
amounts of NO, triggered by various agonists (2). iNOS, however, is calcium-
independent and is expressed in response to certain stimuli such as endotoxins, 
lipopolysaccharide (LPS) and cytokines.   
 
In macrophages, iNOS is the key regulator of NO production which, in low 
concentrations, provides for host protection against bacterial and viral 
infections. NO eliminates pathogens by direct killing of the organism and/or 
weakening the mechanisms, used by the pathogen to avoid immune 
recognition. Prolonged inflammation, however, leads to the production of high 
levels of NO which, in turn, leads to inflammation-associated cellular and tissue 
damage (2) as observed in chronic autoimmune disease. Nevertheless, there 
are also studies showing that NO could act as a negative regulator of 
inflammation, as shown by its ability to down-regulate the development of Th17 
T-cells and, thus, potentially modulate autoimmune mechanisms in diseases 
such as RA and psoriasis (3). Interestingly, NO also plays pivotal roles in 
immunity independent of its pro-or anti-inflammatory effects.  
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In addition to cytokines and NO, arachidonic acid metabolites are also produced 
during inflammation. In response to a variety of nonspecific stimuli, 
phospholipase A2 induces the production of arachidonic acid from membrane 
phospholipids which are further catalysed by cyclooxygenases 1 or 2 (COX-1/2) 
leading to the production of prostanoids such as prostaglandin E2 (PGE2) 
PGF2α, PGD2, PGI2 and thromboxane (Tx) A2. Numerous studies have shown 
prostaglandins play key roles in pathophysiology involving complex interactions 
with many cell types including innate and adaptive immune cells (4-7)  
 
Among the prostaglandins, PGE2 is the most abundant in the body. The function 
and mechanisms of PGE2 actions in host defences and in modulating adaptive 
immune responses have acquired particular interest and are widely studied. 
Apart from its role in driving inflammation (5, 8) and as a tumour inducer (9), a 
number of  studies have suggested that it has an anti-inflammatory role (9), or 
even immune suppressor similar to non-steroidal anti-inflammatory drugs 
(NSAID) (4) and as an anti-cancer agent (10, 11). During bacterial infections, 
monocytes and macrophages produce PGE2 and interleukin 12 (IL-12). 
Bacterial LPS and IL-1β stimulate COX-2 transcription via the nuclear factor κB 
(NF-κB) transcription factor leading to inflammatory cascades that ultimately 
promote T-cell responses (12). Eventually, the balance between PGE2 and      
IL-12 production determines the type of T-cell response, whether T helper type 
1 (Th1) or Th2. Subsequently, monocyte/macrophage-derived PGE2 results in 
the activation and maturation of immature DCs. Activated/mature DCs then 
migrate to lymph nodes to serve as antigen-presenting cells (APCs) for naive T-
cells (Th0 cells). Mature DCs produce chemotactic cytokines (chemokines) 
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stimulating Th1 or Th2 cell migration to sites of inflammation and leading to 
adaptive immune responses against pathogens. 
 
Studies of the role of PGE2 in adaptive immunity have revealed that exposure of 
DCs to PGE2 leads to DC maturation with suppressed ability to secrete IL-12, 
thus, lowering their Th1-promoting capacity and promoting Th2 immunity (7, 
12). This proposition that PGE2 promotes Th2 immunity is supported by in vivo 
studies in BALB/c mice which showed Th2-dominant immune responses that 
were PGE2-dependent (8, 13). More recently, it was observed that PGE2 
activates the Th17 pathway, increases IL-17 production while inhibiting IFN-γ 
production (14). The effect of PGE2 on DCs and Th cells was speculated to 
occur through three potential modes of signalling (Figure 1.1). These are: 1) 
that PGE2 acts through the EP-4 receptor on DC to produce IL-23 production 
which, in turn, promotes Th17 cell differentiation; 2) PGE2 acts directly through 
the EP2 and EP4 receptors on naive T-cells leading to Th17 expansion by 
activating cAMP-PKA pathway; and 3) IL-12-induces Th1 differentiation through 
activating the phosphoinositdie-3-kinase (PI3K) (8). Paradoxically, similar to 
NO, PGE2 is a ubiquitous metabolite and could act as a pro- or an anti-
inflammatory mediator depending on the micro environment. Hence, 
understanding the mechanisms involving PGE2 release and actions could be 
beneficial in designing a new anti-inflammatory agent. 
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Figure 1.1: The diverse effects of PGE2 on DC and Th1 and Th17 cells. 
PGE2 produced during inflammation can: a) interact with EP-4 to stimulate DC 
to produce IL-23 via cyclic AMP (cAMP)-the EPAC pathway; b) interact with 
EP2 and EP4 receptors to facilitate activation of cAMP-PKA pathway that leads 
to IL-23-induced Th17 differentiation; c) interact with EP2 and EP4 to facilitate 
IL-12-induced Th1 differentiation through the activation of phosphoinositdie-3-
kinase (PI3K). Adapted from Chizzolini et al., 2009 (8). 
 
The presence of cytokines, free radicals and prostanoids further triggers the up-
regulation of other pro-inflammatory cytokines and chemokines at sites of 
inflammation and, thus, increase the expression of many cellular adhesion 
molecules including selectins and integrins. The production of cytokines induces 
dilation of vascular smooth muscles and increases permeability of blood vessel 
which increases blood flow and outflow of fluid throughout the endothelium of 
blood vessel. These cytokines induce adhesion and migration of PMNs through 
the endothelium of the blood vessels to the site of infection inducing 
inflammation, which in turn causes pain.  
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Pathogens and other infectious agents invade and replicate in two intracellular 
compartments of the host cells; in the cytosol or in vesicles.  During infection, 
peptides from antigen fragments derived from pathogens bind to major 
histocompatibility complex (MHC) proteins which present antigen peptides on 
the cell surface to activate antigen-specific T-cells. MHC class I (MHC-I) 
molecules deliver peptides from antigens produced into the cytosolic 
compartments to the surface creating peptide: MHC-I complexes are then 
recognised by cytotoxic CD8+ T-cells. CD8+ T-cells act immediately to eliminate 
cells infected with viruses and cytosolic bacteria. In contrast, extracellular 
pathogens that are endocytosed by immune cells and their products are 
processed in the vesicular compartment are presented within the context of 
MHC class II. These complexes are then recognised by helper CD4+ T-cells. 
This T-cell population is further classified  into two functional subsets; Th1 cells 
which promote cellular immunity including the activation of macrophages to kill 
pathogens, and Th2 cells which primarily function by activating  B cells to 
produce antibodies against pathogens (12). 
 
Lymphocytes play pivotal roles in immune surveillance and upon stimulation by 
foreign antigens counteract danger by mounting specific immune responses 
and initiating appropriate effector mechanisms. Naive T-cells circulate between 
blood and secondary lymphoid tissues where they differentiate into effector Th1 
or Th2 cells after encountering antigen presented by APCs in secondary 
lymphoid organs. Naive T-cells activated by IFN-γ develop and expand into Th1 
cells while those activated by IL-4 expand into the Th2 cell lineage. Th1 cells 
produce IFN-γ and TNFα, and mediate immune responses against intracellular 
bacteria, viruses and tumour cells. Th2 cells mostly produce IL-4, IL-5 and       
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IL-13, and stimulate humoral responses against extracellular parasites. Another 
subset of Th cells, Th17 cells, which secrete IL-17, are involved in host 
defences and provide immunity to extracellular bacteria and fungi (15). 
 
1.2 Immune responses within the skin 
 
Skin is the largest organ in the body. It consists of the epidermis and the 
dermis. The main cell types in the epidermis are keratinocytes, 
melanocytes, Merkel cells, Langerhans cells and innate immune including 
macrophages and leukocytes. The epidermis can be further subdivided into the 
stratum-corneum, -lucidum, -granulosum, -spinosum and -basale layers    
(Figure 1.2a). Skin cell divisions occur in the basal layer (stratum basale) and 
then proliferate, differentiate and mature into specialised cells such as 
keratinocytes and melanocytes as it approached the epidermal outmost layer, 
the stratum-corneum. The dermis is the layer of skin beneath the epidermis and 
consists of connective tissue that protects the body from environmental 
elements including stresses and strains. The skin serves as an element of host 
defence, or barrier to the entry of foreign substances including infectious 
pathogens as it is equipped with a network of immune cells and resident 
cutaneous cells referred to as “skin-associated lymphoid tissue (SALT)” or “skin 
immune system” (16). SALT acts as a peripheral lymphoid organ that provides 
instantaneous immune protection against pathogens and environmental 
changes in skin (16, 17).  
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Langerhans cells (LCs) are dendritic cells (DCs) of the epidermis. They are 
normally present in the stratum spinosum and lymph nodes. Studies have 
identified distinctions between LCs and dermal DCs in terms of their roles in 
mediating immune responses in skin-draining lymph nodes. Thus, whereas LCs 
have prominent roles in the induction of T-cell responses, such as cell 
activation, dermal DCs induce humoral responses (18). As mentioned earlier, 
resting DCs have an essential ‘house-keeping’ role in maintaining tissue 
homeostasis. However, in an environment of chronic inflammation such as in 
autoimmune disease involving the skin, such as psoriasis, DCs mature into 
inflammatory cells that sustain and exacerbate the inflammatory response,  
 
Keratinocytes, the largest cell component of the epidermis, play an integral part 
in skin-associated immune responses. Thus, keratinocytes can function as 
APCs, produce innate immune mediators, and subsequently stimulate skin 
homing and local activation of immune cells. Many types of TLRs are expressed 
by keratinocytes that have been activated in response to microbial stimuli. 
Engagement of TLRs induces keratinocytes to release pro-inflammatory 
cytokines including TNFα, IL-1α, IL-6 and IL-18, chemokines such as IL-8 and 
chemokine ligand 20 (CCL20)  and  antimicrobial peptides such as human β-
defensin (HBD) -2, HBD-3 and Cathelicidin (or LL37 peptide) (19). 
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Figure 1.2: Cross section of epidermal layer of normal and pathological 
skin.  (a) shows epidermal layers of the skin, (b) and (c) depicts differences 
between normal and psoriatic skins manifesting hyper-proliferative epidermis 
and inflammatory cell infiltrates (blue stain). Adapted and modified from 
http://hg.wustl.edu/bowcock/ps.html 
 
Numerous studies have suggested that crosstalks between immune cells and 
keratinocytes act as the central mechanism that maintains skin immune 
homeostasis. However, altered crosstalk due to defects in the regulation of 
multiple genes could initiate, sustain and exacerbate skin inflammation as seen 
in skin disease including psoriasis, atopic dermatitis and skin allergy. 
Autoimmune diseases result from a hyperactive immune system attacking 
normal tissues as if they were foreign organisms. This results in a chronic 
process and often leads to disruption of immune homeostasis and complete 
destruction of the target tissue. Figure 1.2 shows the difference of skin 
morphology in (b) normal and (c) psoriatic skin. In psoriatic skin, there is 
increased keratinocyte proliferation, disrupted terminal differentiation and 
excessive infiltration of immune cells. In contrast with normal skin, psoriatic 
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lesions are characterised by elongated epidermal rete and thickened skin which 
exhibit the characteristics of disorganized cornified layer (stratum corneum) at 
the skin surface (Figure 1.2c). 
 
1.3 The pathology of psoriasis 
 
Psoriasis is an autoimmune disease mediated by aberrant T lymphocyte and B 
lymphocyte responses. The aetiology of psoriasis is unknown but there is good 
evidence that susceptibility to the disease involves the interaction between 
genetic and environmental factors (20-23). Clinically, the disease is 
characterised by the appearance of red scaling plaques that range from a few 
lesions to total coverage of the skin. The disease is non-contagious and while 
symptoms can be managed by medical intervention there is, at present, no 
cure. Six clinical sub-types of psoriasis have been clinically distinguishable and 
these range from mild, severe and chronic plaques. These are plaque, guttate, 
pustular, inverse, erythrodermic and psoriatic arthritis (Figure 1.3a-f). The most 
common type of psoriasis is the plaque-type psoriasis (Figure 1.3a). Psoriatic 
lesions are characterised either as localised, or generalised, plaques 
asymmetrically distributed in the vicinity of the elbows, knees, ears, umbilicus, 
gluteal cleft, joints, nails and scalp. The localised plaque-type psoriasis is the 
least severe type that can be treated with topical therapy whereas the 
generalised plaque-type is the most severe and needs oral medications, 
ultraviolet light treatment and the provision of medical care as outpatients or 
inpatients (24). 
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Guttate psoriasis is characterized by the presence of small, scattered papules 
that develop after an acute upper respiratory tract infection (Figure 1.3b). 
Pustular psoriasis is characterised by the appearance of blisters of non-
infectious pus on the skin (Figure 1.3d). This subtype may be triggered by 
medication, infection, stress or exposure to certain chemicals. Most severe 
psoriatic patients experience smooth red patches in the folds of the skin, near 
the genitals, or armpits and this type is also known as inverse psoriasis      
(Figure 1.3e). More severe types can be seen on patients with erythrodemic 
psoriasis which is characterised by widespread reddening and scaling of the 
skin (Figure 1.3f). The occurrence of this type of psoriasis may be due to severe 
sunburn, or a prolonged period of increased activity of psoriasis which is poorly 
controlled. Lately, severe psoriasis was found to be associated with the 
occurrence of arthritis and this type is referred to as psoriatic arthritis        
(Figure 1.3c). 
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
(f) 
 
 
Figure 1.3: Clinical sub-types of psoriasis. Psoriasis are categorised 
clinically into: a) Plaque; b) Guttate; c) Psoriatic arthritis; d) Pustular; e) Inverse 
and f) Erythrodermic psoriasis. Among these, occurrence of plaque psoriasis is 
the most prevalent. Adapted from https://www.psoriasis.org with consent. 
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Lesion formation is caused by excessive growth and aberrant differentiation of 
keratinocytes where the normal differentiation process has been altered (Figure 
1.2c). The granular layer in the psoriatic skin is reduced or absent. The  
abnormal differentiation process caused by the failure of the corneocytes to 
stack normally causes scaling and consequential break of the cutaneous skin  
(25). Altered differentiation of keratinocytes is equivalent to the “regenerative 
maturation’, a cell differentiation process momentarily expressed during wound 
repair (25).  
 
Other features of the disease include visible redness of lesions. This is caused 
by marked dilation of blood vessels due to the adherence of lymphocytes, 
monocytes and PMNs to endothelial cells. Endothelial cells in psoriatic lesions 
are activated and have characteristics of the high endothelial venules present in 
lymph nodes. During the inflammatory process, the COX pathway is activated 
and this causes the release of PGE2 which promotes the dilation of capillaries 
and, thus, facilitates a chemoattractant environment for PMN. Such an 
environment favours the migration of intermixed T-cells and dendritic cells 
(DCs) to the lesion whereby the lesion functions as an organized lymphoid 
tissue. Leukocytes transmigrate to the reactive blood vessel while resident 
leukocytes expand and become dense infiltrates. Studies using immunostaining 
detected the presence of PMNs within small foci in the stratum corneum and 
significant amount of mononuclear infiltrates in the epidermis, as well as in the 
dermis region and in the hyperplastic blood vessels between the epidermal rete 
within the psoriatic skin (25). These immune cells are the source of the pro-
inflammatory factors that induce the formation of psoriatic lesions. 
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The pathogenic mechanism that underpins psoriasis basically involves the 
interaction between resident skin cells and an altered immune system that 
mediates a combination of innate and adaptive effector immunity. In a normal 
healthy skin, keratinocytes mediate the trafficking of immune cells. In 
susceptible individuals, however, the trafficking of immune cells, especially 
leukocytes, is higher and trafficking cells are activated. 
 
1.4 Immunopathogenic mechanisms in psoriasis 
 
Potential inflammatory pathways likely to be involved in psoriasis pathogenesis 
have been extensively studied. Increased interest in this area of research has 
been driven by the increasing number of patients diagnosed with the disease. 
Multistage immunopathological pathways have also been suggested to be 
involved in the induction of asymptomatic skin lesions that lead, eventually, to 
psoriatic plaques. According to these scenarios immunopathological processes 
that underpin psoriasis pathology could be triggered by extrinsic signals 
(pathogen-associated signals), or by intrinsic signals, such as by heat-shock 
proteins, HIV-1 infection or by medications. This leads to a sensitisation phase 
whereby naive T-cells evolve into effector, or memory T-cells under the 
influence of APCs including DCs in secondary lymphoid organs (Figure 1.4). 
This stage is followed by an asymptomatic phase which can vary in duration. 
The next phase is the effector phase, which involves the infiltration and 
activation of T-cells and other immune cells. These events are then followed by 
visible skin alteration during which keratinocytes respond to the activation of 
immune cells. The condition is, thus, an overshoot of the skin regeneration 
process. Currently, patients are treated during this stage of the disease. Even 
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though patients do recover from skin lesions, the chances of reoccurrence are 
still high whereby the disease veers from the silent to the effector phase under 
the influence of intrinsic or extrinsic factors. 
 
 
 
Figure 1.4: The phases of psoriasis pathogenesis. a) Sensitisation phase 
involves the induction of effector and memory T-cell as a result of interaction 
with activated DC in secondary lymphatic organ; b) The silent phase is an 
asymptomatic stage of psoriasis; c) The effector phase involves the interaction 
between infiltrating immune cells and keratinocytes leading to an overshot of 
skin re-generation. Adapted and modified from Sabat et al., 2007(26). 
 
1.4.1 The role of T-cells in the pathogenesis of psoriasis.  
 
There are several lines of evidence supporting the hypothesis that psoriasis is 
mediated mainly by T-cells. Psoriatic patients treated with T-cell targeting drugs 
such as Ciclosporin (27, 28), or given allogeneic bone marrow transplantation 
from normal individuals show clinical improvement (29). The majority of studies 
implicate pathogenic roles for CD8+ and CD4+ T-cells as well as for Th1-type 
cytokines in stimulating keratinocyte proliferation and plaque formation (30). 
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CD4+ T-cells normally reside at the dermis layer whereas CD8+ T-cells, which 
when activated upregulate CD25, CD69 and HLA-DR expression, are found in 
the epidermis at twice the number of CD4+ T-cells. The differentiation of T-cells 
at plaque sites appears to be polarized towards Th1 cells, based on their ability 
to produce IFN γ and TNFα (31).  
 
Evidence implicating Th1- and Th17-induced inflammatory pathways in the  
pathogenesis of psoriasis is demonstrated by a linear relationship between 
proximal inducer cytokines, such as IL-23, IL-12, IFN-γ, TNFα and activation of 
many IFN-responsive genes through signal transducer and activator of 
transcription (STAT) -1 and/or -3 (25) (Figure 1.5). Induction of the cascades 
leads ultimately to the production of keratinocyte-derived cytokines such as 
ECGF, VEGF and PDGF as well as IL-1α, IL-7, IL-19, IL-20 and IL-22 which 
play parts in keratinocytes proliferation.  
 
Th1 cells are activated by APCs that produce IL-12. In contrast, differentiation 
of naive T-cells to Th17 cells is promoted by the presence of IL-23. The 
increased proportion of Th17 in psoriasis has been associated with single 
nucleotide polymorphisms (SNPs) in the il-12b gene which encodes for            
IL-12/IL23p40, the subunit of IL-12 and IL-23, as well as in the il-23r gene. 
Studies of cytokine expression in psoriatic skins have identified high levels of IL-
12/IL-23p40 and IL-23p19 and an abundance of Th17 cells (32). Understanding 
the IL-12/IL-23p40 subunit is regulated has led to the establishment and 
application of Ustekinumab, an IL-12/IL-23 inhibitor for the treatment of 
psoriasis (33-35). 
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Figure 1.5: Involvement of Th/Tc1 and Th17 in the pathogenesis of 
psoriasis.  Interactions between Inflammatory DCs (IDCs) such as TIP-DCs 
(TNFα and iNOS positive DCs), plasmacytoid DCs (pDCs) and T-cells promotes 
Th1 and Th17 differentiation and inflammation mediated by these cells subsets. 
This inflammation involves the production of chemokines, cytokines including 
IL-23, IL-12, IL-17, IL-22, IL-20, TNFα and IFN-γ. These cytokines, in turn, 
enhance the production of innate defence products upon keratinocyte activation 
Adapted and modified from Lowes et al., 2007 (25). 
 
The infiltration of Th17 cell leads to the production of IL-17 and IL-22. IL-22 is a 
critical cytokine in the establishment of an inflammatory environment that 
promotes autoreactive T-cell activation. Production of IL-17 is also facilitated by 
IL-22. Thus, Ma et al. (2008) reported that blockade of IL-22 resulted in a 
decrease in the number of Th17 cells, but, surprisingly, led to an increase in 
IFN-γ (Th1 cytokine) production (36). This finding indicates that IL-22 regulates 
both Th17 and Th1 cells.  
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Although Th1 and Th17 cells are highlighted as key players in the pathogenesis 
of psoriasis, CD8+ cells or cytotoxic cell (Tc), also play important roles in 
initiating and sustaining the inflammatory process in psoriasis. CD8+ cells are 
known to be involved in innate and adaptive immune response (37). CD8+ cells 
can be subdivided into two subpopulations, termed Tc1 and Tc2 in accordance 
with the Th1 and Th2 T-cell paradigm. Tc1 cells are characterised by the 
production of IFNγ, TNFβ and IL-2 whilst Tc2 cells produce IL-4 and IL5. 
According to studies by Ovigne et al. (2001), CD8+ T-cells of the Tcl subtype 
found in patients with chronic psoriasis plaques produce higher levels of IFNγ 
compared with matched healthy controls (30). IL-4 and IL-10, however, were 
either found at low levels, or not detected following stimulation with PMA. 
Studies by Torres-Alvares et al. (2007) revealed that CD8+ T-cells expressing 
CD69 were consistently found in psoriatic plaques after treatment with 
methotrexate while other inflammatory cells were reduced in number (38). 
CD69 is an activation inducer molecule involved in activation, differentiation and 
proliferation of T-cells. It is also persistently expressed on CD8+ infiltrating cells 
in RA (39).  The persistence of CD8+CD69+ T-cells in psoriatic plaques was 
thought to contribute to the reactivation and recurrence of psoriasis after 
cessation of treatment (38). Most recently, the pathogenesis of psoriasis was 
associated with another T-cell subset, Th22 cells. The notion that expansion of 
Th1 and Th17 cells are indirectly influenced by IL-22 suggested that IL-22 could 
play a specific role in psoriasis. The link between Th17 and Th22 is that both 
are activated by IL-23, denoting IL-23 as the possible key cytokine in psoriasis 
pathogenesis. However, there is no evidence that Th22 is a Th-17 subtype in 
that Th22 cells only produce IL-22 but not IL-17 (32). Nevertheless, Th17 cells 
produce both IL-17 and IL-22. Furthermore, in innate immune responses, Th22 
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cells are stimulated by Langerhans cells (LC) whilst Th17 cells are activated by 
CD11+ dermal DCs (40). IL-22 has been shown to demonstrate additive or 
synergistic pathogenic effects with IL-17 and with other cytokines (41). IL-22 
itself, however, does not have profound effects in psoriasis. IL-22 and IL-17 
have been shown to synergistically induce the secretion of anti-microbial 
peptides in the keratinocytes (42, 43). The presence of IL-22, however, has 
limited effects on the expression of chemokines such as CXCL1 and CXCL3 
when compared with IL-17.  
 
In epidermal keratinocytes, IL-22 induces IL-20, an upstream inflammatory 
product in the epidermis of psoriatic skins, which specifically cause phenotypic 
skin changes including hyperproliferation and aberrant differentiation. Although 
IL-22 has been shown to induce hyperproliferation and altered differentiation in 
epidermal keratinoctes in vitro that resemble acanthosis, its role in the 
manifestation of psoriatic lesions might be magnified by presence of IL-20 (41). 
Nevertheless, detailed studies on the role of the Th22 pathway in psoriasis 
might be an interesting area to be explored in the future. 
 
1.4.2 Role of dendritic cells and macrophages in psoriasis. 
 
Myeloid DCs (CD11c+), which are abundant in the dermal layer, are known as 
TNF and inducible nitric oxide synthase (iNOS)-producing DCs, or TIP-DC. In 
addition to producing high levels of TNF and iNOS, TIP-DCs produce IL-23,   
IL-12 and IL-20 which activate T-cells and upregulate gene transcription in 
keratinocytes through activation of STAT-3 (Figure 1.5). TIP-DCs are found in 
large numbers in psoriatic lesions and, in some cases, outnumber T-cells in 
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psoriatic plaques (31). Cytokines produced by TIP-DCs play critical roles in 
initiating Th1 and Th17 cell differentiation and proliferation.  
 
DCs and macrophages also produce NO in response to mediators of 
inflammation (44). NO has been shown to potently-regulate keratinocytes 
growth and differentiation that are implicated in psoriasis and studies have 
shown that this could be influenced by NO synthase gene polymorphism (45). 
More recently, upregulation of NO has been noted even at the mesenchymal 
stage of skin development as high immune expression of iNOS in a 
comparative study carried out in psoriatic and atopic dermatitis patients and 
normal individuals (46). This preliminary study proposed that psoriasis has an 
early onset that could develop as early as the mesenchymal stage. 
Mesenchymal cells, thus, can produce angiogenic and pro-inflammatory 
mediators which contribute to the pathophysiology of psoriasis.  
 
Some DCs mediate direct effector immune functions and have significant 
effects on the inflammatory process. These DCs are known as ”inflammatory” 
DCs (IDCs). IDCs include plasmacytoid and myeloid DCs (pDCs and mDCs, 
respectively), which are responsible for bridging the innate and adaptive 
immune systems.  
 
1.4.3 Crosstalk between DCs, T-cells and keratinocytes in psoriasis. 
 
Overall, interactive cellular responses in psoriatic lesions appear to be due to an 
imbalance between the activation of both innate and acquired immune systems 
and factors produced by keratinocytes that directly influence T-cells and DCs 
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(25). PMNs, mDCs and CD11c+ mDCs are effector innate immune cells that are 
stimulated by chemokines produced by keratinocytes in the epidermis. 
Consequently, immune cell-derived cytokines produced through this interaction 
activate the transcription of genes encoding pro-inflammatory proteins and 
those that promote keratinocyte proliferation. Guttman-Yassky et al. (2007) 
proposed two models for the pathogenesis of psoriasis based on numerous 
reports of therapeutic approaches, histological and immunological studies 
(Figure 1.6) (31). The first model is based on the presence of primary growth 
defects in keratinocytes which initiate regenerative activation by various 
immune-activating cytokines and chemokines. This model is built on passive 
immunity in which cytokines and chemokines play significant roles in activating 
and recruiting leukocytes. The second model focuses on the role of activated 
leukocytes as the initiator of the inflammatory process by infiltrating focal skin 
regions and inducing epidermal hyperplasia. Following activation, keratinocytes 
produce further immune mediators which exacerbate the inflammatory 
response. These two models support a link between innate and adaptive 
immunity in initiating the pathogenesis of psoriasis (25).  
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Figure 1.6: Proposed models for the immunopathogenesis of psoriasis. 
Two types of immunity could underpin the immunopathogenesis of psoriasis: a) 
passive immunity in which leukocytes are activated by cytokines and 
chemokines produced by keratinocytes (KC), and b) active immunity in which 
DCs stimulate a conventional T-cell mediated immune response. (Adapted and 
modified from Guttman-Yassky et al., 2007)(31). 
 
2 Factors that predispose to the development of psoriasis. 
 
2.1 Genetic susceptibility factors 
 
The development of psoriasis has been associated with a number of genetic 
loci including genes in the MHC-I locus (10% penetrance) known as Psoriasis 
Susceptibility 1 (PSORS1) locus. The PSORS1 includes genes for the human 
leukocyte antigen (HLA) Cw6 (HLA-Cw6). Several other psoriasis susceptibility 
loci have been identified (47). These include PSORS2 on 17q, PSORS3 on 4q, 
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PSORS4 on 1cen-q21, PSORS5 on 3q21, PSORS6 on 19p, PSORS7 on 1p, 
PSORS8 on 16q and PSORS9 on 4q31.  
 
The available evidence indicates that HLA-Cw6 contributes to the onset of 
psoriasis and severity of lesions. Studies on HLA association with psoriasis 
indicate that psoriatic patients with HLA-Cw6 have an early age of disease 
onset compared with psoriatic patients with other types of HLA-C (48). Most 
Cw6-positive patients have severe symptoms such as observed in patients with 
guttate psoriasis. Indeed, Gudjonsson et al. (2002) observed that the clinical 
features of guttate psoriasis in patients depended on the HLA-Cw6 gene (48). 
Patients with the HLA-Cw6 allele experience more severe plaques and higher 
incidences of the Koebner phenomenon. The Koebner phenomenon is a 
condition of a worsening psoriasis that occurs along the site of injury. 
Gudjonsson and colleagues concluded that early age onset of psoriasis is 
associated with homozygosity for HLA-Cw*0602 (49). Nair et al. (2006)(50) 
confirmed that HLA-Cw6 is the PSORS1 risk allele and Azfar et al. (2008)(51) 
suggested that HLA-Cw6 was a key factor in pathogenicity of psoriasis, but may 
not be the only risk allele within the PSOR1. 
 
Other susceptible loci contributing to the genetic predisposition to psoriasis are 
genes expressed by keratinocytes, LCE3B (late cornified envelope 3B) and 
LCE3C1 (late cornified envelope 3C1), which are involved in skin barrier 
functions and host defence. Environmental triggers, along with LCE3B/ LCE3C1 
gene defects, alter the skin barrier functions and contribute to the formation of 
self-DNA/RNA and microbicidal cathelicidin (LL37) complexes (Figure 1.7). A 
recent study proposed that this scenario could initiate immune responses and 
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inflammatory cascades in psoriasis (19). The self RNA/DNA LL37 complexes 
stimulate maturation of mDCs and the production of IFN-α by pDC. Mature DCs 
induce the production of pro-inflammatory mediators that lead to differentiation 
and expansion of Th0 into Th1 cells (IL-12), Th17 (IL-23, IL-6 and TGF-β1) and 
Th22 (TNFα and IL-6). Presence of Th1 and Th17-related cytokines stimulate 
CCL20 production by keratinocytes, which subsequently promote migration of 
CCR6-expressing DCs and T-cells in the psoriatic skins. Th17-related cytokines 
induce DCs and keratinocytes to produce IL-20 which eventually promotes 
keratinocyte hyperproliferation. Activated keratinocytes further enhance DC 
activation and local inflammation by releasing inflammatory cytokines namely 
IL-1β,IL-6 and TNFα. Besides that, psoriasis is also associated with excess    
IL-23 production and activation of the NF-κB pathway (52). Thus, the PSORS1 
locus includes HLA-C, three IL-23-related genes (IL-23A, IL-23R and IL-12B), 
two genes that encode proteins which act downstream of signaling triggered by 
TNFα binding to its receptors that, in turn, activate the NF-κB pathway (TNIP1, 
TNFAIP3) and il-4 and il-13 genes, which encode IL-4 and 13, respectively. 
These two cytokines are key factors in promoting Th2-mediated responses.  
 
In vitro studies by Reich and colleagues (53) suggested that the early onset of 
psoriasis might be due to gene polymorphism associated with altered cytokine 
production. The inflammatory process in psoriasis is characterised by over-
expression of TNF and IL-1 and down regulation of anti inflammatory 
cytokines IL-10 and IL-1 receptor antagonist (IL-1RA). This indicates that 
psoriasis is associated with a cytokine imbalance. 
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Figure 1.7: Environmental triggers and genetic defects affecting skin 
barriers. These factors have been proposed to initiate the activation and 
maturation of DCs. The activated DCs then produce cytokines that stimulate 
differentiation of effector T-cells, Th1, Th17 and Th22 cells that promote 
keratinocytes hyper-proliferation and increase migration of inflammatory cells to 
the skin which, in turn, exacerbate inflammation and promote epidermal 
hyperplasia. Adapted and modified from Monteleone et al., 2011(19). 
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2.2 Environmental and non-environmental factors that contribute to the 
pathogenesis of psoriasis. 
 
Although psoriasis is strongly associated with genetic factors not everyone with 
the known susceptibility alleles will have the disease nor do all patients have 
plaques or severe disease. Thus, psoriasis and psoriatic flares are also 
influenced by a number of environmental factors such as skin injury, stress, 
smoking and alcohol consumption. 
 
Skin injury could lead to the formation of psoriasis plaques in susceptible 
individuals due to the Koebner phenomenon. The Koebner phenomenon is 
depicted by the appearance of psoriatic lesions in uninvolved skin of psoriatic 
patients due to trauma and injury (54). The appearance of psoriatic skin lesions 
in susceptible individuals might occur 2-6 weeks after skin injury. Such skin 
injury could be caused by abrasion, sunburn, viral rashes, drug-induced rashes 
or irritation due to clothes upon skin rubbing.  
 
Weather changes could also contribute to the development of psoriasis. The 
exposure to different weathers could also determine severity. Generally, 
psoriatic lesions are milder in warmer than cooler seasons. Psychological 
wellbeing could also be a factor in susceptibility to psoriasis. Stress has been 
identified as one of the factors that influence the development and prognosis of 
psoriasis. Stress could trigger, or worsen, conditions of psoriatic plaques. 
Individuals with stressful lifestyles or character are more prone to severe 
psoriasis compared with individuals with a relaxed character. However, the 
evidence also indicates that individuals with severe psoriasis experience more 
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stress and have lower quality of life (QoL) (55) due to their physical appearance 
and other disease side effects. However, the mechanism by which stress 
increases severity of psoriasis is not well understood.  
 
Bacterial and viral infections can also lead to the development of psoriasis. 
Guttate psoriasis in children, for instance, could be caused by streptococcal 
infection, tooth abscesses, cellulites and impetigo (56). In addition,                 
co-administration of incompatible drugs are reported to induce, or worsen 
psoriasis flares  (57). For example, angiotensin-converting enzyme inhibitors, 
beta-adrenergic blockers, lithium and anti-malarial agents and 
hydroxycloroquine (Plaquenil) have all been reported to be exacerbating factors 
for psoriasis  (58). 
 
According to an Italian case study, smoking, or nicotine exposure and alcohol 
consumption are factors that could be linked to the initiation of psoriasis                           
(22). Interestingly, the occurrence of pustular lesions is strongly associated with 
smoking habits, in a dose-dependent manner. Nicotine as well as the other 400 
substances identified in cigarettes could lead to oxidative damage in the body 
which then causes the activation of phagocytic cells. Phagocytic cells produce 
reactive oxygen species and chemokines. Other studies have also shown that 
the nicotinic cholinocytes stimulate Ca+2 influx and accelerates keratinocyte 
proliferation (58). Furthermore, heavy and chronic alcohol consumption worsens 
the existing inflammatory conditions (59), which  contribute to the imbalance 
between oxidants and antioxidants in psoriatic patients (60). This, in turn, leads 
to the up-regulation of TNF converting enzyme (TACE) and increases soluble 
TNF receptor type 1 (sTNF-R1) (60). TACE is a metalloproteinase-disintegrin 
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which releases TNF and its receptors and generates the soluble and mature 
form of the molecules. TNF-R1 binds to TNF and stabilizes the molecule, thus, 
triggering associated inflammatory cascades.  
 
Overall, based on the available knowledge of the aetiology and immune 
mechanisms prevalent in psoriasis, specific gene or drug therapies could be 
highly desirable to disrupt the vicious cycles and re-programme the immune 
system to maintain homeostasis. 
3  Treatment of psoriasis 
 
Early treatments for psoriasis were typically serendipitous observation and no 
specific mechanism of disease was targeted. These treatments included arsenic 
(Fowler’s solution) and ammoniated mercury. The overall aims of current 
treatments are to control the initiation and progression of the disease by 
reducing the volume of lesions and percentage of body surface areas involved, 
promote remission, minimise side effects and improve quality of life (61). 
Topical therapy is the most commonly used treatment in mild-severe forms of 
psoriasis. The most common topical therapies for mild conditions are 
corticosteroids, calcipotriene (Dovonex), coal tar products, tazarotene (tazaroc), 
anthralin (Anthra-Derm) and keratolytic agents. Topical therapies used for 
localised and generalised plaque-type psoriasis are prescribed to patients with 
moderate to severe psoriasis who are resistant to the above-cited topical 
therapies. These patients are generally treated with systemic therapies such as  
intra-lesional corticosteroid injections, phototherapy and systemic therapy with 
oral retinoid, acitretin, methotrexate, Ciclosporin and biologic agents. However, 
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the appropriate therapeutic approach for each patient varies depending on the 
patient’s physiological, immunological and psychological response (61). Based 
on clinicians’ points of view, combination, rotational or sequential therapies are 
more efficacious than administration of monotherapy which has shown to be 
less effective in addition to potentially causing more side effects (61). Among 
systemic agents used, methotrexate (MTX) and Ciclosporin are most frequently 
prescribed individually or in combination with other treatments with appropriate 
dosages and monitoring. A study revealed that both drugs were equally 
effective and tolerable in patients with moderate-severe-psoriasis (62). 
 
3.1 Methoxtrexate. 
 
Methotrexate (MTX) is the drug of choice for treating psoriasis despite the 
systemic side effects it can cause. Administration of this drug needs careful 
monitoring because it can cause hepatotoxicity, gastrointestinal, malaise, 
headache, reactivation of phototoxic reactions, ulcerative stomatitis, 
myelosuppression, anemia, pneumonitis, pulmonary fibrosis, induction of 
lymphomas and teratogenicity (61). The mechanism of MTX action in psoriasis 
involves blocking DNA synthesis in hyper proliferating epidermal cells, inhibiting 
T- and B-lymphocyte responses and interrupting cytokine production (61). 
 
In a 16-week randomized and, controlled trial to investigate the efficacy of MTX 
monotherapy in patients (N=85) with moderate-to-severe plaque psoriasis, 60% 
(26/43) of MTX-treated patients achieved Psoriasis Area and Severity Index 75 
(PASI 75) and 40% (17/43) achieved PASI90, compared with 71% (P=0.29) and 
33% (P=0.55) with Ciclosporin-treated patients, respectively. PASI is an 
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estimate of the severity of psoriatic lesions (redness, scaling and thickness) and 
the area affected into a single score in the range 0 (no disease) to 72 (maximal 
disease). Among patients studies by Barker and colleagues (2011), twelve 
discontinued MTX because of elevated liver enzymes (63). Thus, despite its 
effectiveness, MTX should be used with caution because of its systemic side 
effects. 
 
3.2 Ciclosporin 
 
Ciclosporin is a cyclic non-ribosomal peptide of 11 amino acids that contains a 
single D-amino acid, which is rarely encountered in mammal biochemistry. It 
was isolated from the soil fungus Tolypocladium inflatum Gams when Borel and 
colleagues were searching for novel antifungal agents in 1970 (64). In 1979 it 
was observed to demonstrate anti-psoriatic activity (64, 65). 
 
Ciclosporin is an immunosuppressant drug widely used in post-allogeneic organ 
transplantation to reduce the risk of organ rejection and acts by suppressing the 
activity of patients’ immune system. It has been used in organ transplants, 
treatment of psoriasis, severe atopic dermatitis, pyoderma gangrenosum, 
chronic autoimmune urticaria and, infrequently, in RA and related diseases. 
Ciclosporin acts by specifically targeting Th cells and, indirectly, by affecting     
T-suppressor cells or cytotoxic cells by inhibiting IL-2 , an important cytokine for 
T-cell activation (65). Ciclosporin forms a complex with cyclophilin and inhibits 
the activity of calcineurin and, thus, indirectly inhibits phosphorylation of nuclear 
factor of activated T-cells (NFAT) transcription factor (28, 65). Consequently, 
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NFAT is not transported to the nucleus for the initiation of IL-2 gene 
transcription. In addition, Ciclosporin downregulates keratinocytes 
hyperproliferation (66), histamine release by skin mast-cells (67) and 
expression of cellular adhesion molecules in dermal capillary endothelium (68, 
69). 
 
According to a 2008 National Psoriasis Foundation Consensus Conference 
(27), administration of Ciclosporin with appropriate monitoring significantly-
reduced chances of side effects. Continuous use of Ciclosporin, depending on 
treatment duration and dose, is commonly associated with the development of 
hypertension and renal impairment (70). These side effects are reversible by 
discontinuation of the drug (70). Based on many studies, low doses of 2.5-5.0 
mg/kg/day of Ciclosporin is safe and highly effective in the treatment of the 
majority of psoriatic patients (28, 71). More importantly, to-date, Ciclosporin is 
shown to be effective in controlling psoriatic crises and, treating psoriatic 
conditions which were unresponsive to other treatments and managing 
psoriasis using a rotational approach with other medications.  
 
3.3 Biological therapies 
 
The administration of topical and systemic agents temporarily suppresses 
psoriasis and limits the appearance of psoriatic plaques, thus, continual 
application is needed. Systemic agents, such as MTX and Ciclosporin cause 
side effects such as hepatotoxicity, nephrotoxicity and bone marrow 
suppression (72). In the USA, a majority of dermatologists only prescribe 
systemic agents for complex cases of psoriasis due to adverse side effects. In 
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recent years, however, a new class of therapeutics called biological therapies 
has been developed. Biological therapies, or “Biologics” as they are also known, 
are generated in living organisms. They include recombinant proteins and 
engineered antibodies that target specific molecules such as inflammatory 
mediators (e.g. TNF). Biologics function by either stimulating the immune 
system to act against the diseases, or by neutralizing and inhibiting key 
molecules that drive diseases. 
 
One school of thought is that future treatments for psoriasis should focus on 
four potential targets. These are T-cell trafficking, T-cell activation, inhibiting 
pro-inflammatory cytokines and counteroffensive strategies (73). Mechanisms 
of T-cell trafficking and activation have gained extensive attention through 
studies of the adhesion and migration of T-cells and IDCs to sites of 
inflammation. These studies were followed by the design of several inhibitors 
targeting T-cells using recombinant technology. Counteroffensive strategies 
involve enhancing the number and function of regulatory T-cell subsets (Treg 
cells) in order to counteract the effect of disease-promoting T-cells. Most 
recently, approaches focussed on more specific and selective targeting have 
taken centre stage in treating psoriatic patients by using inhibitors of IL-12/IL-23 
(Ustekinumab), to minimise side effects associated with broad 
immunosuppressive agents. 
 
Many factors should be considered before the application of biologics for 
treating patients due to concern that such therapies might induce long term 
immunosuppression, thus, promoting infections and cancer. To date, three 
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approaches have been widely used and proven to be effective in psoriasis. 
These include inhibition of T-cell receptor binding to antigenic peptides, 
blockade of TNF and most recently inhibitors of IL-12/IL-23 (Ustekinumab).  
 
3.3.1 Inhibiting T-cell receptor binding. 
 
Therapies based on targeting T-cells, or therapies targeting T-cell receptor 
binding were the first to be used. These involve the application of the T-cell 
agents Alefacept (Amevive®) and Efalizumab (Raptiva®). The mechanism by 
which these agents act involve blockade of T-cell receptor (TCR) signaling 
following TCR engagement. Alefacept is a fusion protein consisting of the 
extracellular domain of CD58 (or LFA-3) and the FC region of human IgG1. The 
fusion protein binds to the membrane co-stimulatory molecule CD2. This 
biologic is designed to block the activation of T-cells and DCs and suppress the 
production of pro-inflammatory cytokines. The mechanism of action of Alefacept 
involves enhancing apoptosis of T-cells, by killing NK cells and by blocking T-
cell proliferation by preventing binding to APCs. Binding of the fusion protein to 
the CD2 molecule favours NK cell binding and this causes T-cell killing. The 
fusion protein is designed also to inhibit APC engagement of T-cells.  
 
Efalizumab is also designed to modulate T-cell adhesion and co-stimulation. It 
is composed of a humanized murine monoclonal antibody (mAb) with specificity 
for LFA1 (CD11a). LFA1 is a heterodimer glycoprotein which binds intracellular 
adhesion molecules 1-3 (ICAM1-3) during T-cell circulation and trafficking, 
antigen presentation by dendritic cell and T-cell co-stimulation (74). Efalizumab 
inhibits T-cell migration from blood vessels into the skin by inhibiting the binding 
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of T-cells with cells expressing ICAM1 which functions to mediate T-cell 
transmigration (75).  
 
Both biologics, alefacept and efalizumab have been shown to effectively reduce 
psoriatic lesions in clinical trials (75). Intravenous efalizumab (at  ≥0.3 mg/kg 
per week) was shown to lead to significant clinical and histologic improvement 
in psoriasis, in association with sustained serum efalizumab levels and T-cell 
CD11a saturation and down-regulation (76). Alefacept, given intravenously, 
significantly reduced psoriatic lesions by 75% (PASI 75), after two weeks of 
administration, with 71% of the responders maintained at least 50% 
improvement within 12 weeks follow-up (77). 
 
3.3.2 TNF antagonists 
 
Currently, there are three biologic TNF inhibitors in clinical use. These are: 
Etanercept, Infliximab and Adalimumab. These inhibitors have been 
administered to patients with psoriasis and psoriatic arthritis (PsA). Etanercept 
is a recombinant receptor of human TNF with a backbone of IgG1-FC that 
binds TNF and lymphotoxin α (LT). Studies carried out by Van Lingen and 
colleagues (2008) demonstrated significant reduction in PASI after 12 weeks of 
treatment with Etanercept (78). Such clinical benefits were not achieved with 
the administration of Efalizumab. Efalizumab, however, induced a significant 
reduction in the number of T-cells in the dermis and epidermis and lymphocytes 
in peripheral blood (78). Therefore, it seems that the reduction in the number of 
T-cells might not be sufficient for a clinical response to therapy.  
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Infliximab (Remicade) is a chimeric human-murine mAb against TNF that 
binds both the soluble and receptor-bound forms of TNF. It is administered to 
patients with Crohn’s disease, rheumatoid arthritis, psoriasis, ankylosing 
spondylitis and psoriatic arthritis. Adalimumab (Humira) is the first fully-human 
recombinant Ab that blocks TNF. It specifically binds TNF and blocks its 
interaction with the p55 and p75 surface TNF receptors. 
 
Numerous studies have been carried out to determine the efficacy and side 
effects of these anti-TNF biologics. There have been cases where patients 
with primary diagnoses of RA, PsA, ankylosing spondylitis, Crohn’s disease and 
other diagnosis who were treated with anti-TNF biologics with no history of 
cutaneous inflammatory disease, but then developed cutaneous eruptions such 
as  psoriasis, pustular folliculitis, lupus-like syndromes and others (79, 80). The 
mechanism that caused such adverse side effects, however, is unclear. 
Nonetheless, the cutaneous eruption could be resolved by discontinuation of 
the anti-TNFα agent and by switching to other anti-TNFα treatment, or by 
steroid/topical treatment (79, 80).  
 
Recent studies on the effect of biologics in patients with moderate to severe 
psoriasis showed that Infliximab was 93% more effective than placebo (93% 
probability), followed by a mAb to IL-12 and IL-23 (Ustekinumab) at 90mg (81% 
probability). The 3rd most-effective biologic in psoriasis is Ustekinumab 45mg 
with 79% probability (81). This latter study covered a meta-analysis of 
randomised controlled trials for all biologic treatments currently available in 
Europe. Efficacy studies of infliximab in comparison with MTX have shown that 
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Infliximab was well tolerated and more efficacious than MTX in naive patients as 
well as patients who were unresponsive towards MTX (63). 
 
Overall, these studies have shown that although anti-TNFα biologics have been 
proven to be efficacious, there are side effects. Different individuals appear to 
react differently towards each biologic, therefore, monitoring is mandatory. 
 
3.3.3 IL-12/IL-23 antagonist, Ustekinumab. 
 
Recently, extensive studies were carried out to explore the role of IL-12 and IL-
23 in the pathogenesis of psoriasis by using a fully human IL-12/IL-23 mAb, 
Ustekinumab. This mAb functions by blocking the activity of IL-12 and     IL-23 
that share the same p40 subunit (Figure 1.8). The mAb binds to p40 and 
neutralizes the activity of the two cytokines by blocking their interaction with the 
cell surface receptor, IL-12β1 which forms part of the IL-12R and IL-23R 
complexes (34). The administration of Ustekinumab was shown to be effective 
with prolonged efficacy after one dose, or four weekly doses (31).  
 
Ustekinumab is the first IL-12/IL-23 inhibitor. It was produced using human 
immunoglobulin (Ig)-expressing transgenic mice and the mAb consists of 
human Ig heavy- and light-chain variable-and constant region genes (34).  The 
transgenic mice produced human antibodies after antigen challenge and the 
mAb established by using the hydridoma technology as used in the generation 
of murine mAbs. The advantage of Ustekinumab is that it has a half life 
comparable to endogenous IgG1 as well as lower immunogenicity. Therefore, 
the effect of Ustekinumab is sustained and frequency of dose administration 
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reduced. This was demonstrated in studies conducted on a large number of  
patients with moderate to severe psoriasis (n=2,899), showing that, in some 
individuals, a single intravenous (i.v) dose of Ustekinumab led to rapid and 
significant clinical response that persists for 16-24 weeks (34). This finding was 
supported by a recent clinical study carried out by Reich et al.(2012) which 
showed that Ustekinumab was nearly as effective as Infliximab in the treatment 
of psoriasis (81).  
 
 
Figure 1.8: Mechanism of action of Ustekinumab . Ustekinumab functions by 
binding the p40 subunit of IL-12 and IL-23 and blocks binding of the 
heterodimeric cytokines to IL-12β1 of both IL-12R and IL-23R. This binding 
inhibits intracellular signaling by IL-12 and IL-23 and suppresses activation and 
cytokine production. Adapted and modified from Yielding et al., 2011(34). 
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3.4 Traditional herbal therapies. 
 
Unlike modern medicines, traditional medicines focus mainly on the systemic 
effects of herbs and organic substances to treat skin disorders. In Asia, the 
oldest medicinal therapies include traditional Chinese medicine  and traditional 
Indian medicine.  
3.4.1 Anti-psoriatic treatment in Traditional Chinese Medicine (TCM). 
 
In TCM, the severity of psoriasis is classified into three stages namely blood 
heat, blood dryness and blood stasis (82). Blood Heat refers to reddened skin, 
erosion, pustule, scorching, itching and pain, accompanied possibly by 
constipation and dark urine, as well as heat sensation and thirst. This is 
followed by blood dryness which is characterised by skin damage (xerosis, 
rhagades, squamae, atrophia trichoxerosis and trichomadesis), normally 
accompanied by severe itching. Further, blood stasis is manifested by petechia, 
ecchymosis, violet red or dark red spots, pigmented spots, thickened and 
hardened skin, verrucous vegetations. Based on these symptoms, two types of 
treatments are available that are internal and external treatments. Internal 
treatment involves the use of herbal prescriptions (phytotherapy) whilst external 
treatment focuses on physiotherapy including acupuncture and cupping 
techniques. 
 
Many studies have been carried out to define mechanisms involved in use of 
TCM herbs on psoriasis. Indigo naturalis, one herbal treatment in TCM used in 
psoriasis has gained interest for its immunologic and dermatologic effects (83, 
84). Studies showed that Indigo  naturalis and its active compound, indirubin, 
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inhibit keratinocyte hyperproliferation resulting in decreased levels of the 
proliferating cell nuclear antigen (PCNA) and stimulate their differentiation with 
an increase in involucrin (a differentiation protein) level at both mRNA and 
protein levels (84).  
 
Despite these findings, comparative studies of the effect of MTX vs. TCM 
medicinal herbs (a standardised herb formulation known as wen-tong-hua-yu) in 
psoriatic patients showed that TCM medicinal herbs were less efficacious than 
MTX. Although with less adverse effect compared with MTX, TCM medicinal 
herbs did not achieve PASI 75 which was achieved by MTX with 63% of 
patients achieving PASI 75 (85). It was proposed that this might be due to 
inefficient delivery methods (i.e. use in the form of decoction instead of capsule) 
of the active ingredients of TCM to sites of inflammation, dosage or the 
composition of the active ingredients not been effective for the treatment (85). 
Therefore, it was suggested that further detailed studies to explore the potential 
of TCM and assess the side effects of the medications should be carried out. 
These studies should also aim to eliminate the potential of liver dysfunction, 
cardiomypathy and hepatoxicty as reported by some studies (86, 87). 
 
3.4.2 Anti-psoriatic treatment in Ayurveda. 
 
Ayurveda in traditional Indian Medicine has evolved before the emergence of 
modern medicine. The Ayurveda materia medica has described more than 1500 
herbs and 10,000 formulations for health, well-being and treatment for diseases 
(88). Moreover, it has documented over 5000 signs and symptoms of diseases. 
Ayurveda has also standardised prescriptions for the treatment of skin disorders 
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including psoriasis. Herbal plants used by Ayurveda in the treatment of 
psoriasis that have been studied include Centella asiatica (89), Caesalpinia 
bonduc (L.) Roxb.(90) and Argemone mexicana (91). Extract of Caesalpinia 
bonduc (L.) Roxb has been shown to have  anti-proliferative effects on a human 
keratinocytes cell line (HaCaT), inhibited lipooxygenese and promoted 
significant orthokeratosis (a normal configuration of stratum corneum) in mouse 
tail test (90). In vivo mouse tail parakeratosis is used as a hallmark of psoriatic 
skin.  Argemone mexicana, the plant ingredient in Desoris, botanical drug 
product, has been found to effectively modulate cellular functions in psoriasis 
and has been the subject of phase 3 clinical trial (90). 
 
3.4.3 Anti-psoriatic agents in traditional medicine in Malaysia. 
 
In Malaysia, traditional Malay medicines have diverse uses in applied medicine 
by combining medicine with religion and spiritual beliefs. Vast numbers and 
diverse types of herbs are used to treat skin diseases by topical applications 
and by oral consumption. Centella asiatica has been used for the treatment of 
psoriasis, eczema and ulceration in TCM and Ayurveda. This herb has also 
been used in Malaysian traditional medicine for the same conditions. Studies 
have shown that the constituents of the plant, triterpenoid glycosides displayed 
potency equal to the commercially-available anti-psoriatic agent, dithranol (89, 
92). To date, however, very few reliable scientific studies have been carried out 
to understand the effect of Malaysian herbal traditional medicines on the 
modulation of immunopathogenesis in psoriasis.  
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3.5 Commercially-available plant-derived anti-psoriatic inhibitors  
 
Prior to the emergence of synthetic drugs and biologics, phytotherapeutic 
agents, or drugs originated from plants have been used in the treatment of 
psoriasis (Table 1.1). These drugs were discovered serendipitously and 
normally applied topically in combination with treatment such as ultra-violet (UV) 
light. Anthralin and psoralen have been shown to have excellent efficacy in 
regulating keratinocyte hyperproliferation.  
 
Anthralin originally known as cignolin, was derived from chrysarobin a 
component from the bark of Goa tree or Andira araroba which is a native plant 
of the Amazon. Nonetheless, Anthralin that is available today is synthetically-
produced and is known as Ditranol. Anthralin is used as a topical agent which 
induces clearance of psoriatic lesions and remission from disease. Anthralin 
has been shown to inhibit the release of pro-inflammatory mediators and 
possess anti-proliferative effects on keratinocytes (83). While displaying both 
anti-proliferative (93) and anti-inflammatory effects on psoriasis (94), it also 
induces inflammation on normal skin (95). The inflammation could be controlled 
by including free-radical scavenger and anti-oxidant as part of the treatment. 
Clinical studies on psoriatic patients indicated that anthralin is more potent than 
calcipotriol (83) and similarly effective compared with topical corticosteroid 
(0.05% diflorasone diacetate ointment) and traditional treatment which requires 
overnight application (95). Obviously, this indicates that potent drugs against 
psoriasis could be discovered in herbal plants serendipitously. 
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Psoralen was isolated from Bishop’s weed (Ammi majus) and has been used 
topically to treat psoriasis. The main active component is 8-methoxypsoralen (8-
MOP). There were numerous clinical studies that highlighted the potency of 
psoralen in combination with UVA irradiation, generically known as PUVA. It 
was found that the anti-psoriatic effect of PUVA therapy was due to its ability to 
impair T-cell functions. However, the precise mechanism of action involved in its 
clinical effectiveness in the clearance of psoriatic lesions is still not well 
understood. PUVA treatment in transgenic mice (k5.hTGFb1) which exhibited 
close phenotypic resemblance to human psoriasis had shown that PUVA 
successfully cleared the lesion by suppressing IL-23/Th17 and Th1 pathways 
while activating Th2 cells and by inducing Treg cells and CTLA4 signaling (96). 
 
According to Commission E of the German Federal Drugs Administration, the 
quality of clinical studies on these drugs was classified as LOE A. Level of 
evidence (LOE), according to the UK National Health Service is categorised in 
range of A to D as depicted in Table 2 of the Appendices. This indicates that 
these drugs had undergone the highest level of assessment with randomised, 
controlled clinical and cohort studies, which validate the effectiveness of these 
drugs in the treatment of psoriasis. 
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Table 1.1: Plants and their active compounds with dermatological effects.  
The effectiveness of the compounds is classified according to the former 
Commission E at the German Federal Drugs Administration based on the 
quality of the clinical studies known as LOE. Reference: Reuter et al. JDDG 
(2010) band 8 (83). 
 
Plants Active compound Levels of evidence (LOE) 
Araroba tree 
(Andira araroba) 
 
Anthralin 
A 
Bishop’s weed 
(Ammi majus) 
 
Psoralen 
A 
Indigo naturalis 
(Baphicacanthus 
cusia) 
 
Indirubin 
A 
Cayenne pepper 
(Capsicum 
frutescens) 
 
Capsaicin 
A 
White willow 
(Salix alba) 
 
Salicylic acid 
D 
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4 Hypothesis 
 
Psoriasis is a complex and multifactorial disease that is influenced by genetics 
and environmental factors the combination of which could vary among different 
individuals. Studies on its aetiology, pathogenesis and immunological 
abnormalities have resulted in the development of a range of therapies 
including natural and synthetic drugs and biologics. Despite integrated scientific 
and clinical findings and postulations, key mechanisms and inflammatory 
pathways involved in pathogenesis remain debated. Hence, more insights into 
disease mechanisms, genetic roles, epigenetics and metabolomics are required 
to develop new and better treatments. 
 
Therefore, by gaining further knowledge of the roles of T- and B-cells, 
particularly Th17 cells, in the disease process, using naturally-derived 
compound/s, more targeted therapies could be identified and developed.  
Although, natural products and plant-derived constituents have not been the 
subject of recent drug discoveries, their potential should not be ignored since 
important drugs such as Ciclosporin and dithranol were derived from natural 
product/resources. Plant-derived active compositions and extracts have been 
shown to possess multiple functions in disease therapy. In many, so-called 
traditional medicinal systems such as Ayurveda and Traditional Chinese 
Medicine, nutrition and herbal medication are a normal part of prevention and 
healthcare.  
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With these notions in mind, it is hypothesised that Halia Bara or Z.officinale 
Roscoe var. rubrum (ZOR) may have  therapeutic potential in regulating 
inflammatory events related to psoriasis. Therefore, this study will identify the 
key mechanism of action of this ginger species against inflammatory responses 
relevant to psoriasis. 
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5 Aims and Rationales 
 
The key aims of this study were to evaluate the potential of active constituents 
from Z.officinales Roscoe var. rubrum (ZOR) or Halia Bara as anti-psoriatic 
agents. Specifically, the aims and rationales for this study were; 
 
1. To investigate if ZOR active constituents possess inhibitory effects 
against nitric oxide and prostaglandins produced by activated macrophages. 
This provides a line of evidence wherein these plant-derived constituents may 
act at the early phases of the inflammatory process mediated by the innate 
immune system. 
2. To identify if ZOR-derived active constituents possess inhibitory effects 
against cytokines involved in the induction of Th1 and Th17 cells. These 
cytokines would include TNFα and IL-12/IL-23 produced by activated 
macrophages.  
3. To examine the effect of ZOR samples on leukocyte migration and   T-
cell activation. Thus, the effect of ZOR on the expression of adhesion molecules 
involved in immune cell activation and recruitment to site of inflammation to be 
defined.  
4. To identify ZOR samples suppressive effects on keratinocyte 
proliferation, differentiation and chemokines production. This would define the 
effect of ZOR active compounds on key responses by which keratinocytes 
contribute to pathogenesis.  
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All of these aims, it is hoped, would determine if ZOR has the potential to 
regulate inflammatory pathways involved in psoriasis. For all of these objectives 
to be achieved, the study could raise the possibility that ZOR, or more precisely 
compounds derived from it, could be therapeutically-beneficial in psoriasis and, 
possibly, other inflammatory conditions. This study was, therefore set up to 
address if ZOR and active compound could modulate the key mechanisms 
known to drive inflammation involved in psoriasis and identify functional 
compounds of therapeutic value. 
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1 Introduction 
 
1.1 Zingiber officinale Roscoe var. rubrum (ZOR), ginger variant of South 
East Asia 
 
Ginger (Zingiber officinale) is a versatile plant which has been used as a spice 
and herbal medicine for around 3000 years in India and China (97). Ginger is 
thought to have originated from the Indo-Malayan region (South-east Asia). It 
was disseminated from India throughout Asia, Africa, Mediterranean and Pacific 
Islands through trading activity since the 1st century (98).  
 
Ginger belongs to the genus Zingiber of  the Zingiberaceae family that is part of 
the order Zingiberales and tribe Zingibereae (99). Worldwide, there are 
estimated to be about 1,200 species of Zingiberaceaee belonging to 18 genera. 
Among these, approximately 160 species from 18 genera are found in 
Peninsular Malaysia and, therefore, comprises at least 20%  of the world taxa 
and 40% of the world genera of Zingiberaceae (100) 
.   
Early studies by Ridley (1915), demonstrated that there are four types of ginger 
in Malaysia namely: Halia Betel (true ginger), Halia Bara, Halia Padi and Halia 
Udang. Ridley also described the red variety of ginger, Zingiber officinale var. 
rubra (or rubrum), which has a reddish rhizome skin (101), and  closely 
resembles the ginger sp. of interest, Z.officinale Roscoe var. rubrum, also 
known as Halia Bara. Therefore, this suggests that the ginger variant of interest, 
Halia Bara (ZOR), is most probably local to Malaysia and its neighbouring 
countries in South-east Asia.  
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Halia Bara (ZOR) can be distinguished genetically and phenotypically from 
other ginger varieties and variants. Phenotypically, Halia Bara is slightly 
different from the common culinary ginger whereby its rhizomes are red, 
smaller, more pungent and  have  pinkish rhizomes in its cross section (Figure 
2.1(a)(b)) (102). The base of its leaf shoot is red and it has a reddish petiole 
when young, as well as scarlet red lip blotched with cream (100). Authentication 
of Halia Bara and other local varieties and variants in Peninsular Malaysia was 
carried out by utilising DNA fingerprinting (100). According to DNA fingerprinting 
of a local variety of the species in Peninsular Malaysia, Z.officinale Roscoe var. 
officinale (common ginger), Z.officinale Roscoe var. rubrum (Halia Padi) and 
Z.officinale Roscoe var. rubrum (Halia Bara) are slightly differentiated by their 
DNA profiles at RAPD (Random Amplified Polymorphic DNA) Operon primers; 
OPA1, OPA8 and OPA20  (Figure 2.2 ) (100). RAPD involves the use of a 
single random primer in a polymerase chain reaction which results in the 
amplification of several distinctive DNA products. It is a useful approach to 
identify variation within plant varieties (103). The DNA profiles indicated that the 
varieties were differentiated by the presence of polymorphic banding patterns 
shown as ‘X’ in Figure 2.2 (OPA1: X=1500bp. OPA8: X=2000BP, OPA20: 
X1=1350bp, X2=900bp, X3=800bp, X4=550bp). Halia Bara (ZOR) can be 
differentiated from the common ginger (halia) and halia padi by the presence X3 
band of OPA20 (Figure 2.2). 
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Figure 2.1: Phenotype of Halia Bara or Z.officinale Roscoe var. rubrum 
(ZOR). It is  as indicated by (a) a photograph of the whole plant of and (b) its 
pink reddish  rhizome and the rhizome cross section.  
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Figure 2.2: DNA profiles of three ginger varieties. DNA fingerprinting 
demonstrating slight variations in DNA  between  Z. officinale  (common ginger, 
H) and its varieties; Z.officinales var. rubrum (Halia Bara , HB) and Z.officinales 
var. rubrum (halia padi, HP) (100) Halia Bara and halia padi can be 
differentiated by band X3 and X4 of OPA20. These bands are not observed in 
halia DNA profile. (OPA1: X=1500bp. OPA8: X=2000BP, OPA20: X1=1350bp, 
X2=900bp, X3=800bp, X4=550bp).Adapted from Ibrahim et al. 2007 (100). 
 
Ethnobotanical studies of Zingiberaceae sp. in Peninsular Malaysia by Ibrahim   
et al. (2007) found that, traditionally, many medicinal ginger plants are used for 
female-related ailments, for example to treat post-partum and post-natal 
symptoms after childbirth (100). The Zingiberaceae sp have been effective to 
improve blood circulation and encourage contraction of the uterus during post-
partum period (104). The treatments are in the form of tonics, herbal extracts, 
decoctions (herbal extract prepared by boiling) and ointment, whereby they 
might consist of a single ginger sp. or a herbal mixtures consisting of several 
Zingiberaceae sp. In Malay traditional medicine, Z. officinale Roscoe var. 
rubrum  (Halia Bara) was used to treat aching joints, being applied topically as a 
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mixture of rhizome juice and vinegar, or drank as a rhizome juice (100). Thus 
far, the anti-arthritic effect of this ginger variant has not been determined 
scientifically though it was reported in several studies on Z. officinale Roscoe 
sp. (105, 106). 
 
To-date, few studies have been carried out on this particular ginger variant in 
terms of the chemical composition of the rhizomes,apart from a single study that 
indicates that an essential oil from the rhizomes consisted mainly of geranial 
(28.43%), neral (14.20%) and  geranyl acetate (8.77%) (107). The essential oil 
of the common ginger, however, consists mainly of zingiberene (16.7%), (E,E)-
α-farnesene (13.10%) and geranial (7.60%). Thus, geranial seems to be a 
compound present in the essential oil of both ginger species. Therefore, it could 
be deduced that closely related ginger variants might share one or two common 
compounds. Nonetheless, there are a very limited number of studies carried out 
on the composition of the oleoresin (a mixture of extracted essential oil and 
resin) of Halia Bara and its potential biological effects. 
 
1.2 Chemical components of ginger in general 
 
The rhizome of ginger  consists  mainly of volatile (constituting the essential 
oils) and non-volatile compounds (101), that appear to contribute to its healing 
properties (108). More than 66 compounds have been identified in the volatile 
oil which are mainly sesquiterpene hydrocarbons that include zingiberene, 
curcumene and farnesene, β-sesquiphelandrene, bisabolene, 1,8-cineole, 
linalool, borneol, nerol, geraniol, camphen, limonene, myrcene,β-phellandrene, 
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α-pinene, citronellol, geranial, neral and others (109). These constituents of 
essential oil contribute to the distinct aroma and taste of ginger. The essential 
oil is normally used in small amounts by the pharmaceutical, cosmetic and 
perfumery industries. As well as its use as a fragrance, the essential oil 
possesses therapeutic effects (97). A high yield of essential oil is obtained by 
steam distillation and supercritical carbon dioxide extraction. It is also detected 
as a product in solvent extraction (97, 110).   
 
The major characteristic of ginger is the pungent odour which is due to its 
oleoresin content. The oleoresin mainly consists of non-volatile pungent 
compounds, which are classified as phenols such as gingerols, shogaols, 
paradols, zingerone and related compounds, and resin. The oleoresin is a dark 
brown viscous liquid which contains 20-25% volatile oil, 25-30% pungency 
stimuli and non-flavour compounds; fats, waxes and carbohydrates (111). Some 
trace elements of the usual organic and inorganic compounds found in food, as 
well as a high content of vitamin C, manganese and iron were also identified in 
ginger  (97, 110). 
 
Biochemically, these active compounds are produced through the 
phenylpropanoid pathway that mainly controls the production of gingerols, the 
major pungent compounds in ginger (111). Hence, this pathway indirectly also 
becomes the limiting factor for the generation of other related metabolites. 
Studies indicate that gingerol and shogaol are the major compounds that 
contribute to the pungent smell in both fresh and dried ginger (111). Gingerols 
are mainly observed in the oleoresin of fresh ginger with yield of 20%-33% of 
the oleoresin (97). In dried ginger, gingerols are converted to shogaols. 
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Shogaols are found in increasing amounts during the drying process of ginger 
as a result of dehydration of gingerols. Therefore, shogaols are the dehydrated 
products of gingerols and, thus, are more chemically and thermally stable than 
gingerol (112). Studies by Connell (1970) indicated that gingerols are 
biosynthesized from dihydroferrulic acid via condensation with mevalonic acid 
and hexanoic acid to give the intermediate gingerdione. Among the gingerols, 6-
gingerol is the highest content. In the production of 6-gingerol, Macleod & 
Whiting proposed that a diketone, 6-dehydrogingerdione, is the initial product 
which undergoes two reduction steps which are C=O and C=C reduction that 
lead to the conversion into 6-gingerol (113). In this biosynthesis reaction, 6-
dehydrogingerol is the intermediate product (Figure 2.3). Upon dehydration, the 
6-gingerol are converted to 6-shogaol and when undergoes hydrogenation, 6-
shogaol is converted into 6-paradol upon storage. Hence, this demonstrates 
that  the presence of the ginger compounds in the pathway are inter-related and 
varied according to the biochemical environment such as the presence of 
enzymes, pH etc (97). The presence and biological activity of these compounds 
differ depending on the state of the rhizome whether it is in a fresh, dried or 
roasted condition, the cultivar, storage, processing condition (114) and methods 
of extract preparation (115). 
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Figure 2.3: Synthesis of gingerol-related compounds. The biosynthesis 
pathway of 6-gingerol, with 6-dehydrogingerdione as the initial product and 6-
dehydrogingerol and 6-gingerdione as the intermediate products. Ar= C7H7O2 
and R=C5H11. Adapted and modified from Macleod et al 1979 (113).  
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1.3 Bioactivity-structure relationship of known ginger constituents 
 
Over the centuries, ginger has been used to cure colds, inflammation, 
gastrointestinal discomfort, rheumatic disorders, neuralgia and motion sickness 
(112).  Despite the efficacy of ginger in treating these symptoms, the exact 
mechanisms of ginger-containing-herbal preparations remain unclear. 
Nonetheless, it is still used in traditional medicines such as in Traditional 
Chinese Medicine, Ayurveda and others. The challenge in understanding the 
mechanistic properties of traditional medicines is that such traditional medicines 
normally contain several types of herbs with each herb containing several 
potentially therapeutically effective compounds. 
 
To-date, many studies have been carried out to understand the bioactivity-
structure relationship (SAR) of ginger’s constituents. Several bioactive 
compounds have been identified in ginger, known as phenylpropanoids such as 
gingerols, and gingerol-related compounds; shogaols, gingerdiones and 
paradols. Among these compounds, the bioactivity of the gingerols, 6-gingerol 
in particular, has been widely studied. It has been shown, for example, that       
6-gingerol possesses antioxidant, anti-inflammatory, anti-microbial, anti-
thrombotic, antispasmodic, anti-tumour and anti-arthritic properties (96, 97). 
Recently, it was shown that  the dehydrated form of 6-gingerol, 6-shogaol, was 
a more potent antioxidant and anti-inflammatory agent than gingerols due to its 
‘drug-like’ structure (116). Among the gingerols, 6-gingerol was the least potent 
while 10-gingerol was the most potent antioxidant agent. It was proposed that 
the length of the alkyl side chain determines the potency of these compounds. 
The longer the carbon side chain the more potent the compound. This was 
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evidenced by the interaction of phenylpropanoid with the human serotonin 5-
HT1A receptor for anti-anxiolytic effects, whereby the binding affinity of 
compounds is correlated with the length of the aliphatic chain. 
Phenylpropanoids with a longer chain such as 10-gingerol, 10-shogaol and      
1-dehydro-10-gingerdione were shown to have the strongest affinity among the 
tested phenypropanoid (117).  
 
The presence of an α,β-unsaturated ketone moiety within the carbon chain of 
the alkyl group of gingerol and gingerol-related compound was speculated to 
contribute to its potency. A study was carried out by Kimura and colleagues 
(2005) to gain insight into the possible interaction of these compounds with 
endogenous target ligands such as prostaglandin F-2α, which is involved in the 
modulation of eicosanoid responses in mouse mesenteric veins, in a study 
related to mechanisms in diabetes mellitus. Mesenteric veins are involved in 
controlling blood flow from the liver to the digestive organs such as the 
intestines. This subsequently regulates blood glucose levels in the circulation. 
Kimura and colleagues (2005) showed that 6-gingerol and hexahydrocurcumin 
potentiated PGF-2α-induced contraction of mice mesenteric veins whilst            
6-shogaol and 6-gingerdione inhibited PGF-2α (112).  
 
In contrast, no potentiation of PGF-2α-induced contraction of mice mesenteric 
veins by 6-dehydrogingerdione or 6-gingerdiacetate was observed. 
Interestingly, however, 6-gingerdione in aqueous solution demonstrated 
increasing potentiating effects on PGF-2α production. In aqueous solution,         
6-gingerdione with a α,β-unsaturated diketone moiety at C-3 and C-5, is 
stabilised into an enolic  form, employing both carbonyl and hydroxyl(112). This 
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is believed to be due to conversion of the keto to the enol-OH, as a result of the 
activation by the carbonyl group of the α,β-unsaturated ketone moiety, which 
favours  enolisation. Therefore, the effect of the hydroxyl group that mimics 
PGF-2α is  evidence that  part of the chemical structure of gingerol and related 
compounds in ginger resemble prostanoids (112)  (Figure 2.3).  
 
Equal potentiation effects of 6-gingerol in normal and diabetic states suggest 
that it could be involved in the activation of COX-1. 6-shogaol and other 
gingerol-related compounds have been shown to exhibit inhibitory effects on 
COX-2 on the basis of three structural features. These are; 1) lipophilicity of the 
alkyl side chain, 2) substitution pattern of hydroxyl and carbonyl groups on the 
side chain and, 3) substitution pattern of hydroxyl and methoxy groups on the 
aromatic moiety (118).  
 
The above cited data, therefore, indicate that the effect of ginger constituents on 
prostaglandins could be due to the close resemblance between the structure of 
prostaglandins such as PGF, PGE2 and PGH and  the compounds present in 
ginger such as gingerols, shogoals, hexahydrocurcumin, gingeracetate and 
gingerdiones (112) (Figure 2.4). It was also highlighted that only compounds 
that contain the hydroxyl group at C-5 in the side chain produced potentiation 
effects on PGF-2α-induced contraction in mice mesenteric vein (Figure 
2.4(a)(b)). Kimura and colleagues (2005) concluded that the different effects of 
gingerol and shogaol on potentiation of PGF-2α-induced contraction in mice 
mesenteric vein suggested that a combination of both compounds could have 
synergistic effects against diabetes and other inflammatory conditions (112) .  
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The findings cited above, therefore, suggest that ginger phenylpropanoids have 
‘drug-like’ effects, possibly similar to those by NSAIDs such as aspirin, 
ibuprofen and indomethacin. The ‘drug-like’ structure of phenylpropanoids as 
stated by Dugasani and colleagues (2010)(116)  is in accordance with Lipinski’s 
rule of ﬁve (Ro5) (119). According to Lipinski, a ‘drug-like’ compound is 
potentially orally active when it follows four simple physicochemical parameters, 
1) molecular weight ≤500; 2) lipophilicity, expressed by log P≤5 (P= calculated 
octanol/water partition coefficient); 3) H-bond donors ≤5  (calculated as the sum 
of OHs and NHs within the structure) and, 4) H-bond acceptor ≤10 (calculated 
as the sum of Ns and Os within the structure). These characteristics are based 
on 90% of orally-active drugs that have achieved phase II clinical trials (119). 
Log P is useful in predicting the distribution of drugs within the body whereby 
high log P values indicate hydrophobic drugs which are predominantly 
distributed into the hydrophobic compartments such as lipid bilayers while the  
preferred, hydrophilic drugs with low log P, are distributed into hydrophilic 
compartment such as blood serum. Therefore, a lower log P value may lead to 
better drug-delivery. To qualify as a drug , a compound must reach the target 
site, interact with a molecular target and preferably be structurally similar to the 
native  ligand, in this case, catecholamines, prostanoids, indoles and quaternary 
amines (120). 
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Figure 2.4: Structure-activity interaction of the phenylpropanoid (gingerol-
related compounds) and prostaglandin F-2α  (PGF-2α)  . Structure comparison 
between six ginger phenylpropanoids (a-g) with (h) PGF-2α.  It was proposed 
that the presence of hydroxyl group on the side chain of the phenylpropanoids 
mimics PGF-2α. Adapted and modified from Kimura et al. 2005 (112). 
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In summary, ginger contains potential ‘drugs’ or therapeutically active 
compounds that will be characterised and discussed in terms of their effect on 
modulating inflammatory mediators related to psoriasis later in the following 
chapters. 
2 Objectives 
 
This chapter focuses on the fractionation of Zingiber officinale Roscoe var 
rubrum (ZOR) or Halia Bara extract, isolation and chemical characterisation of 
compounds with therapeutic effects. Prior to the start of this study, 20 extracts 
from 12 types of plants from Malaysia were screened for their inhibitory effects 
on the production of NO and PGE2 as well as changes in the expression of 
iNOS and TNFα by PCR (detailed in Chapter 3 and 4). Amongst the plant 
extracts tested, ZOR was identified with the most efficacious activity against NO 
and PGE2 production by macrophages, thus, it was selected for further 
characterisation both chemically and biologically. The bioactive compounds 
were isolated using conventional isolation methods, such as vacuum liquid 
chromatography (VLC), solid phase extraction (SPE) and preparative thin layer 
chromatography (Prep-TLC) and characterised via nuclear magnetic resonance 
(NMR) spectroscopy, mass spectrometry, infra red (IR) and ultraviolet (UV) 
spectrometry.  
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3 Methods 
3.1 Preparation of plant extracts and profiling 
 
Preparation of plant extracts were carried out in two stages. Phase I involved 
preparation of extracts from a number of plants of known therapeutic effects 
(Table 1 of the Appendices). These plants were  labeled as indicated in Table 
2.1. Phase, II involved modifying the original extraction protocols to obtain a 
ZOR extract for detailed assessment. 
3.2 Sample preparation 
 
Twelve varieties of plants were collected for the initial screening (Table 2.1). 
These plants were collected from three states in Malaysia; Selangor, Negeri 
Sembilan and Pahang. Based on the biological potency in initial biological 
assays (will be discussed in chapter 3), a ginger species, Zingiber officinale 
Roscoe var rubrum (Halia Bara) (ZOR) was selected for further detailed studies. 
Rhizomes from ZOR were collected from Pahang, Malaysia and specimens 
deposited at Kew Gardens Herbarium, Kew, and U.K (voucher: Nordin 1). It was 
classified as Zingiber officinale sp. native to Peninsular Malaysia according to 
the morphology of the leaves and petiole. It is known as  variant  rubrum  due to 
the purplish rhizome and pungent odour (99). It was identified as Halia Bara due 
to its pungent smell and red-skin rhizome (Figure 2.1). The rhizomes were 
washed, sliced and dried for 48 hours at 40±5°C. The dried rhizome were then 
grounded into powder and stored at 4°C until used.  
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Table 2.1: Selected plants with known therapeutic effects. These plants 
were  collected from Malaysia and extracted using sonication (SN) and shaking 
(SK) methods described in 3.3. Their general use in traditional medicine are 
summarised in Table 1 of the Appendices.  
Plants Coding Extraction method 
Leaves of Mangifera indica  MP SK, SN 
Rhizomes of Ipomoea batatas  UB SK, SN 
Leaves of Crinum asiaticum TS SK 
Leaves of Pandanus amaryllifolius  DP SK, SN 
Rhizomes of Zingiber officinale  Roscoe 
var. rubrum (Halia Bara)   
HB SK 
Leaves of Artocarpus heterophyllus  DN SK, SN 
Leaves of Artocarpus altilis  DS SK, SN 
Leaves of Piper sarmentosum DK SK, SN 
Leaves of Morinda citrifolia MG SK, SN 
Roots of Tinospora crispa AB SK 
Seeds of Archidendron bubalinum   KD SK, SN 
Rhizomes of Marantha arundinancea UBM SK 
 
 
 
 
                              CHAPTER 2                                                                                                                   
 
67 
3.3 Extraction phase I: Preliminary studies 
 
The first stage involved preparation of extracts from twelve varieties of the 
plants in Table 2.1. The extractions were carried out using 80% ethanol by two 
different methods. 
 Method 1: Dried ground plants (30g) were extracted in 100 mL 80% ethanol. 
The extraction was carried out on a shaker at 40°C for 24 hours. The extracts 
were filtered and then concentrated using a rotary evaporator at 72 Pa at 
<40°C. The samples were re-dissolved in 80% ethanol for bioassays. 
Method 2: Dried ground plants (30g) were extracted in 100 mL 80% ethanol. 
The extraction was carried out by sonicating the samples at 50°C for 30 
minutes. The extracts were filtered and the remaining solid fractions sonicated 
twice more. Filtered extracts were combined and concentrated in a rotary 
evaporator at 72 Pa at <40°C. The samples were re-dissolved in 80% ethanol 
for bioactivity studies. 
 
3.4 Extraction phase II: Zingiber officinales Roscoe var. rubrum (ZOR) 
(Halia Bara) 
 
Phase II involved an optimised extraction protocol for ZOR. Active components 
in new batch of ZOR powder (499g) were extracted with 3 L chloroform for 30 
minutes using sonication and then maceration for 5 days at room temperature. 
The extract was collected, filtered and evaporated using a rotary evaporator at 
200 Pa at 45°C. The powder residue was then re-extracted with  absolute 
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ethanol and water using the same approach. The aqueous extract was dried 
using a freeze-drier. 
 
3.5   Instruments and Protocols 
 
3.5.1 Vacuum Liquid Chromatography (VLC) 
 
Outline of method: Fractionation is used to separate groups of active 
compounds according to a gradient of nonpolar: polar solvent ratios. In this 
study, fractions from a gradient of 100% hexane to 100% ethyl acetate were 
collected using vacuum liquid chromatography (VLC).  
Protocol: 10-40 g of ZOR extract was subjected to VLC on silica (Silica gel 60 
PF254+366, MERCK) and 21 fractions were collected from gradients of a hexane: 
ethyl acetate mixture. The fractions were evaporated via rotary evaporator and 
the concentrated fractions left to dry at room temperature.  
3.5.2 Solid Phase Extraction (SPE) 
 
Outline of method: SPE is a chromatographic method used to isolate 
compounds by eluting them from a normal phase column. SPE uses the affinity 
of solutes in a liquid mobile phase, for a solid through which the sample is 
passed (stationary phase) to separate a mixture into desired and undesired 
components. The amount of sample loaded depends on the size of the column.   
Protocol: 200-400 mg of sample was loaded onto a 10 g/60 mL Giga tube 
normal phase column (Strata SI-1 Silica, 55 μm, 70A, Phenomenex). Prior to 
sample loading, the column was conditioned with hexane. Once the sample was 
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loaded, elutions with increasing polarity from 100% hexane to 100% ethyl 
acetate were carried out. Each eluent was collected and evaporated. TLC and 
NMR were used to determine the profile of each fraction before further 
purification.   
  
3.5.3 Preparative Thin layer chromatography (Prep-TLC) 
 
Outline of method: One of the first steps in obtaining a good separation of 
pure compounds is the selection of an appropriate mobile phase.. The use of 
Thin Layer Chromatography (TLC) TLC will be discussed here to deal with the 
successful correlation between the TLC separation and the preparative silica 
column. TLC is a liquid-solid adsorption technique where the mobile phase 
ascends the thin layer of stationary phase coated onto a backing support, such 
as glass, by capillary action. There is a similar relationship with column 
chromatography where the solvent travels down the column’s adsorbent. This 
similar relationship allows TLC to be a rapid method for determining solvent 
composition for preparative separations. The optimum separation of compounds 
by TLC is usually achieved when retention values (Rf) are between 0.3–0.5.  
The Rf   value is defined as the ratio of the distance moved by the solute (test 
samples) and the distance moved by the solvent (the solvent front) from the 
point where the sample is initially applied to the TLC sheet.   
 
In most cases, adjusting the compound’s Rf to 0.3–0.5 is crucial for a TLC 
separation. For scale-up to preparative separations, the TLC solvent system’s 
polarity must be decreased to lower the Rf to between 0.15–0.35. This Rf range 
is optimal for a preparative separation, in terms of sample load, resolution, 
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residence time, and solvent usage. Several solvent systems were used in this 
study which ranged from 70-95% hexane in ethyl acetate and 80-98% toluene 
in ethyl acetate. 
 
Protocol: Selected SPE fractions were purified by preparative TLC 
(20 mm × 20 mm, 60F254; Merck), which is essentially TLC, only on larger scale. 
A large developing tank and large thickly-coated plates were used. The plates 
used were capable of separating around 10-20 mg, depending on the 
separation efficiency required. Identification of an efficient solvent system which 
will adequately separate the compounds is crucial. Once the compounds were 
separated, the bands were scraped and extracted from the silica using varying 
ratios of chloroform and methanol. The filtrates were collected and evaporated. 
 
3.5.4 Nuclear Magnetic Resonance (NMR) 
 
Outline of method: NMR spectroscopy is an effective method for structural 
identification and orientation of compounds. It involves magnetic nuclei in 
magnetic fields absorb and re-emit electromagnetic energy. This energy is at a 
specific resonance frequency which depends on the strength of the magnetic 
field. Theoretically, the resonance frequency of a particular substance is directly 
proportional to the strength of the magnetic field.  
Protocol: Samples were dissolved in a deuterium solvent such as CDCl3, 
CD3OD and C3D6O and analysed using the 400 and 500 MHz NMR 
spectrometer (Bruker) at the London School of Pharmacy. Data obtained were 
analysed using the Bruker TopSpin application. 
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3.5.5 Mass Spectrometry (MS) 
 
Outline of method: MS is an analytical technique that measures the mass-to-
charge ratio of charged particles. It is used for determining masses of particles, 
for determining the elemental composition of a sample or molecule, and for 
elucidating the chemical structures of molecules, such as peptides and other 
chemical compounds. The technique has both qualitative and quantitative uses. 
These include identifying unknown compounds, determining the isotopic 
composition of elements in a molecule, and determining the structure of a 
compound by observing its fragmentation. The structure elucidated through 
NMR were confirmed by electro spray ionisation (ESI), accurate mass and 
electron impact (EI) spectrometer conducted by the Mass Spectrometry 
Department at the School of Pharmacy and University College London. 
 
3.5.6 Infra-red (IR) spectrophotometer 
 
Protocol: IR spectrum of the compounds were captured using a Perkin Elmer 
spectrum Express version 1.02 at the School of Pharmacy. The wavelength was 
scanned between 600-4000 cm-1. 
 
3.5.7 Ultra-violet (UV) spectrophotometer 
 
Protocol: UV spectrum of the compounds were obtained using a Syngene 
G:Box Transluminator at the School of Pharmacy. The wavelength used was 
200-800 nm.  
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4 Results 
 
4.1 Zingiber officinale Roscoe var. rubrum (ZOR) was selected for 
determination of active compounds that exhibited anti-inflammatory 
effects associated with psoriasis. 
 
In the preliminary stage of this study, twelve plants from Malaysia were 
screened for anti-inflammatory activity as measured by the suppression of NO 
and PGE2 production (will be discussed in detail in chapter 3). These extracts 
were obtained using two methods, which are the shaking and sonicating 
methods. Table 2.2 summarised the potency of the extracts based on their IC50, 
the concentration required to inhibit 50% of NO production by LPS-stimulated 
macrophages (RAW 264.7). Among these extracts, the extract from the ginger 
sp., Zingiber officinale Roscoe var. rubrum (Halia Bara) (ZOR) obtained via 
shaking method (HB01), was the most potent inhibitor of NO production with an 
IC50 of 10.2 ± 0.76 μg/mL. Based on these preliminary studies, it was decided to 
select Z. officinale Roscoe var. rubrum (Halia Bara) (ZOR) for further 
characterisation in this thesis. 
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Table 2.2: NO inhibitory effect of the selected plants. Comparison between 
extracts from indigenous Malaysian plant in their IC50 on the inhibition of NO 
production by stimulated RAW 264.7 cells.  
Code Plants 
NO inhibition (IC50, µg/mL) 
Shaking (SK) Sonication (SN) 
MP Mangifera indica 26.0 ± 6.9 17.0 ± 1.7 
KD 
Archidendron 
bubalinum 
489 ± 81 190 ± 69.0 
DN 
Artocarpus 
heterophyllus 
68.0 ± 10.0 45.1 ± 21.0 
MG Morinda citrifolia 417 ± 124 571 ± 260 
DS Artocarpus altilis 123.5 ± 21.5 >1000 
UB Ipomoea batatas >1000 >1000 
DK Piper sarmentosum NA 216 ± 101 
DP 
Pandanus 
amaryllifolius 
NA 2059 ± 255 
TS Crinum asiaticum 129.5 ± 3.5 NA 
HB01 
Zingiber officinale  
Roscoe  var. rubrum 
(Halia Bara) 
10.2 ± 0.8 NA 
UBM 
Marantha 
arundinancea 
>1000 NA 
AB Tinospora crispa 290 >1000 
 
Selected plant extracts with the best NO inhibitory effects (with the lowest IC50)  
are highlighted. The results represent the mean ± SD of at least three separate 
sets of experiments each with two replicates. *NA= not available. IC50 of           
L-NAME is 7.3 ± 1.8 μg/mL 
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Figure 2.5: Bioassay-guided fractionation process involved a series of 
anti-inflammatory screening of the selected plants. A work flow of the 
screening process of potential plant and active compounds with potent anti-
inflammatory effects relevant to psoriasis pathology. 
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The extraction method was optimised based on reported studies associated 
with ginger extraction method (97). Extract from ZOR was obtained using the 
solvent extraction method described in section 3.4. Extracts were obtained for 
comparison of biological effects using chloroform, ethanol or water (Figure 2.5).  
 
In the first stage of the extraction, ZOR powder was obtained by sonication for            
30 minutes in chloroform and left to macerate for 5 days at room temperature             
(Method section 3.4). The filtrate was collected and evaporated, and coded as 
HB02. The residue was left to dry and re-used for the next stage of extraction 
which was with ethanol with the same procedure and the extract coded HB03. 
Finally, water extraction was carried out and the collected filtrate was dried 
using a freeze drier and coded HB04. 
 
Bioactivity-guided fractionation studies of these ZOR extracts were carried out 
by screening of the most efficacious extract (Figure 2.5) based on their effect on 
the inhibition of NO (Table 2.2) production by activated macrophages 
(discussed in Chapter 3). Among the tested extracts, HB02 was selected due to 
its higher potency (IC50 = 10.2 ± 0.8 μg/mL) and, thus, further fractionated into 
21 fractions using VLC (Table 2.3a). Figure 2.6 shows the TLC profiles of the 
VLC fractions. Undergoing the same screening procedure, the VLC fraction, 
(F6) exhibited the highest potency among the 21 fractions. F6 was fractionated 
using a solvent mixture of 80% hexane in ethyl acetate. The TLC as well as 1H 
NMR profiles of F6 signified the presence of major and minor compounds. 
Therefore, in order to determine the specific compound/s contributing to the 
potency of F6, it was further fractionated using SPE (Table 2.3b) with solvent of 
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increasing polarity.  Based on the TLC and 1H NMR profiles of seven SPE 
fractions fron F6 obtained, fractions 3 indicated the presence of a mixture of 
compounds with the solvent system of 80% hexane in ethyl acetate (Figure 
2.7). Optimisation of the solvent system was carried out to obtain the best 
compound separation. 90-93% of hexane in ethyl acetate was the best solvent 
mixture for the isolation process. The purity of each of the compounds isolated 
from this process was assessed by NMR. Distinct separation of the NMR peaks 
indicates purity of a compound. Prep-TLC procedure was used to separate 
components from SPE fractions 3 (Figure 2.7).  
 
Finally, two compounds were identified after several stages of isolation and 
purification using SPE fraction 3 of F6 (Figure 2.7). Compound 1 (brown box) 
was purified using a solvent system of 93% hexane in ethyl acetate with 2% 
acetic acid in  2 stages of isolation.The percentage yield of compound 1 was 
0.017% from the crude extract (HB02). Compound 2 was isolated in two stages 
of prep-TLC in solvent system of 90% hexane in ethyl acetate with 2% of acetic 
acid.  The percentage yield was 0.012% from the crude extract (HB02). Both 
compounds were characterised by 1H-, 13C-NMR, DEPT and 2D-NMR      
(COSY, HMQC, HMBC) analysis. The structures were validated using ESI-MS 
in both positive and negative ion modes, accurate mass and electron impact 
MS. 
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Table 2.3: ZOR fractionation process utilising a) VLC and b) SPE method 
using hexane: ethyl acetate solvent system at variable ratio. 
VLC fractions Solvent system (volume in mL) 
Hexane : ethyl acetate 
1 200 : 0 
2 190 : 10 
3 180 : 20 
4 170 :30 
5 160 :40 
6 150 :50 
7 140 : 60 
8 130 :70 
9 120 : 80 
10 110 : 90 
(a) 
 
SPE fractions Solvent system (volume in mL) 
Hexane : ethyl acetate 
1 100 : 0 
2 90 : 10 
3 80 : 20 
4 70 :30 
5 60 :40 
6 50 :50 
7 40 : 60 
(b) 
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Figure 2.6: TLC profiles of VLC fractions from HB02 extracts of ZOR. Twenty one fractions (F1-F21) were fractionated from HB02 
extracts using VLC fractionation method as described in Method 3.5.1. Each of the fractions was spotted on TLC in hexane: ethyl acetate 
solvent system with a ratio of 80:20 The TLC profiles indicated abundance of compounds in each fraction. The anti-inflammatory effect of 
the fractions on NO production produced by macrophages was studied. The most potent fractions were further fractionated using SPE 
method as described in 3.5.2. 
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Figure 2.7: Isolation process of active compounds from ZOR. Fractionation and isolation processes of ZOR fractions 
(yellow) and compounds; compound 1 (brown) and compound 2 (green). VLC and SPE fractionation methods were used, 
utilising variable ratios of hexane and ethyl acetate mixture as the solvent system. These yielded a number of fractions. 
Compounds were isolated using Prep-TLC with solvent system of hexane: ethyl acetate (EtOAc): acetic acid. The structure of 
the isolated compounds was characterised and identified using NMR, MS, IR and UV as described in Methods. 
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4.2 Identification of anti-inflammatory components in F6 
4.2.1 Identification of compound 1 as 6-Shogaol 
 
Compound 1 from fraction 6 (F6) was a pale yellow liquid. Its structure was 
elucidated as 6-shogaol (Figure 2.8) by 1H and 13C NMR spectroscopy, and 
confirmed by comparison with data in the literature (121-123) 
 
Figure 2.8: The established structure of 6-shogaol 
1H NMR data of the compound showed proton signals of 1, 2, 4-substituted 
benzene rings (6.6-6.81, 3H), a methoxy signal (3.86, 3H), a benzyl proton 
signal (2.84, 2H). ketone α-proton signal (2.84, 2H), two olefinic proton signals 
(6.06-6.09, 1H and 6.84, 1H), signals for methylene groups (1.42, 2H, 1.26-1.32 
4H, 2.17-2.21 2H) and a methyl signal (0.89, 3H). Therefore, the compound is 
identified as 6-shogaol with a molecular formula of C17H24O3 and calculated 
molecular weight of 276.37.  
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Figure 2.9:  Electron impact (EI) MS spectrum of 6-shogaol. The spectrum 
indicates the presence of peaks at m/z 137, 205 and 276 due to fragmentation 
of keto group at C-3. 
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Figure 2.10: Fragmentation of the keto group at C-2.   EI  fragmentation of  
6-shogaol is consistent with previous findings (122). 
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Based on EI, the major peak was at m/z 137 (Figure 2.9). The product of 
fragmentation via electron bombardment  was similar to the product observed 
by Jiang et al (2005) (Figure 2.10)(122). Based on Figure 2.10, the 
fragmentation was most probably due to the keto group, a protonated group 
which favours ionisation to take place and thus leads to fragmentation at the α 
position at C-2.  
1H NMR (500MHz, CDCl3), δ: 0.89 (3H, t, H-10), 1.26-1.32 (4H, m, H-8 and H-
9), 1.42 (2H, m, H-7), 2.17-2.21 (2H, m, H-6), 2.84 (4H, m, H-1 and H-2). 3.86 
(3H, s, OCH3), 6.06-6.10(1H, dt, J= 3, 19, H-4), 6.60 (1H, td, J=2, H-6’), 6.70 
(1H, td, J=1.5Hz,H-2’), 6.81 (1H, d, J=7.5 Hz, H-5’) , 6.84 (1H, d, J=15.5 Hz,    
H-5). (Please refer to Figure 1 in the Appendices). 
13C NMR (125 MHz, CDCl3) δ: 13.7 (C-10, d), 22.6 (C-9, d), 27.9 (C-7, s), 29.6 
(C-8, m), 31.1 (C-1,d), 32.2 (C-6,s), 42.1 (C-2, s), 56.0 (OCH3, s), 111.0 (C-2’ , 
d), 114.2 (C-5’, s),120.5 (C-6’, s), 130.8 (C-4, s), 133.4 (C-1’, s), 143.8 (C-4’, s).                 
146.4 (C-3’, s), 148.3(C5, s), 200.2 (C-3, s) (Figure 2 in the Appendices). 
DEPT, COSY, HMQC, HMBC (Figures 3-6, the Appendices) 
IR Spectrum (cm-1): CH: 2930 (s), 2856 (m), C=C: 1667 (m) 1693 (m), 1516 (s),            
Aromatic: 1431-1464(m), C-O: 1271.41(s), OH: 3200-3600 (b) (Figure 7 of the 
Appendices). 
UV spectrum: 227 nm, 285nm (Figure 8 of the Appendices) 
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4.2.2 Identification of compound 2 as 1-dehydro-6 gingerdione 
 
Compound 2 identified in F6 was characterized as a pale yellow liquid. The 
structure (Figure 2.11) of this compound was elucidated by 1H and 13C NMR 
spectroscopy. 
 
1H-NMR data on the isolate showed proton signals of a 1,2,4-substituted 
benzene ring (6.91-7.09, 3H), methoxy signal (3.90, 3H), two olefinic proton 
signals (6.32, 1H and 7.54, 1H), ketone α-proton signal (5.62, 1H), ketone β-
proton signal ( 2.38, 2H), signals for methylene groups (2.38, 2H, 1.30-1.33 4H, 
1.56-1.67 2H) and a methyl signal (0.89, 3H). The compound could be identified 
in three tautomeric structures, based on keto-enol tautomerism. However, 
based on the 1H NMR data, it was suggested that the compound was an enol 
with the presence of a broad peak of an enol-OH at 15.53 ppm and CH at 
position 4 instead of a CH2 indicated in Figure 2.11(a). In order to differentiate 
whether the compound was a keto or an enol, a drop of methanol-D4 was added 
to the chloroform-D solution of the compound. The presence of the enol-OH 
peak was evident, whereby addition of a drop of methanol-D4 to the chloroform-
D solution of the compound eliminated the enol-OH peak at 15.53 ppm  
(compare figure 9 and 10 in the Appendices).   
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The UV spectrum of the compound in chloroform had two maxima at 258 and 
370 nm, which are associated with the ketonic and enolic forms, respectively. 
Their intensity, however, varied with the solvent (112). Morton et al (1934) 
observed that for benzoylacetone, two peaks were observed; 247 and 310 nm 
that were associated with total ketone and enol content. In addition, Kimura and 
colleagues suggested that UV absorption at 235 and 280 nm are characteristics 
of keto and enol of 6-gingerdione (112). Hence, these observations suggested 
that the peaks at 258 and 370 nm indicate the presence of ketonic and enolic 
forms within the alkyl chain of compound 2. However, there are two possible 
structures of the enol tautomer that have to be considered, as elucidated in 
Figure 2.11b) and c). To determine which of the enol conformations was 
dominant, MS analysis was carried out. 
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Figure 2.11: Tautomerism in the structure of 1-dehydro-6-gingerdione. 
Three tautomers were considered for the structure of compound 2 which were: 
a) a keto, and enol tautomers b) and c) of the dehydrogingerdione. 
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Electrospray ionisation, (+) ESI (Figure 2.12a) and (-) ESI (Figure 2.12b) 
indicated peaks of relative abundance at [M+H]+=291 and [M-H]-=289, 
respectively. This was consistent with findings by Jiang et al. (2005). The 
accurate mass validates the peak at 291.16 (Figure 18 in the Appendices). The 
calculated molecular weight, however, is 290.35. This suggested that the 
compound might be prone to accept and donate one hydrogen atom when 
ionisation occurs.  
 
The structures in Figure 2.11 indicate the tendency of the hydrogen at C-4 or 
the diketonic carbonyl at C-3 or C-5 to undergo ionisation in acidic and basic 
environments as demonstrated in Figure 2.13. Therefore, this indirectly 
validates the structure depicted in Figure 2.11(b) and (c). However, this was 
insufficient to validate the orientation of the speculated enolic diketone.  
 
Therefore, the sample was analysed via EI-MS using a forced fragmentation 
approach targeting at C-4 of the elucidated structure (Figure 2.14). 
Fragmentation at C-4 of the ketone-α proton yielded m/z at 177.15 indicating 
that the broken fragment contained a hydroxyl group at C-5. Thus, implying that 
a carbonyl group was present at C-3 in close proximity to the benzene ring. 
Hence, verifying the structure as elucidated in Figure 2.11(b).  
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(a) 
 
 
(b) 
Figure 2.12: ESI-MS of 1-dehydro-6-gingerdione .ESI spectrum a) (M+H)+ 
and  b)(M-H)-  indicate the presence of two major peak at 291.1 (M+H)+ and 
289.1 (M-H)- confirming the suggested molecular weight of 290.35 of the 
elucidated structure of the compound. 
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Base 
 
Acid 
 
Figure 2.13: Enol formation via basic and acidic-catalysed processes. 
Adapted from http://www.chem.ucla.edu/harding/notes/notes_14D_enolates.pdf 
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Figure 2.14: EI-MS of 1-dehydro-6-gingerdione. The approach manipulated 
forced fragmentation specifically at C-4 hence, supporting the 1H and 13C NMR 
data. The EI-MS data confirmed the enolic structure of 1-dehydro-6-gingerdione 
as elucidated in Fig.2.12 (b).   
 
1H NMR (500MHz,CDCl3 ), δ: 0.89 (3H, t, J=7Hz, H-10), 1.30-1.33 (4H, m, H-8 
and H-9), 1.56-1.67 (2H, m, H-7), 2.38 (2H, m, H-6), 3.90 (3H, m, OCH3), 5.62 
(1H, s, H-4), 6.32 (1H, d, J=16, H-2), 6.91 (1H, d, J=8.5, H-5’), 7.02 (1H, d, 
J=1.5, H-2’), 7.09 (1H, dd, J=2, 8.5, H-6’), 7.54 (1H, d, J=15.5, H-1), 15.53 (1H, 
brd, enol-OH). (Figure 9 and 10, the Appendices)  
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13C NMR (125 MHz, CDCl3) δ: 14.3 (C-10, t), 22.6 (C-9, t), 25.5 (C-7, t), 31.7 
(C-8, q), 34.1 (C-6, s), 56.1 (OCH3, s), 100.4 (C-4, s), 109.6 (C-2’, s), 114.0    
(C-5’, d), 120.74 (C-2, s), 122.8 (C-6’, d), 130.2 (C-1’, d), 139.8 (C-1, s). 146.93 
(C-4’, s), 147.81 (C3’, s), 178.17 (C-3, s), 200.9 (C-5, s). (Figure 11, the 
Appendices).  
 
DEPT, COSY, HMQC, HMBC (Figures 12-15, the Appendices) 
. 
IR spectrum (cm-1): C-H aromatic; 3012 (w), 1592.4 (brd, m), 1513 (s), 1434- 
1465 (m), C-H Aliphatic; 2933.1(s), CH aldehyde: 2867.4(m), enolic β-diketone: 
1640.6 (m), =CH OOP- (out-of-plane); 756.96 (Figure 16, the Appendices) 
 
UV spectrum:  258nm and 370 nm (Figure 17, the Appendices) 
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5 Discussion 
5.1 Bioactivity-guided fractionation of ZOR enabled identification of two 
active compounds. 
 
At the conception of this investigation, twelve plants of known traditional 
medicinal use from Malaysia were identified and collected. The constituent 
components of the plants were separately extracted using two extraction 
methods namely, shaking in 80% ethanol or sonication in 80% ethanol   
(Method 3.3).  
 
The extracts were tested for their anti-inflammatory effects by determining their 
ability to suppress the production of NO (Table 2.2) and PGE2 by activated 
macrophages (refer to Chapter 3). The results revealed that the extracts from 
ZOR demonstrated the strongest inhibitory effects for both inflammatory 
mediators. Thus, ZOR was selected for detailed analyses and to identify 
possible effects on inflammatory mechanisms relevant to psoriasis. Prior to this, 
the best solvent to use for the extraction for ZOR therapeutic components was 
determined. ZOR was extracted using maceration in chloroform, ethanol or 
water. Comparison of the inhibitory effects of the three extracts on NO and 
PGE2 production in activated macrophages was carried out. The analyses 
revealed that the extract obtained with chloroform (named HB02) had the 
strongest inhibitory effects on NO and PGE2 production and, thus, was further 
fractionated using VLC. This process yielded 21 fractions that were then 
individually analysed. Using the same procedure, these fractions were screened 
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for their effect on NO and PGE2 production and fraction 6 (F6) was selected for 
further assessment due to its potent inhibitory effects. F6 was further 
fractionated and characterised using the same screening procedures. At the 
end of the fractionation, isolation and purification processes, two compounds 
from F6 were obtained and characterized and these were determined to be 6-
shogaol and 1-dehydro-6-gingerdione, both gingerol-related compounds. 
 
These fractionation and isolation approaches were bioassay-guided and that led 
to the isolation of potential compound/s with the most potent anti-inflammatory 
effects relevant to psoriasis. This approach has enabled the development of 
shorter screening procedures and helped to determine the most effective 
therapeutic compounds in ZOR. Previous studies of ginger chemistry had 
suggested a range of extraction and isolation methods. As mentioned earlier, 
solvent extraction and supercritical CO2 extraction have been proposed to be 
best methods to extract pungent compounds that are temperature labile. The 
methods used in this study avoid the loss of potential compounds with 
therapeutic effects which could otherwise be lost by the use of high temperature 
(124), which is part of the steam distillation and soxhlet extraction processes. 
Furthermore, by utilising the prep-TLC technique, separation of components 
from small amounts of sample/starting material was possible.  
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5.2 1-dehydro-6-gingerdione and 6-shogaol are the initial and dehydrated 
products of 6-gingerol biosynthesis, respectively. 
 
The studies have identified two major compounds that were effective anti-
inflammatory components in the fraction 6 (F6), obtained from the chloroform 
extract HB02. 6-shogaol and 1-dehydro-6-gingerdione were isolated in 
respective percentages 0.017% and 0.012% from the oleoresin HB02       
(Figure 2.7).  6-shogaol is a pungent compound predominantly identified in 
dried ginger. It is a dehydrated form of 6-gingerol, a major pungent compound in 
ginger. In contrast, 1-dehydro-6-gingerdione is the initial product of the 
biosynthesis process of 6-gingerol. 
  
6-gingerol is susceptible to chemical transformation to less pungent constituents 
such as  6-shogaol during handling and processing due to its instability (111). It 
is thermally labile due to the presence of a hydroxy keto group in its alkyl side 
chain and is, thus, easily dehydrated to shogaol during storage (115). In a 
quantitative study by Kim et al. (2002) of 6-gingerol contents in 14 samples of 
ginger collected  in Korea, the investigators observed  that 6-gingerol is 
approximately 0.36% in fresh ginger, which decreased during processing to 
0.31% (111). Assuming that the percentile loss was due to dehydration of 6-
gingerol to 6-shogaol, 0.05% could be the maximum yield of 6-shogaol during 
the dehydration process. 6-gingerol can also be converted to other less pungent 
compounds such as 6-zingerone and hexanal by base catalysis, or by heat at 
temperatures above 200ºC (111). In this study, however, this is not the case, 
since the extraction processes were carried out at room temperature and 
elevated temperatures were not used. The conversion of gingerols to their 
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dehydrated forms is an indication of consequent deterioration in quality. The 
longer the drying period, the higher the loss of content of pungent compounds. 
Therefore, there could also be a reduction in the amount of 6-shogaol. During 
storage, 6-shogaol can  also undergo hydrogenation upon dehydration and 
convert to 6-paradol (Figure 2.16) (97). Therefore, the amounts of these 
compounds vary depending on various parameters before and after processing. 
 
The presence of these pungent compounds can be influenced by many 
variables such as ginger species (varieties and variants), geographical location 
of the ginger being collected, cultivation parameters and variables during 
storage (97, 111, 124). The extraction efficiency is also dependent upon other 
extraction variables such as solvents used, and the duration and method of 
extraction (111). The major pungent compounds, gingerols, were detected after 
6 hours of extraction in organic solvent and 2 hours  in liquid CO2 (125). 
Therefore, the percentage of these compounds in extracts is dependent on the 
consistency of the parameters used during pre- and post harvest, as well as 
extraction procedures used (115).  
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Figure 2.15: The process of 6-gingerol conversion to 6-shogaol and          
6-paradol. Adapted from Vernin et al. 2005 (97). 
 
Therefore, considering these variables and the limited number of studies on 
ZOR, the exact yield of 6-shogaol in ZOR was unknown. Its presence will 
increase during the drying process, nonetheless, at the same time it might be 
converted to other gingerol-related compound, such as 6-paradol. Unlike         
6-shogaol, 1-dehydro-6-gingerdione (GD) was proposed to be the initial product 
or precursor in 6-gingerol biosynthesis (Figure 2.3) (97, 126). This indicates that 
the presence of GD is an initial product in the biosynthesis of 6-gingerol in dried 
and processed ginger. It was proposed by Macleod et al. (1979) that in the 
biosynthesis of 6-gingerol (Figure 2.3), 6-dehydrogingerdione is the initial 
product after the incorporation of hexanoate, malonate and ferulate. 
Subsequently, either 6-dehydrogingerol or 6-gingerdione will be intermediate 
products, which then commence via C=O and C=C reduction to produce           
6-gingerol (113, 127). This mechanism was supported by Harvey (1981), except 
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for the suggestion that the precursor prior to GD synthesis is dihydroferulate 
instead of  ferulate (128).  
 
Only F6 of the VLC fractions was selected based on its highest anti-
inflammatory potency in comparison with the other fractions when compared 
with several established anti-inflammatory agents (Chapter 3). The data 
presented in this thesis, therefore, suggest that 6-shogaol and 1-dehydro-6-
gingerdione are likely to be the active therapeutic components of ZOR. 
 
5.3 1-dehydro-6-gingerdione isolated from ZOR exists in two forms of 
enolic tautomers 
 
6-Gingerdiones and 6-dehydrogingerdione in ginger were discovered as the 
intermediates in the biosynthesis of 6-gingerol, the major pungent compound in 
ginger (113). 6-Gingerdione was shown to possess both keto and enol forms in 
liquid and chloroform solvents. The enol form was shown to be dominant when 
chloroform was used as the solvent (ca. 80%) (129). The enolate form is 
favoured in an excess base environment and unsubstituted at the inter-carbonyl 
position which gives rise to steric inhibition of resonance. Therefore, the 
conformation is pH-dependent. 6-dehydrogingerdione, however, was suggested 
to exist in through-conjugated enolate in solid state and in solution.  
 
In neutral and acidic environments, both the keto and enol forms exist in 
equilibrium (130). Most carbonyl compounds exist in the keto form at equilibrium 
rather than the enol form which is normally present at a small percentage and 
difficult to isolate (131). However, increasing the acidicity of the environment 
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enables stabilisation of the keto tautomer through hydrogen-bonding interaction 
with solvent molecules. In contrast, in aprotic and nonpolar solvents, the enol 
tautomer predominates and it is stabilised by intramolecular hydrogen bonding. 
This suggests that tautomerisation is strongly influenced by the hydrogen-bond 
donor and acceptor properties of the solvent used (130). In terms of solubility, 
compound 2 is soluble in non-polar solvents such as hexane and chloroform, 
but insoluble in 70% ethanol, which is characteristic of an enol. It could also be 
a chelated enol, which is associated with lower solubilities in water but higher 
solubility in non-polar solvents compared with ketone (132).                            
This suggests that compound 2 which was identified as 1-dehydro-6-
gingerdione (GD) could have an enolate form rather that an open-chained enol 
which is characterised by higher solubility in hydroxylic solvents rather than 
hydrocarbons. 
 
In reference to studies by Denniff et al. (1981), the structure and molecular 
mass of 6-dehydrogingerdione closely resembles compound 2 obtained in this 
study (129). However, the structural orientation of the enolic moiety of                       
6-dehydrogingerdione was similar to the structure in Figure 2.11c while the 
structural characterisation of compound 2 is based on Figure 2.11b. The 
structure elucidation described here was supported by the presence of one        
α-hydrogen atom at C-4 between the two carbonyl atoms as indicated by the 1H 
NMR peak at 5.62 ppm (Figure 9 in the Appendices). The hydrogen atom is 
prone to be protonated and lead to the formation of an enolate ion in strong 
base. Enolate is a resonance hybrid for both keto and enol by the delocalisation 
of negative charges over both carbonyl groups. In this case, the delocalisation 
results in the formation of  enol, shown by the presence of the highly 
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nucleophilic double bond at C-4 which fits the structure elucidated in Figure 
2.11b. 
 
5.4 Compounds 1 and 2 demonstrate ‘drug-like’ structures. 
 
Numerous studies have shown that ginger has a broad spectrum of anti-
inflammatory activity involving multiple mechanisms of action. Several studies 
have demonstrated that ginger extracts possess similar effects to NSAID in 
inhibiting PG synthesis by inhibiting COX activity (115). Interestingly, some 
ginger constituents were found to have dual inhibitory effects against COX and 
LOX (lipooxygenase), thus, reducing the occurrence of gastrointestinal and 
renal side effects while expressing their anti-inflammatory effects (115). In 
addition, ginger extracts and its components have been shown to suppress 
expression of genes related to inflammation including genes encoding TNFα,  
IL-1β and the transcription factor, NF-κB (115, 117). Intriguingly, this highlights 
the potency of ginger as an anti-inflammatory agent with minimum side effects. 
 
Recently, studies have been carried out to determine the anti-inflammatory 
mechanism of action of ginger constituents using structure-activity relationship 
(SAR). In terms of their effect on COX-2, it was suggested that the presence of 
the phenolic hydroxy group adjacent to the methoxy group was critical for the 
inhibition of PG synthesis, A (Figure 2.16); as well as the substitution pattern of 
the hydroxyl and carbonyl moiety on the side chains, B (Figure 2.16) and the 
length of the side chain itself, C (Figure 2.16) (115, 118). Length of the side 
chain contributes to the lipophilicity of the compound. Based on the elucidated 
structures of 6-shogaol and 1-dehydro-6-gingerdione isolated from ZOR, the log 
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P value was estimated using the software known as jlogP; 
http://www.vls3d.com/JME_EditorOK.dir/run_jlogp.htmL. 
 
As mentioned earlier, log p is an estimated value of lipophilicity of a structure. 
The estimated log P value of 6-shogaol and 1-dehydro-6-gingerdione are 3.53 
and 3.12 respectively. These values are similar to those of ‘drug-like’ 
compounds according to Lipinski’s Rules of five Ro5 (logP ≤5) (133). Based on 
studies on the effect of gingerol-related compounds carried out by Tjendraputra 
et al.(2001) using IC50 vs. log P relationship, 6-shogaol demonstrated more 
potent activity than 8-shogaol (log P=4.9) with IC50 of 2.1 ± 0.3 μM and            
7.2 ± 0.4 μM, respectively. Thus, supported by the Lipinski’s Rules of five, the 
logP of a ‘druggable’ compound should be ≤5. This, therefore, suggests that     
6-shogaol and GD isolated from ZOR have the potential as ‘druggable’ 
compounds with good distribution and delivery to targeted systems. 
 
The structural orientation of 6-shogaol and 1-dehydro-6-gingerdione are 
differentiated by the orientation at B (Figure 2.16), which is the substitution 
pattern of the hydroxyl and carbonyl moiety on the side chain. Compared with   
6-shogaol, GD has a hydroxyl group as part of an enolic moiety which could be 
easily chelated. 6-shogaol only features one free hydroxyl whilst GD has a free 
hydroxyl and enol-hydroxyl groups in the alkyl chain. Therefore, the activity of 
both compounds could be differentiated by the presence of an enolic moiety 
which is more reactive as an enolate ion in basic solution. Both compounds 
contain one oxygen atom and at least one hydroxyl group which are hydrogen 
acceptors and donors, respectively.  
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Thus, this satisfies the criteria of a ‘druggable’ compound (hydrogen-donor≤5 
and hydrogen-bond acceptor≤10). However, Lipinski’s Rules of five is not an 
absolute indicator of the efficacy of a compound as a drug, instead, it is used as 
a preliminary guideline to identify drug candidates in natural product research 
and drug discovery. 
 
 
 
 
 
 
 
 
 
Figure 2.16: The structural orientation of a) 6-shogaol and b) 1-dehydro-6-
gingerdione. Structural orientation of 6-shogaol and -dehydro-6-gingerdione 
denotes by A , B and C, contribute to the activity of the compounds (112, 115, 
118). 
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6 Conclusions 
 
To-date, various studies have been performed to identify active therapeutic 
constituents and potential biological activity of various ginger species. The 
majority of these studies identified a number of non-volatile pungent agents as 
potentially the major components that potentially contribute to specific functional 
effects of various types of ginger extracts. The most studied are the gingerols 
and gingerol-related compounds. The biological efficacy and potency of these 
compounds are suggested to be determined by the presence of: a) the phenolic 
hydroxy group adjacent to the methoxy group; b) the substitution pattern of the 
hydroxyl and carbonyl moieties on the side chains; and c) the length  of the side 
chain itself  (115, 118). 
 
There are, however, very limited studies on the chemical composition and 
biological activity of ZOR. This study has identified two constituents from the 
most active fraction of ZOR which are 6-shogaol and 1-dehydro-6-gingerdione. 
Previously, these compounds have been discovered and structurally 
characterised in common ginger and other ginger species (121, 134, 135). This 
study show that 1-dehydro-6-gingerdione isolated from ZOR is in the enolic 
conformation as shown in Figures 2.11(b) & 2.16c. This structure is 
characterised by the presence of a carbonyl group near the aromatic ring rather 
than a hydroxyl group as elucidated by Macleod et al. (1979) and Denniff et al 
(1981) (113, 129). The significance of the –OH at C-5 was discussed by 
Tjendraputra et al. (2001) whereby, gingerol-related constituents with this 
orientation were shown to exhibit inhibitory effects on COX-2 activity via H-
bonding and hydrophobic interaction to the binding site of this enzyme. 
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Based on previous studies, 6-shogaol is known to be present in dried ginger  
(111) whilst 1-dehydro-6-gingerdione is present in fresh and dried ginger (121).          
6-shogaol is a dehydrated form of 6-gingerol whilst 1-dehydro-6-gingerdione is 
an initial product in 6-gingerol biosynthesis. Assuming that 6-gingerol is 
essentially present in fresh ginger, 1-dehydro-6-gingerdione should be available 
as well. Therefore, this could be an indication of the ‘freshness’ or the ‘quality’ of 
the extract. It is worth noting that, the proportion of these compounds varies 
between species and variants, depending on the pre- and post- harvest 
processes. 
 
Through the evaluation of the structure orientation of each compound, it could 
be deduced that they demonstrate ‘druggable’ criteria as stated by Lipinski’s 
Rule of Five (Ro5)(133) and match the proposed SAR characteristics of 
gingerol-related compounds proposed by in previous studies (112, 115, 118). 
Therefore, due to their ‘druggable’ potential, these compounds were studied for 
their effects on key mechanisms implicated in the pathogenesis of psoriasis as 
will be discussed in the following chapters. 
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CHAPTER 3 
 
Modulatory effects of ZOR in 
inflammation: Inhibition of NO 
and PGE2 production 
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1 Introduction 
1.1 Macrophage activation by autoreactive lymphocytes promotes 
psoriasis pathogenesis 
 
Numerous studies have provided evidence  that the initiation of psoriatic 
plaques is a consequence of the activation of dendritic cells (DCs) and 
macrophages (136). Both DCs and macrophages serve as antigen presenting 
cells (APC) to T-lymphocytes during adaptive immune responses. The two cell 
types are differentiated partly by their migratory ability. Thus, macrophages are 
non-migratory cells, as they normally reside in tissues. Whilst, DC migrate and 
interact with naive and memory T-lymphocytes throughout their migratory 
routes. Further, due to the plasticity of these two cell types, their functions could 
only be distinctly differentiated by the cytokines they produce upon their 
activation (137). 
 
In the early stages of inflammation, DCs and macrophages play significant roles 
in combating the source of inflammation by releasing nitric oxide (NO) and 
prostaglandin (PGs). However, prolonged inflammation causes the production 
of high levels of these pro-inflammatory mediators, leading to chronic 
inflammation-associated cellular and tissue damage as seen in various 
autoimmune diseases such as rheumatoid arthritis and psoriasis. Polymorphism  
in the promoter region of iNOS has been suggested to attenuate the affinity with 
which transcription factors bind to gene, thus, leading to various diseases (138). 
The role of iNOS and its products have been implicated in the pathogenesis of 
psoriasis. Early findings indicated that iNOS was detected in the basal 
epidermis of lesional skin in concert with the production of IL-8, a known 
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chemotactic cytokine involved in the initiation of inflammation (139). Further 
findings by Bruch-Gerharz and colleagues (1996) suggested that iNOS may be 
involved in the early phases of psoriatic lesion formation and that its presence 
within the lesion could be induced by IL-8 (139). 
 
Myeloid DCs (CD11c+), which are abundant in the dermal layer, are known as 
TNF- and iNOS-producing DCs, or TIP-DCs. In addition to producing high 
levels of TNF and iNOS, TIP-DCs produce IL-23, IL-12 and IL-20 which 
activate T-cells and upregulate gene transcription in keratinocytes through 
activation of STAT-3. TIP-DCs are found in large numbers in psoriatic lesions 
and, in some cases, outnumber T-cells in psoriatic plaques (31). Cytokines 
produced by TIP-DCs play critical roles in initiating Th1 and Th17 T-cell 
differentiation and proliferation (31).  
 
During inflammation, iNOS-induced NO production in the dermal layer is 
mediated by macrophages and keratinocytes. Consequently, NO potently 
regulates keratinocytes growth and differentiation, and is implicated in psoriasis. 
(45). This indicates that NO plays an important role in molecular signaling that 
facilitates crosstalk between macrophages, T-cells and keratinocytes in 
psoriasis. In addition to NO, PGE2 has been suggested to participate in the 
pathogenesis of psoriasis. PGE2 is known to induce DC to produce IL-23 which, 
in turn, promotes Th17 cell differentiation (8). These findings suggest a key role 
for DCs and macrophages during the initiation of inflammation. 
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1.2  NO and PGE2 can play paradoxical roles in autoimmune 
inflammatory diseases 
 
NO is produced as a result of the action of nitric oxide synthase (NOS) on          
L-arginine. There are two isoforms of NOS: 1) constitutive NOS including 
endothelial NOS (eNOS) and neuronal NOS (nNOS) and 2) inducible NOS 
(iNOS). Constitutive NOS is a key regulator of homeostasis. In contrast, iNOS 
plays an important role in host-defence responses. The iNOS protein is 
composed of two catalytic domains encoded by 27 exons; 1-13 for the 
oxygenase domain while 14-27 encode the reductase domain. Unlike 
constitutive NOS that are only present in specific cells and produce small  
amounts of NO,  iNOS is present in various cells and produce high levels of NO 
for a prolonged period of time (140). 
 
PGE2, in contrast, is generated via cyclooxygenase (COX). Similarly, COX 
exists in two isoforms; one is constitutive (COX-1) and one is inducible (COX-2). 
The inducible forms of NOS and COX have been implicated in many 
inflammatory conditions as a component of the inflammatory response. Once 
these enzymes are activated, NO and PGs are produced continuously at sites 
of inflammation. Paradoxically, however, these inflammatory mediators play 
double-edged roles, both in sustaining homeostasis and exacerbating 
inflammation. Various studies have been carried out to understand the 
pathogenic and therapeutic roles of NO and PGE2.  
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iNOS and COX-2 are induced and regulated through a number of mechanisms 
and by a number of mediators. Crosstalk between these two pro-inflammatory 
enzymes has attracted much interest but data generated so far are conflicting. 
A number of studies indicate that NO could activate and regulate COX enzyme 
activity and, thus, regulate PGE2 production. For instance, adding IL-1β and NO 
donors, such as sodium nitroprusside (SNP), to human foetal fibroblast was 
shown to increase PGE2 production, which decreased with the addition of 
haemoglobin, a known NO scavenger (141). However, prolonged induction (>24 
hours) of PGE2 with NO donor  was shown to inhibit COX-2  (142).  This 
observation was supported by D'Acquisto and colleagues, showed that NO 
donors SNP and S-nitroso-glutathione (GSNO) inhibited COX-2 and PGE2 
production by increasing IκB-α protein expression and, thus, blocking NFκB 
activation (143). These findings identify the potential negative feedback 
mechanism by which NO down-regulates COX-2 activity.  
 
Liu and colleagues (2009) suggested that COX-2 activity is modulated by NO 
through transcriptional and post-transcriptional mechanisms (141). It is 
established that both COX-2 and iNOS are regulated by modulation of NF-κB, a 
transcription factor located in cytoplasm, which consists of a p50/p65 
heterodimer attached to an inhibitor protein subunit, IκB. Upon stimulation by 
endotoxins (e.g. LPS), or by cytokines, IκB kinase (Iκk) phosphorylates the 
regulatory domain of the inhibitory κB (IκB) protein leading to its degradation. 
The degradation of IκB enables NF-κB to enter the nucleus where it initiates the 
transcription of many pro-inflammatory genes. It was reported that NO 
enhances the activity of IKK-α, or DNA-binding of NF-κB (142). This in turn 
could lead to the activation of COX.  Moreover, NO was proposed to modulate 
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COX-2 enzymatic activity via iNOS selective binding to COX moiety which 
enables accessibility of NO molecule to the COX-2 active site. NO could also 
up-regulate COX-2 activity by nitrosylation of the cysteine residue at position 
152 (Cys-152) within the active site of COX-2, or suppress COX-1 activity by 
nitration of tyrosine residues (Tyr385) at COX-1 active site (144). This supports 
the suggestion by Salvemini et al. of an inter-relationship between the two 
pathways (140, 145). Thus, these investigators proposed a direct interaction 
between NO and COX leading to increased COX activity. During acute 
inflammation, excess amounts of free radicals, such as superoxide, are 
generated that in turn scavenge NO to produce highly reactive peroxynitrite 
(ONOO-) (Figure 3.1). Together with NO, peroxynitrite plays a role in further 
activating COX (Figure 3.1) which, leads to increased prostaglandin (PG) 
production.  
 
However, questions were raised as to whether COX and its products could 
modulate the NO pathway. Earlier studies proposed that products of the COX 
pathway do not modulate iNOS activity as suggested by the  effect seen with 
indomethacin (a non-selective COX inhibitor) on arthritis, whereby the drug only 
blocked PG rather than NO production (145). In contrast, D'Acquisto and 
colleagues showed that iNOS protein expression in the LPS-stimulated J774 
mouse macrophage cell line was down-regulated by PGE2 and iloprost             
(a prostacyclin analogue) through the inhibition of NF-κB. Nevertheless, the 
study showed that PGE2 and iloprost were only effective at the transcriptional 
level and had no direct effects on iNOS enzymatic activity (146). Thus, it has 
been regarded as an advantage of selective iNOS inhibitors that would have a 
dual inhibitory effects on both NO and NO-driven COX-s activation, while 
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maintaining cytoprotective roles of constitutive enzymes such as cNOS against 
inflammation (140). 
 
The overall picture, therefore, reveals an inter-relationship between iNOS and 
COX during inflammation (Figure 3.1). The presence of both enzymes is 
important in innate immunity during infections and inflammation. Nevertheless, 
when produced in excess, they cause chronic inflammation as seen in 
autoimmune diseases. These observations have led to the emergence of a 
number of non-steroidal anti-inflammatory (NSAID) drugs that modulate the 
COX pathway. However, although there are numerous studies on drugs 
targeting the NO pathway non-specifically, few drugs have been designed to 
specifically target this pathway, particularly targeting iNOS (141).  
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Figure 3.1: A sketch showing the proposed crosstalks between the iNOS 
and COX-2 pathways. The crosstalk involves molecular mechanisms at 
transcriptional and post-translational levels via the NF-κB pathway. Solid arrow 
indicates direct effects whilst dashed arrow indicates indirect effects. Adapted 
and modified from Salvemini(140). 
 
1.3 Anti-inflammatory effects of ZOR extract, fractions and constituents 
 
It is established that ginger extracts have modulatory effects on various 
mechanisms and pathways involved in inflammation. For example, a number of 
studies have suggested that extracts from dried ginger inhibit prostaglandin 
biosynthesis (112). As cited in chapter 2, phenylpropanoids, or gingerol-related, 
compounds isolated from ginger including gingerol, shogaol and paradol have 
anti-oxidative, anti-inflammatory and anti-cancer effects. These inhibitory effects 
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on prostaglandin biosynthesis appear to correlate with the length of their 
aliphatic tail, with longer chains leading to higher affinity and enhanced 
inhibitory effects (117). Among these compounds, 10-gingerol, 10-shogaol and 
1-dehydro-10-gingerdione(1-DH-6-GDO) show the strongest effects. 
Interestingly, it appears that the orientation of hydroxyl, methoxy and carbonyl 
groups in the structure of these compounds is important to determine the 
potency of the phenylpropanoid species as anti-inflammatory agents (115).  
 
Although ginger has been shown to contain some of these constituents there 
have been limited studies on the effectiveness of extracts obtained from ZOR 
and on the potential anti-inflammatory constituents of ZOR. Previous studies 
have identified some potentially-active ingredients from the essential oil of this 
ginger species (107). Further, anti-bacterial effects of ZOR has also been 
studied (102). To-date, ethanolic extracts from ginger species similar to ZOR 
collected from Indonesia have been studied for their anti-arthritic effects in 
acetic acid-induced mouse writhing model (147). This study showed that the 
ethanolic extract had major inhibitory effects on PGE2 but minor effects on NO 
inhibition. The inhibitory effects on NO production were reported to be due to 
the presence of high levels of 6-shogaol, gingerdiol and proanthocynidin in the 
extract. 
 
Studies by Frondoza and colleagues identified potential mechanisms that could 
underlie the effect of ginger on inhibiting COX-2  and NF-κB activity to induce 
PGE2 and  TNFα production in human synoviocytes, respectively (148).  This 
finding was supported by Pan and colleagues who showed that 6-shogaol 
obtained from ginger inhibited iNOS and COX-2 gene transcription in 
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macrophages through down regulation of NF-κB activation and blocking the 
activation of PI3K/Akt/IKK and MAPK (149). As discussed earlier, NF-κB is 
involved in the transcription of the genes encoding NOS and COX. Besides the 
effect ginger in suppressing gene induction by NF-κB, computational modelling 
of protein ligand docking has provided further insights that 6-gingerol and          
6-shogaol,  can directly inhibit COX. These compounds have been suggested to 
have the potential as direct inhibitors of COX-2 enzyme due to their affinity for 
COX-2 active sites (150). Although, by and large, this is a theoretical approach, 
it provides a useful possibility to understand how ginger could modulate 
inflammation. 
2 Objectives 
 
The objectives of the experiments in this chapter were to explore the anti-
inflammatory potential of ZOR in comparison with established pharmaceutical 
compounds, its mechanisms of action and the specific effects of compounds 
isolated from this species of ginger. Twenty four crude extracts from 12 
Malaysian plants were initially studied for their anti-inflammatory effects such as 
the inhibition of NO and PGE2 production and suppression of iNOS and TNFα 
gene transcription. Among the plants studied, ZOR extract was selected due to 
its highest efficacy in inhibiting NO and PGE2 production. ZOR extracts were 
further refined and characterised as reported in chapter 2. Further, compounds 
isolated from the most active fraction of ZOR were studied in detail for their 
effects on mediators of inflammation that are produced by activated 
macrophages. 
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3 Methods 
 
3.1 Samples 
 
Concentrated stocks of extracts and HB02 VLC fractions described in Chapter 2 
were prepared in DMSO at 50 mg/mL. HB02 compounds were prepared at     
10 mg/mL. These stocks were diluted in DMEM and tested at various 
concentrations throughout the experiments. The effect of HB02, fractions and 
compounds on the inhibition of NO production was compared with L-NAME     
(L-NG-Nitroarginine methyl ester)(Sigma) a known NO inhibitor. Similarly the 
effect of the test samples on inhibiting PGE2 production was compared with 
Indomethacin (Fluka), a known inhibitor of PGE2 production and with 
dexamethasone (Sigma). 
 
3.2 Cell culture   
 
The murine macrophage cell line (RAW 264.7) was used in stimulation 
experiments to induce NO and PGE2 production. The cell line was maintained in 
DMEM (BioWhittaker LONZA) supplemented with 10% FBS (GIBCO) and     
1000 U/mL penicillin and 100 μg/mL streptomycin. The cells were incubated at 
37ºC with 5% CO2 in a humidified incubator. The cells were sub-cultured when 
reaching 90% confluence by dilution at 1:10 ratio with fresh medium, or at 
approximately 2 x 105cells/mL in fresh medium. Generally, the cells reached 
confluence after 2 days of incubation. Subsequent experiments to determine 
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optimal conditions for using the cells showed that it was essential to make sure 
that the cells were in the log phase before splitting them for stimulation.  
Assessment of the best conditions for the growth of RAW 264.7 cells was 
carried out for high cell viability (more than 80% confluence). Before 
subculturing, cells were detached from the plate using trypsin EDTA (170000U) 
(BioWhittaker LONZA) and viable cells was counted using an inverted 
microscope (Nikon TMS). The cells in suspension and the trypan blue solution 
were mixed at equal volumes and cells counted in 4 chambers of the 
haemocytometer. The number of cells in the suspension was determined 
according to the calculation: 
 
Cells per 4 grids x dilution factor* x 104** = number of cells/mL 
(*Dilution factor =2 as the cell suspension was diluted with an equal volume of 
trypan blue; **the haemocytometer retained a volume of 10-4mL.  
 
3.3 Optimisation of protocols used for cell culture conditions, treatment 
and stimulation to induce NO and PGE2 production 
 
During the early stages, it was decided to optimize the methods to identify the 
most favourable conditions for murine macrophages to induce maximal 
amounts of NO and PGE2. In order to determine the most effective stimulation 
method for NO and PGE2 production, the RAW 264.7 cells were stimulated 
using two approaches: 1) the cells were stimulated with LPS; and 2) the cells 
were stimulated with a cocktail of pro-inflammatory cytokine and LPS. The 
stimulating cocktail contained 10 μg/mL LPS (Sigma), 20 ng/mL TNFα 
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(Peprotech) and 20 ng/mL IL-1β (Peprotech) whereas in the LPS stimulation 
assay, the cells were stimulated with 0.1 μg/mL LPS. Besides using additional 
amounts of pro-inflammatory cytokines, in the cocktail method, higher density of 
cells with longer incubation periods were used. NO produced by the activated 
RAW 264.7 cells was compared in two stimulation protocols namely stimulation 
with LPS+TNFα+IL-1β (LPS + CT) and stimulation with LPS. The efficacy of 
these methods was assessed on the amount of NO produced. The method that 
produced the highest and NO was selected.  
 
Prior to stimulation with the LPS and the cytokine cocktail, RAW 264.7 cells 
were cultured at a density of 1x106 cells/mL in 12 well plates and incubated for 
24 hours at 37°C in 5% CO2. After incubation, dilutions of the extracts, or 
positive control, (L-NAME, a NO inhibitor), were added to the cells and cultured 
for a further 24 hours before stimulating the cells with the cytokines cocktail    
(10 μg/mL LPS, 20 ng/mL TNF-α and 20 ng/mL IL-1β). After 24 hours of culture, 
supernatants were collected for NO and PGE2 measurements and the cells 
harvested for RNA extraction. This approach was used in the preliminary study 
on the NO and PGE2 inhibitory effects of the twelve types of plant.  
 
In the subsequent studies on the effect of Z,officinale Roscoe var. rubrum 
(ZOR) (Halia Bara) extracts, fractions and compounds on NO and  PGE2 
production,  RAW 264,7 cells were stimulated only with LPS. Two culture 
conditions were used to assess the optimal activation conditions for the       
RAW 264.7 cells with LPS. In the first approach, the cells were cultured in       
24-well plates at a density of 2.5x105 cells/mL with 1 mL per well. The cells 
were then incubated for 24 hours at 37ºC in 5% CO2. A range of plant extract 
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dilutions were prepared and 100 µl of each dilution added to a total volume of 
1000 µl to each well and incubated for 30 minutes. The cells were then 
stimulated with 0.1 μg/mL LPS and cultured for a further 24 hours. Supernatants 
from the cultured cells were collected and centrifuged at 1700 g at 4ºC to 
remove cell debris. NO and PGE2 measurements were then performed. The 
level of pro-inflammatory cytokines was also determined in the supernatants by 
enzyme linked immunosorbant assay (ELISA). mRNA level of cytokines were 
determined using quantitative reverse transcription polymerase chain reaction 
(qRT-PCR). 
 
For the second culture condition, the cells were first stimulated with 0.1 μg/mL 
LPS for 12 hours before treatment with ZOR extract (HB02), fractions or 
compounds. The treated cells were then incubated for a further 24 hours. 
Supernatants were then collected as indicated previously. NO and cytokines 
protein levels were then quantified. The cells were used for mRNA extraction 
and cytokine gene transcript levels using qRT-PCR (real-time PCR). 
 
3.4  Measurement of NO 
 
The NO content of the supernatants was measured using the Griess reagent 
which measures nitrite, a stable product of NO. One hundred μl of culture 
supernatants were dispensed into 96 well plates followed by the addition of     
100 μl of Griess reagent (1% sulphanilamide in 2.5% phosphoric acid and 0.1% 
naphthylenediamine in dH2O). Absorbance at 560 nm was measured within     
10 minutes using a microplate reader (TECAN GENios). Nitrite contents were 
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calculated by extrapolation from a standard curve constructed using known 
concentrations of sodium nitrite, 0-100 μM. 
 
3.5 Measurement of PGE2 
 
PGE2 was measured using a PGE2 ELISA kit (R & D Systems) and an HTRF 
PGE2 kit (CISBIO). The PGE2 ELISA kit was used as one of the screening tools 
in the preliminary study to select plants with anti-inflammatory activity for further 
studies. Supernatants from the cultured RAW 264.7 were collected as 
described above and stored at -80ºC until tested.  
 
For the PGE2 ELISA kit, 150 µl of supernatants, negative control and PGE2 
standard dilutions (0-2500 pg/mL) were added to each well, that were pre-
coated with goat anti-mouse polyclonal antibody. To the samples was added   
50 µl of primary antibody with specificity to PGE2 with the exception of wells 
designated as blank (NSB) to which only 50 μl of buffer was added. The plate 
was incubated for 1 hour at room temperature on a horizontal orbital shaker at       
500 ± 50 rpm. Later on, 50 µl of PGE2 conjugated to horseradish peroxidise 
(HRP) was added and the plate was incubated for a further 2 hours on the 
shaker. The wells were then aspirated and washed 4 times with wash buffer 
(PBS containing 0.05% Tween 20; PBS/T). The plate was aspirated and blotted 
dry on a clean paper towel to remove any residual wash buffer. Two hundred µl 
of the substrate was added into each well and the plate incubated for               
30 minutes on the bench with minimal light exposure. Finally, 100 µl of stop 
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solution (2N sulphuric acid) was added and the OD measured at 450 nm 
(reference: 560 nm) using microplate reader (TECAN, GENios).  
The HTRF PGE2 kit (CISBIO) was used in the subsequent experiments to more 
precisely assess the therapeutic effect of ZOR extracts, fractions and 
compounds in regulating PGE2 production by activated RAW 264.7 cells. 
Assays were performed in a 96-well microtitre plate format, requiring 25 μl of 
each reagent (which were anti-PGE2 antibody labelled with cryptate (anti-PGE2 
cryptate), PGE2-d2 and buffer) and 50 μl of sample, standard or diluents (for 
negative control) to a total volume of 100 µl. PGE2 standard was diluted in a 
range of 0-1667 pg/mL from a stock solution of 5000 pg/mL.  
 
This assay is a competitive immunoassay based on HTRF® technology 
(Homogeneous Time-Resolved Fluorescence) and involves competitive binding 
between PGE2 produced by cells and d2-labeled PGE2 to monoclonal anti- 
PGE2 antibody labelled with Cryptate.  The HTRF® is based on Forster’s 
Resonance Energy Transfer (FRET) between a Europium (Eu3+) Cryptate 
(donor) and a second fluorescent label (acceptor), d2 when both are in close 
proximity. The excitation of the donor at 620 nm triggers FRET toward the 
acceptor leading to detection of emission signal at 665 nm using a Berthold 
Mithras LB 940 mutlimode plate reader (Berthold Technologies). The signal is 
inversely proportional to the concentration of PGE2 in the sample. PGE2 levels 
were calculated by interpolation from a PGE2 standard curve plotted using 
known standards and a curve fit program (GRAPHPAD PRISM).  
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3.6 RNA extraction 
 
RNA was extracted in a RNase and DNase free environment and using sterile 
consumables. RAW 264.7 cells were harvested and lysed using lysis/binding 
solution of RNAqueous®-4PCR kit. Sample lysates were mixed with ethanol and 
applied onto the provided AMBION®  column  which selectively bound to mRNA 
and larger ribosomal RNA. The RNA extracts were treated with ultra-pure 
DNase I to remove any contaminating DNA. mRNA yields varied depending on 
the type and amount of sample. Generally, about 1 µg of mRNA was obtained 
from 1x105 cells. The yield of mRNA (ng/μl) was determined using a NanoDrop 
1000 spectrophotometer, at 260 nm. Ratio of 260/280 nm was used to assess 
the purity of the isolated RNA. The ratio of pure RNA is ~2.00. RNA was stored 
at -80 ºC prior to use. 
 
3.7 RT-PCR 
 
Twenty ng of total RNA extracted from cell lysates were reverse transcribed to 
single-stranded cDNA in a 20 μl reaction mixture using High-Capacity cDNA 
Reverse Transcription Kit. The master mix was prepared on ice prior to addition 
of mRNA. The master mix contained a final concentration of 1x RT buffer, 4 mM 
dNTP mix, 1x RT primer, RNase inhibitor (100U)  and multiscript reverse 
transcriptase (50U). RNA samples were pre-heated at 65ºC for 5 minutes prior 
to mixing with the master mix. The condition for reverse transcription was; 
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Denaturation 95ºC   10 minutes 
Annealing 37 ºC   120 minutes 
Extension 85 ºC   5 second 
  
The generated cDNA was then used for PCR for assessing the level of pro-
inflammatory cytokines transcripts using glyceraldehydes 3-phosphate 
dehydrogenase (GAPDH) gene as a control. The reactions were carried out 
using a PCR kit (PROMEGA). Master mixes were prepared prior to adding 
cDNA from the above experiments. The master mixes consisted of final 
concentration of 1x TAQ buffer, 1.5 mM MgCl2, 2 mM dNTP, selected forward 
and reverse primers (2 mM) and GoTaq DNA polymerase enzyme (5U). 
Samples were subjected to 34 amplification cycles using Peltier Technology 
Thermal Cycler (PTC-200 MJ Research) according to these conditions; 
 
Initial denaturation 95 ºC   2 minutes (1 cycle) 
Denaturation 95 ºC   30 second  (34 cycle) 
Annealing 60 ºC   30 second  (34 cycle) 
Extension 72 ºC   30 sec/ kb (34 cycle) 
Final extension 72 ºC   10 second  (1 cycle) 
  
 
                                                                                                           CHAPTER 3                                                                                                                                                                                                                            
 
 
121 
The PCR products were visualized with ethidium bromide (10 mg/mL, BDH) for 
DNA staining following agarose gel electrophoresis. The gels consisted of 1% 
agarose in 0.5x TAE buffer (containing 0.02M Tris acetate and 1 mM Na2EDTA 
pH 8) and 5 μl ethidium bromide. Fragment sizes were confirmed by 
comparison with a 1 kb DNA ladder molecular weight marker (Invitrogen). The 
level of iNOS transcripts were assessed using primers for the murine iNOS 
gene (95 bp) and TNFα (175bp),  and house-keeping gene, GAPDH (480 bp) 
(Table 3.1). 
 
Table 3.1: Summary of PCR primers used in the experiments. 
Primer Sequence 5’ – 3’ 
GAPDH_for CACCATCTTCCAGGAGCGAGA 
GAPDH_rev ACGGAAGGCCATGCCAGTGA 
iNOS_for CAGCTGGGCTGTACAAACCTT 
iNOS_rev CATTGGAAGTGAAGCGTTTCG 
TNFα_for CATCTTCTCAAAATTCGAGTGACAA 
TNFα _rev TGGGAGTAGACAAGGTACAACCC 
 
3.8 Real time PCR (quantitative PCR) 
 
Real time PCR enables the monitoring and quantification of changes in RNA 
levels. The target gene is detected when it is first amplified at a given point of 
time during the DNA amplification process. 5.5 μl of ABsolute SYBR Green 
ROX mixes (THERMO Scientific) and 0.5 μl of TAQMAN® gene expression 
assay probes (Table 3.2) were mixed with 6 μl of the samples cDNA. TAQMAN 
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gene expression consists of 3 oligonucleotides which are forward and reverse 
primers along with a TAQMAN probes with attached fluorosphores; reporter dye 
and a quencher.  The primers bind to specific targets and anneal to the DNA 
template. The TAQMAN probe covalently bind DNA template between the two 
primers. During PCR, DNA polymerase adds nucleotides and removes the 
TAQMAN probe. This permanently separates the quencher from the reporter 
fluorophore and energy is then emitted by the reporter fluorophores which is 
detected as fluorescence. Thus, signal increase is proportional to the amount of 
the PCR product. DNA concentrations can be quantified by plotting 
fluorescence against cycle number on a logarithmic scale.  
 
A threshold of fluorescence above background is established. The sample 
fluorescence which intersects the threshold is called the cycle threshold (CT). 
The expression of gene of interest (GOI) in  test samples was normalised to 
GAPDH (reference gene) and expressed as a relative value using the 
comparative CT method (
Ct) (151). The reference gene is used as the 
baseline for the expression of the target gene and is considered a benchmark. 
The CT value of the target gene is determined and normalized with the CT 
values of the reference gene to obtain Ct. Ct values which are the relative 
quantitative expression of the target gene. This method relies on measuring the 
GOI relative to that of a reference gene which in these studies was the GAPDH 
gene (Table 3.2). 
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Table 3.2: TAQMAN pre-designed primers from murine source   
Primer Sequence Amplicon length 
GAPDH TAQMAN assay ID: Mm99999915_g1 
NCBI RefSeq: NM_008084.2 
107 
iNOS TAQMAN assay ID: Mm01309898_m1 
NCBI RefSeq: NM_010927.3 
81 
 
3.9 Bicinchoninic acid assay (BCA assay) for protein quantification 
 
The purpose of conducting this assay was to standardise the amount of protein 
to be loaded on the NuPAGE gel (Invitrogen) for Western blot analyses. Cells 
were washed with PBS and lysed using RIPA buffer (50 mM Tris-HCl, pH 8.0, 
with 150 mM sodium chloride,1.0% Igepal CA-630 (NP-40), 0.5% sodium 
deoxycholate, and 0.1% sodium dodecyl sulphate) and 10 µl/mL protease 
inhibitor cocktail (containing AEBSF, Aprotinin, Bestatin, E64, Leupeptin and 
Pepstatin) (Sigma). Cells were left on ice for 10-15 minutes and then 
centrifuged (1700 g) at 4ºC for ~10 minutes to eliminate any protein residues. 
The supernatants were collected and either tested immediately or stored at         
-80ºC until tested.  
 
The concentration of proteins in the cell lysates was determined using the 
BCATM protein assay kit (Thermo Scientific). Cell lysates were diluted in RIPA 
(1:1 ratio). The diluted cell lysates were dispensed in 96-well plate and mixed 
with working reagent solution (WRS) in 1:20 ratio. The mixture was incubated 
for 30 minutes at 37 ºC on horizontal shaker. The total protein concentration 
was measured at 562 nm using multiwall plate reader (TECAN GENious). 
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Visually, the reaction is exhibited by a colour change of the sample solution 
from light blue to purple in proportion to protein concentration. The assay 
involves two stages of reaction manipulating the well-known reduction of Cu2+ to 
Cu1+ by protein in an alkaline medium which then gives a light blue colour. The 
cuprous cation (Cu1+) was then reacts with bicinchoninic acid and chelated into 
BCA/copper complex which gives an intense purple-coloured reaction product.  
 
3.10 Western blotting 
 
Equal amount of proteins (30 μg) were mixed with reducing loading buffer (LB) 
in a volume ratio of 1:3 (LB: sample). The mixture was then heated at 100ºC for 
5 minutes to denature the proteins, and then centrifuged briefly. Ready-made 
Bis-Tris 4-12% NuPAGE gels (Invitrogen) were used in these experiments. 
Sample LB mixtures were loaded in each well of the NuPAGE gel alongside 
with 10-250kDal Precision Plus protein standard. The gel was run for 2 hours at 
150V in 1x NuPAGE running buffer (Invitrogen). The next stage involved 
blotting the gel onto a nitrocellulose membrane whereby the gel is sandwiched 
with sponges, filter paper and the nitrocellulose membrane in a cassette. This 
step was carried out carefully to avoid breakage of the gel. The blotting was 
carried out for 2 hours at 30V. Once proteins were transferred onto the 
nitrocellulose membrane, the membrane was blocked with 5% fat-free milk in 
PBS for 1 hour at room temperature (RT). The membrane was then incubated 
with the primary antibody, which was mouse iNOS specific rabbit antibody (Cell 
Signalling) in 5% milk (ratio of 1:1000) to detect the level of total iNOS protein. 
The membrane was incubated overnight at 4ºC. 
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The blot was then washed 4 times (for 15 min each) with PBS/T (0.05% Tween-
20 in 1x PBS) and then incubated with the secondary antibody, sheep anti-
rabbit IgG polyclonal antibody conjugated with horseradish peroxidase (AbD 
Serotec). The membrane was washed 4 times again with PBS/T and soaked in 
enhanced chemiluminescence (ECL) solution for 1 minute. The membrane was 
exposed to autoradiography film for different periods of time (1, 10 or 30 
minutes) and film developed using SRX-101A (Konica Minolta). These steps 
were repeated for the detection of Actin using rabbit anti-Actin antibody 
(Sigma). Prior to incubation with the antibody, the membrane was washed with 
mild stripping buffer to eliminate bound iNOS antibody. 
 
3.11 Statistical analysis 
 
Data was analysed using GraphPad Prism software (GraphPad Prism, San 
Diego, California). Means and standard deviation were used to describe 
normally distributed data. The significance of differences between groups was 
assessed using One-way ANOVA (Tukey’s or Dunn’s multiple comparison test) 
or Two-way ANOVA (Bonferroni posttest). Comparison between two selected 
groups was performed using Student t-test. Difference of p<0.05 is considered 
significant. 
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4 Results 
 
4.1  Assessment of optimal culture condition for the RAW 264.7 
macrophage cell line  
4.1.1 Assessment of the bioactivity of transfected and un-transfected          
RAW 264.7 cells  
 
One aim of experiments described in this chapter was to assess the effect of 
plant extracts on the production of NO and PGE2. The transcription of genes 
encoding these inflammatory mediators is under the influence of NF-κB. 
Therefore, the usefulness of RAW 264.7 cells stably transfected with the 
Luciferase gene under the control of the NF-κB promoter was examined.  The 
readout of this assay was the activity of luciferase, which catalyses a reaction 
with luciferin to produce a change in colour to blue. However, studies of the 
transfected cells showed that they produced less than half the amount of NO 
produced by un-transfected cells upon LPS stimulation. Previous studies have 
shown that activation/inactivation of NF-κB related to changes in the 
concentration of NO (152). This may suggest that a positive feedback 
mechanism may exist whereby low concentrations of NO induce NF-κB 
activation to promote further NO production. Once biologically optimum levels of 
NO levels have been reached, excess NO could then act to reduce NF-κB 
activation to turn off further NO production. It, thus, appeared possible that the 
transfected RAW 264.7 cells were less efficient in responding to alter NO levels 
than un-transfected cells. Based on these results, it was decided to use un-
transfected RAW 264.7 cells for stimulation and measurement of NO production 
and inhibition by plant extracts. 
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4.1.2 Assessment of protocol for the stimulation of RAW 264.7 cells. 
 
Experiments to identify the optimal protocol for reproducible stimulation of    
RAW 264.7 cells were carried out. Stimulatory optimal effects for NO production 
by two alternative protocols were examined, stimulation with LPS alone and 
LPS in combination with a pro-inflammatory cocktail (CT) of cytokines (Method 
in section 3.2 of this chapter). 
 
Contrary to reports in the literature, results of the comparison revealed that LPS 
was more efficient (p<0.001) and more reproducible than LPS together with the 
CT under the culture conditions established by the earlier experiments in 
inducing NO production by the RAW 264.7 cells (Figure 3.2). Based on these 
experiments, all subsequent studies on the anti-inflammatory properties of the 
extracts, fractions and identified compounds were tested using stimulation with 
LPS.  
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Figure 3.2: Comparison between the level of NO produced by RAW 264.7 
cells stimulated with LPS or with LPS + CT relative to untreated cells. 
Statistical analysis for the difference in the level of NO production (in μM) was 
performed using the paired t-test on data from seven experiments (n=7).Data 
presented as mean ± SD. LPS produced significantly higher amounts of NO 
compared with LPS + CT (***P<0.001). CT=pro-inflammatory cocktail of 
cytokines (TNF-α and IL-1β) 
 
4.2 Anti-inflammatory effects of extracts from Malaysian plants 
  
The part of the studies to assess the potential anti-inflammatory effects of the 
plant extracts started with screening experiments for 12 types of indigenous 
Malaysian medicinal plants. Two different extracts were obtained for each plant 
as described in chapter 2. One extract ionmethod relied on shaking of the dried 
plants in 80% ethanol in water while the other relied on sonication of the dried 
plants in the same solvent. The extracts were assessed for their effects on 
inhibiting NO and PGE2 production. In the preliminary study, RAW 264.7 cells 
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were stimulated with LPS+CT. The outcome of this experiment determines the 
most potent plant extract against NO production, and thus, selected as the 
focus of this thesis. 
4.2.1 Inhibition of NO: Ethanolic extract of ZOR had comparable effects 
to L-NAME. 
 
Extracts from the 12 native Malaysian plants (described in Chapter 2 and Table 
1 in the Appendices), were tested for their ability to inhibit the NO production by 
RAW 264.7 cells stimulated with LPS and CT cocktail the cells were incubated 
with the extracts prior to stimulation. The potency of the extracts was 
determined based on their IC50, the concentration required to inhibit 50% of NO 
production by the stimulated cells. 
 
This data was compared to the IC50 of L-NAME (L-N
G-Nitroarginine methyl 
ester). Among these extracts, the extract from the ginger sp.,Halia Bara or  
Zingiber officinale Roscoe var. rubrum (ZOR)  obtained by the shaking method 
(HB01), was the most potent inhibitor of NO production with an IC50 of 10.2 ± 
0.8 μg/mL (Table 3.3). HB01 had comparable NO inhibitory activity to L-NAME 
(7.3 ± 1.8 μg/mL). This is followed by extracts from Mangifera indica (MP) that 
were extracted using sonication method (IC50= 17.0 ± 1.7 μg/mL) and shaking 
method (IC50= 26.0 ± 6.9 μg/mL). MP extracted using sonication (SN) was 
slightly more active than the one extracted using shaking method (SK). This 
was also demonstrated for the effect of Artocarpus heterophyllus (DN) and 
Archidendron bubalinum (KD). However, it was the opposite for Morinda 
citrifolia (MG) and Artocarpus altilis (DS), which showed higher potency when 
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extracted using the shaking method. Therefore, based on the inhibition of NO 
production by the plant extracts listed in Table 2.2, no clear distinction could be 
drawn on the efficiency of either type of extraction procedure as more efficient 
than the other. Hence, the differential NO inhibitory effects of both extraction 
methods indicate that the potency of the extracts are more likely influenced by 
the active components than the extraction protocol. 
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4.2.2 Inhibition of PGE2 production 
 
Since the plant extracts showed strong inhibition on NO production, it was 
decided to test the effect of some of the more promising extracts on PGE2 
production. HB01, MP and DN which were extracted using the shaking method, 
were tested. The concentrations of HB01, MP and DN used were approximately 
10, 20 and 60 µg/mL respectively, based on the IC50 values obtained in the NO 
inhibition experiments as indicated in Table 2.2. PGE2 production was 
measured using a PGE2 ELISA. The results of PGE2 production by stimulated 
RAW 264.7 cells are summarised in Figure 3.3. The data showed that HB01 
was more potent by two-fold or more than the other two extracts in inhibiting 
PGE2 production (Figure 3.3). This finding is consistent with the noted potency 
of HB01 in inhibiting NO production.  
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Figure 3.3: The inhibitory effects of HB01, MP and DN on PGE2 production 
by RAW 264.7 cells. The RAW 264.7 cells were stimulated with the LPS+ CT 
cocktail. Before stimulation the cells were pre-cultured with 10 μg/mL HB01,     
20 μg/mL MP or 60 μg/mL DN. Their inhibitory effects on PGE2 production were 
determined. The concentrations were based on the IC50 obtained for inhibition 
of NO production (Table 3.3). The inhibitory effects on PGE2 production was 
measured relative to untreated but stimulated RAW 264.7 cells. Values are 
mean ± SD of % inhibition of PGE2 production from two independent 
experiments conducted in triplicates.  
 
4.2.3 The inhibitory properties of plant extracts: NO versus PGE2 
production 
 
The extracts of ZOR (HB01), M. indica (MP) and A. heterophyllus (DN) showed 
good inhibitory effects on NO and PGE2 production. Amongst these 3 extracts, 
however, HB01 had the most potent inhibitory effects on NO, and this effect 
was favourable in comparison with L-NAME.   
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Based on these results, it was decided to further explore the mechanisms of 
action, extent of anti-inflammatory effects of ZOR and identify compounds that 
could have therapeutic potential in treating psoriasis. Results in Table 3.3 and 
Figure 3.3 revealed that the HB01 extract inhibited 50% NO and PGE2 
production (IC50) at concentration of ~10 μg/mL. The observation on the ability 
of HB01 to inhibit both NO and PGE2 suggested that this plant possesses dual 
inhibitory effects on both pro-inflammatory pathways. It was previously reported 
that iNOS-derived NO activates COX which subsequently induces PGE2 
production (153). This implies that HB01 might have an effect on iNOS 
expression which could explain its inhibitory effects on PGE2 production. 
Studies to address the effect of the ZOR on iNOS expression were, therefore, 
carried out and preliminary results are presented later in this chapter. 
 
4.2.4 Effect of HB01 on iNOS and TNFα gene transcription. 
 
mRNA for iNOS and TNFα genes in stimulated RAW 264.7 cells with and 
without pre-treatment of the cells with HB01 andL-NAME at of concentrations  
10 μg/mL and 7 μg/mL, respectively, was assessed using conventional PCR. 
mRNA for the TNFα gene was detectable in both stimulated and unstimulated 
RAW 264.7 cells. However, mRNA levels for the gene were less abundant in 
stimulated cells treated with HB01 than cells that were not pre-treated with the 
extract (Figure 3.4). Nevertheless, since the PCR protocol does not provide 
information on the amount of mRNA, it was decided to carry out quantitative 
real-time PCR to verify the observation. The PCR results showed that mRNA 
levels for iNOS did not change in cells pre-treated with the extract. This latter 
observation is interesting since the early data showed that HB01 has a 
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suppressive effect on NO production at the same concentration used for the 
PCR (Table 3.3). Figure 3.4 depicts, that despite the observation that L-NAME 
is a potent inhibitor of  NO, the PCR experiment did not show inhibition of iNOS 
gene transcription by the compound. This finding may suggest that the effect of         
L-NAME may not be through down regulating iNOS gene transcription. 
  
Interestingly, however, the results showed that HB01 reduced the level of 
mRNA for the TNFα gene. Previous studies have shown that TNFα is a 
principal mediator of inflammation in most inflammatory conditions.  Therefore, 
the ability of HB01 to down-regulate TNFα mRNA levels is interesting but more 
evidence is needed to verify this observation. 
 
 
 
 
 
 
 
Figure 3.4: PCR analysis for iNOS and TNFα mRNA levels in stimulated 
RAW 264.7 cells. Lane 1 shows PCR products for mRNA obtained from 
unstimulated RAW 264.7 cells (negative control). Lane. 2 depicts PCR result of 
cDNA amplification from RAW 264.7 cells stimulated with the LPS + CT 
cocktail. Lane 3 shows PCR products for stimulated RAW 264.7 cells pre-
treated with L-NAME at 7.0 μg/mL. Lane 4 shows PCR products for stimulated 
RAW 264.7 cells pre-cultured with HB01 at 10.0 μg/mL. 
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iNOS 
 
 1 2 3 4 
CT - + + + 
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4.3 Comparison of solvents for the optimal preparation of extracts with 
maximal anti-inflammatory properties from ZOR 
 
The experiments described above on NO and PGE2 production by extracts 
showed that the HB01 extract from ZOR had the most potent inhibitory activity 
on both mediators. Due to these properties, it was decided to carry out detailed 
studies on ZOR to further assess the extent of its anti-inflammatory effects, 
mechanisms of action and identify therapeutic compounds inducing such 
effects. For this purpose, new extracts of ZOR were prepared with 3 alternative 
solvents: chloroform (HB02), ethanol (HB03) and water (HB04) (Chapter 2). 
 
ZOR rhizomes were obtained and processed as described in Method 3.4 
(Chapter 2) and labelled as indicated in Table 3.4. Briefly, active components 
from 499g of ZOR powder were extracted with 3 L chloroform in 30 minutes 
using sonication and then maceration for 5 days at room temperature (RT). The 
extract was collected, filtered and evaporated using a rotary evaporator at     
200 Pa at 45°C and labelled as HB02. The powder residue was then dried and 
re-extracted with ethanol (HB03) and then with water (HB04) using the same 
approach. The aqueous extract was dried using a freeze-drier. The same 
extraction approaches using chloroform and ethanol were carried out on 
common ginger, Z.officinale and labelled as HC01 and HC02, respectively. 
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Table 3.3: Preparation of ZOR extracts using different solvents. 
Code Extract Description 
HB01 ZOR extracted in ethanol using the shaking method*  
HB02 ZOR extracted in chloroform using the soaking 
(maceration) method 
HB03 ZOR extracted in ethanol using the soaking (maceration) 
method 
HB04 ZOR extracted in water  using the soaking (maceration) 
method 
HC01 Z.officinale (common) extracted in chloroform using the 
soaking (maceration) method 
HC02 Z.officinale (common) extracted in ethanol using the 
soaking (maceration) method 
*Prepared in the preliminary study 
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4.3.1 Extraction of ZOR with chloroform (HB02) produces an extract with 
potent inhibitory effects on NO production. 
 
The inhibitory effects of ZOR and the common ginger extracts (Table 3.4) on 
NO and PGE2 production by stimulated RAW 264.7 cells were compared. The 
extracts were dissolved in DMSO. DMSO was chosen due to its ability to 
dissolve lipophilic compounds and its use in most in-vitro assays (154). The 
concentration of DMSO most widely-used is 0.1%, which was also used in 
these studies. The potential effect of using DMSO on the viability of the 
stimulated RAW 264.7 cells was determined. For this purpose, a range of 
DMSO concentrations were tested for the effect on cultured RAW 264.7 cells. 
Viability of the cells was determined using the MTT viability assay. The results 
showed that the concentration of DMSO that could be used without affecting 
cell viability should be less than 1.7 ± 0.01% so that >50% macrophages remain 
viable. The best DMSO concentration which enables 90% macrophage viability 
was found to be in the range of (0.4 ± 0.02) %.  
 
The findings from these experiments are consistent with previous observations 
on DMSO concentration which suggested that its concentration for culture cells 
should not exceed 2% (154). These investigators used human cryo-preserved 
hepatocytes and rat primary cultured hepatocytes to assess the expression of 
1137 sets of gene probes for drug-metabolising enzymes at a range of DMSO 
from 0.1-2%. The investigators have observed that DMSO concentration of up 
to 0.75% can be tolerated with the expression of only a minority of the genes 
studied affected (154). Therefore, the maximum percentage of DMSO used in 
this study was 0.5%. 
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ZOR extracts with the three different solvents and common ginger extracts were 
dissolved in DMSO and at a final maximum concentration of 0.2%  when  tested 
for inhibition of NO production by LPS-stimulated RAW 264.7. The results 
showed that HB02, HB03, HC01 and HC01 were all more potent than L-NAME 
in inhibiting NO production (Figure 3.5). These findings also showed that the 
chloroform and ethanol extracts of both gingers were effective in inhibiting NO 
production and more potent than L-NAME. However, HB01, the ethanol extract 
of ZOR prepared using shaking method was similar to L-NAME but less potent 
than HB02 and HB03. The least effective extracts were obtained in aqueous 
extraction, HB04, which was incapable of 50% inhibition of NO production even 
at the concentration of 1 mg/mL. HB04 was, therefore, not studied further. It 
was also noted that L-NAME and HB01 showed less potency (higher IC50 
values) on NO production by RAW 264.7 stimulated with LPS compared with 
the previous studies on LPS+CT-stimulated RAW 264.7 cells (Table 3.3). 
Although different stimulation protocol resulted in different IC50 values, the effect 
of HB01 and L-NAME were comparable. 
 
The efficacy of ZOR extracts, HB01, HB02 and HB03 were variable. HB02 was 
significantly more effective in inhibiting NO production when compared with     
L-NAME (p<0.001). HB02 was also significantly more effective than HB01 and 
HB03. This suggests that chloroform extract of ZOR yielded more potent 
compound/s than of ethanol plus shaking. Chemically, chloroform extracts non-
polar compounds from ZOR since it is a non-polar solvent, whereas, ethanol is 
a polar solvent and extracts mainly polar compounds. As discussed in chapter 
2, recent studies indicate that a majority of anti-inflammatory properties of 
ginger are attributed to the non-polar components, such as the 
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phenylpropanoids. This might suggest that the potent NO inhibitory effect of the 
chloroform extract, HB02 could be attributed to the presence of more non-polar 
compound/s from ZOR.  
 
In addition to the effect of solvent on the efficiency of extracting therapeutic 
compounds from ZOR, the results also indicate that the extraction protocol itself 
has an influence. HB02 and HB03 were extracted using a 5 day-maceration 
protocol while HB01 was extracted using the shaking at 40ºC for 24 hours. 
Comparison between the ethanol extracts, HB03 and HB01, which were 
extracted using different protocols showed a significant difference (p<0.05), 
wherein HB03 (IC50= 21.1 ± 2.1 μg/mL) was about twice as active as HB01 
(IC50= 35.0 ± 5.0 μg/mL) in inhibiting NO production. This data shows that 
gradual extraction at room temperature is more efficient than fast extraction at 
40ºC in extracting anti-inflammatory compounds. Theoretically, extraction of 
therapeutic compounds at higher temperature might lead to the destruction of 
some active ingredients (111). Storage, can also lead to gradual degradation of 
active compound/s (114). This may explain the reduced activity of HB01, which 
was prepared prior to the other extracts and stored until tested. 
 
Based on these observations, HB02 extract was selected for detailed studies to 
assess its anti-inflammatory effects. In addition, the anti-inflammatory effects of 
HB02 were compared with those obtained for common ginger to determine if 
variation between close species existed. In the results shown in Figure 3.5, 
ZOR had similar inhibitory activity on NO production to common ginger when 
using similar extraction protocols. Thus, no significant differences were 
observed between the two ginger species (HB and HC) based on the IC50 value 
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alone (Figure 3.5). The chloroform extracts of both species (HB02 and HC01) 
showed similar potency in inhibiting NO production. This was also seen for the 
ethanol extracts of both species.  This finding may imply that both ginger 
species share the same or similar anti-inflammatory compound/s acting on NO 
production by macrophages. To test this proposition the extracts were assessed 
for their inhibitory effects on PGE2 production. 
 
Figure 3.5: IC50 for inhibition of NO production by ZOR and common 
ginger extracts obtained using different solvents. The effect of the extracts 
in inhibiting NO production was tested at a range of concentrations (0.5-100.0 
µg/mL). NO inhibitory effects of the extracts were assessed relative to untreated 
LPS-stimulated RAW 264.7 and the IC50 (in µg/mL) was obtained. The 
histograms represent the IC50 (μg/mL) for the different extracts. The inhibitory 
effects of ZOR extracts were compared with L-NAME using One-way ANOVA 
Dunnet’s test. Probability values (p) are indicated as: * for p <0.05 and ** for 
p<0.01. The data is mean ± SD of at least three independent experiments 
(n=3).  
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4.3.2 HB02 inhibition of PGE2 production.  
 
PGE2 production was measured using a kit based on Homogenous Time-
Resolve Fluorescence (HTRF) technology (CISBIO). The effects of the extracts 
(for both types of gingers) and known COX inhibitors, indomethacin (INDO) and 
dexamethasone (DEX) at 10 μg/mL on PGE2 production by stimulated 
macrophages were determined. The concentration was chosen based on the 
IC50 value for the most potent extract (HC01) in inhibiting NO production as 
shown in Figure 3.5. The results revealed that HB02 had the most consistent 
and potent inhibitory effects on PGE2 production (Figure 3.6). The inhibitory 
effects of HB02 on PGE2 production were higher than those of HB03, HC01 and 
HC02 although differences were not statistically significant. The extracts showed 
comparable effects with indomethacin and dexamethasone when tested at the 
same concentration (10 μg/mL) in ihbiting PGE2 production,  
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Figure 3.6: The inhibitory effects of extracts obtained from ZOR (HB-) and 
common ginger (HC-) on PGE2 production. Extracts were assessed for their 
ability to inhibit PGE2 production by RAW 264.7 stimulated with LPS. The 
columns represent mean ± SD of % inhibition of PGE2 production of at least 
three independent experiments. Comparison of the inhibitory effect of all the 
extracts with respect to the positive controls, indomethacin (INDO) and 
dexamethasone (DEX), was performed using One-way ANOVA (Tukey’s test). 
No significant difference was observed. 
 
Based on this data on NO and PGE2 production (Figure 3.6), it was decided to 
further study the composition of HB02 and identify potential therapeutic 
compound(s). In the first stage, HB02 was to be further fractionated and the 
inhibitory properties of the fractions examined in detail. 
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4.3.3 Vacuum liquid chromatography (VLC) fractionation of HB02 and 
assessment of anti-inflammatory properties of individual fractions.  
 
As described in chapter 2, HB02 was fractionated using VLC. The individual 
factions were then screened for their inhibitory effects on NO production by 
LPS-stimulated RAW 264.7. Twenty one fractions were obtained and each 
fraction was tested at 20 μg/mL, a concentration of approximately the IC50 of 
HB02 in inhibiting NO (Figure 3.5). As a control, L-NAME was used at             
50 μg/mL, an approximate concentration of its IC50 value (Figure 3.5). 
 
Figure 3.7 depicts the data obtained for the inhibitory effects of the 21 fractions 
on NO production. Fractions 5, 6, 7 and 10 (column in black) at tested 
concentration of 20 μg/mL, inhibited NO production by LPS-stimulated RAW 
264.7 cells by >80%. The inhibitory effects were clearly higher than that of 
HB02 and L-NAME, but the differences were not statistically significant. F5 and 
F6 exhibited high inhibitory activities. This observation was consistent as 
indicated by the relatively low SEM values obtained for the repeat experiments. 
F5, 6, 7 and10 were selected for further studies and molecular characterisation.  
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Figure 3.7: The inhibitory effects of HB02 and its fractions on NO 
production. HB02 was fractionated by VLC as described in chapter 2.The 
concentration of the fractions were adjusted to 20 μg/mL and fractions were 
tested for their inhibitory effects on NO production by RAW 264.7 cells 
stimulated with 0.1 μg/mL LPS. L-NAME at 50 μg/mL was used as a positive 
control and for consistency and reproducibility of the assays. The columns 
represent mean ± SD from two sets of independent experiments (n=2).   
 
4.3.4 Selected HB02 fractions inhibit NO production without reducing 
macrophage cell viability 
 
The MTT assay was used to assess the effect of the fractions on cell viability 
(Figure 3.8). Based on the viability assay results shown in Figure 3.8, F7 
appeared to be the most toxic to the RAW 264.7 cells at the higher 
concentration range (50 and 100 μg/mL) with the viability reduced to              
53.0 ± 2.8% at 50 µg/mL whilst culture with HB02 and its other fractions 
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resulted in more than 80% viability. The effect of DMSO in the culture medium 
on RAW 264.7 macrophage cell viability was also studied. The results showed 
50% (IC50) and 90% (IC90) viability at percentage of 1.7 ± 0.01% and               
0.4 ± 0.02%, respectively. The maximum concentration of DMSO used was 1% 
at 100 µg/mL of HB02 extract and fractions. Thus, these results indicate that the 
% of DMSO which was used to prepare the stocks of HB02 and the fractions did 
not affect viability of RAW 264.7 cells. Based on these results, the concentration 
of HB02 and fractions used in all subsequent studies were ≤50 μg/mL. 
 
Further studies to determine the IC50 of the HB02 and its fractions on the 
inhibition of NO production showed that these were significantly lower (p<0.05) 
than the IC50 of L-NAME (Figure 3.9). The fractions had lower IC50 than the 
crude HB02 extract. F6 was particularly effective in inhibiting NO production           
(IC50= 8.5±1.1 μg/mL), two-fold lower than HB02 (16.0 ± 1.9 μg/mL). 
Importantly, the IC50 for the fractions were significantly lower than their potential 
toxicity levels (>50 μg/mL) (Figure 3.8).  
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Figure 3.8: Viability of RAW 264.7 cells in response to treatment with HB02 
extracts and fractions from VLC fractionation. RAW 264.7 cells were 
cultured and treated with the ZOR HB02 extract or with fractions at a range of 
concentration from 0.5-100 μg/mL and incubated for 24 hours. The maximum 
concentration of DMSO used was 1% at 100µg/mL of HB02 extract and 
fractions. The viability of the RAW 264.7 cells was determined usingthe MTT 
assay. The results represent the mean ± SD of three independent experiments 
(n=3). The effect of DMSO in culture medium on RAW 264.7 macrophage cell 
viability resulted in 50% (IC50) and 90% (IC90) viability were: 1.7 ± 0.01% and 
0.4 ± 0.02%, respectively.  
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Figure 3.9: IC50 of HB02 and its fractions obtained by VLC fractionation for 
inhibition of NO production. HB02 and fractions at a range of concentration 
(0.5-100 µg/mL) were tested for the inhibitory effects on NO production by LPS-
stimulated RAW 264.7 cells. The maximum DMSO % used when tested was up 
to 0.2%. The data is the mean ± SD of six independent experiments (n=6). One-
way ANOVA (Dunnet’s test) analysis indicates that HB02 and its fraction 
demonstrate very significant difference (***p<0.001) compared with L-NAME.  
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4.3.5 F6 and its isolated compounds show comparable inhibitory effects 
on NO production.  
 
The next sets of experiments examined the effect of compounds isolated from 
F6, 6-shogaol (6S) and 1-dehydro-6-gingerdione (GD) on NO production by the 
stimulated macrophages.The inhibitory effects of 6S and GD on NO production 
(IC50) were compared with F6 (Figure 3.10). Both compounds showed 
comparable effects to F6. Although not significant (p>0.05), F6 is better NO 
inhibitor than its compounds as suggested by the lower IC50 value                  
(8.5 ± 1.1 µg/mL) while 6S showed better inhibitory effect than GD. 
 
Figure 3.10: IC50 of F6 and its isolated compounds 6S and GD, in inhibition 
of NO production. Two major compounds were isolated from F6 by Prep-TLC. 
These were identified as 6S and GD. The effect of 6S and GD in inhibiting NO 
production was tested at a range of concentration and the IC50 (in µg/mL) was 
determined. The data is the mean ± SD of at least five independent experiments 
(n=5). 
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4.4 HB02 fractions and 6S and GD show potent inhibitory effect on PGE2. 
 
Since F6 and its compounds; 6S and GD have variable but significant effects on 
NO production at 8-12 µg/mL (Figure 3.10), the effect of HB02, the fractions and 
the compounds from F6 on PGE2 production was assessed. The fractions were 
tested (all at 10 μg/mL) for their ability to inhibit PGE2 production by RAW 264.7 
cells before their stimulation with LPS. HB02 and its fractions had inhibitory 
effects on PGE2 production comparable to indomethacin and dexamethasone 
(Figure 3.11a). They reduced PGE2 production by >80% compared with 
stimulated but untreated cells. Amongst the fractions, F6 had the most potent 
inhibitory effect on PGE2 production.  
 
Assessment of 6S and GD showed that 6S had similar potent inhibitory effects 
to F6 on PGE2 production (Figure 3.11b). GD had lower inhibitory effects. The 
potency of F6 and both compounds was comparable to indomethacin and 
dexamethasone (p>0.05). This observation complements the effect of F6 and 
its compounds on NO production (Figure 3.10). 
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Figure 3.11: The inhibitory effects of HB02, selected fractions and 
compounds on PGE2 production. RAW 264.7 cells were pre-treated with a) 
HB02 and fractions b) 6S and GD. Dexamethasone (DEX) and Indomethacin 
(INDO) at 10 µg/mL, were the positive controls. The inhibitiory effect on PGE2 
production were measured relative to untreated but LPS-stimulated cells. The 
data represents four set of independent experiments and was analysed using 
One–way ANOVA (Tukey’s Test). The effect of the test samples was compared 
to INDO and DEX. The differences were not significant.  
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4.5 The effect of the ZOR extract and fractions on the expression iNOS  
gene transcripts 
 
The experiments described so far assessed the potential anti-inflammatory 
effects of ZOR extracts, fractions and compounds for  their suppressive effects 
on NO and PGE2 production. To determine the basis for the inhibition of NO 
production and extent of effects, their effects on the expression of iNOS at 
mRNA level before and after stimulation of RAW 264.7 cells with LPS, were 
examined. The rationale for these experiments was to determine the potential 
mechanism of action and whether inhibition was at the transcriptional level of 
the gene encoding iNOS or the release of NO from the stimulated RAW 264.7 
cells.  
 
4.5.1 Conventional RT-PCR does not show altered levels of iNOS gene 
expression by HB02 or its fractions. 
 
The production of NO is regulated by iNOS and production is increased in 
activated macrophages during inflammation. Figure 3.9 shows that HB02 and 
the tested fractions effectively suppressed the production of NO by at least 50% 
at concentrations <20 μg/mL when added to the cultured RAW 264.7 cells 
before stimulation with LPS. To assess whether this observation was due to 
reduced iNOS expression, a conventional RT-PCR was carried out. iNOS gene 
expression by LPS-stimulated RAW 264.7 untreated or treated with 20 μg/mL of 
HB02 or tested fractions F5, F6, F7 and F10 were compared with cells treated 
with L-NAME at 54 μg/mL (200 μM) The concentrations are based on IC50 value 
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reported in figure 3.9. The results showed no significant difference in the level of 
iNOS mRNA between RAW 264.7 cells treated or untreated with HB02 or the 
fractions before stimulation with LPS (Figure 3.12). The results also showed 
that L-NAME did not affect iNOS mRNA levels at 54 μg/mL. These results 
suggest that the suppressive effects of HB02 and its fraction on NO production 
may not occur at the level of iNOS gene transcription. However, it was also 
possible that the conventional RT-PCR used was not capable of detecting small 
changes in iNOS mRNA levels. 
 
GAPDH 
 
iNOS 
 
 
1 2 3 4 5 6 7 8 
LPS 
- + + + + + + + 
Samples - - 
HB02     F5          F6          F7          F10          LN    
 
Figure 3.12: The effect of HB02 and fractions (F5, F6, F7 and F7) on iNOS 
mRNA by conventional PCR. The effect of HB02 and fractions at 20 μg/mL 
(lane 3-7) on the level of iNOS mRNA expression by stimulated RAW264.7 cells 
was assessed in comparison to the effect of L-NAME(LN) at 54 μg/mL (lane 8). 
The figure depicts the results of analysing RT-PCR products on a 1% agarose 
gel in the presence of ethidium bromide. RT-PCR for mRNA for the house-
keeping gene GAPDH was used as an internal control.  
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4.5.2 Quantitative RT-PCR reveals that HB02 and its fractions reduce 
iNOS mRNA level before and after LPS stimulation 
 
To further explore the question of whether HB02 and its fractions influence 
iNOS mRNA transcription, quantitative RT-PCR (qRT-PCR) was used. The 
reasons for exploring this issue were to determine mechanisms that underpin 
the inhibitory effects of HB02 (fractions and compounds) on NO production. It 
was hoped that the results could determine whether ZOR could be effective 
after inflammation starts and thus, be used as therapy. The experiments were 
based on the knowledge that the ability to inhibit gene expression before 
macrophage activation indicates that HB02 acts at transcription levels, i.e. more 
effective before inflammation starts while inhibition after macrophage activation 
implies that HB02 could inhibit transcription and also iNOS catalytic activity 
(146).  
 
Comparisons between the level of iNOS mRNA in the presence of HB02/its 
fractions before and after LPS stimulation of RAW 264.7 cells showed 
reductions in both settings (Figure 3.13a) compared with the control (untreated 
but LPS-stimulated cells). F6 was particularly effective in down regulating the 
level of iNOS mRNA when added before or after RAW 264.7 cell stimulation 
with LPS wherein it was a better iNOS inhibitor that L-NAME (P<0.001). 
Interestingly, F7 was significantly more effective than L-NAME (p<0.01) and 
marginally more effective than F6 and F10 when added to the cultured cells 
after stimulation.HB02 and F5 were as effective as L-NAME when added before 
and after LPS stimulation. Thus, these results indicate that HB02 is likely to 
contain compounds which inhibit both iNOS transcription or message stability 
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and enzymatic activity which are comparable to L-NAME. These findings are 
consistent with the ability of HB02/fractions to inhibit NO production (Figure 3.9, 
Figure 3.13b). 
 
To verify these findings, the level of inhibition of NO production by RAW 264.7 
cells treated with HB02/its fractions at 20 μg/mL before and after stimulation 
were determined. Figure 3.13(b) shows the inhibitory effects of HB02/its 
fractions on NO production by RAW 264.7 cells before and after LPS 
stimulation. The results show that HB02/its fractions had stronger inhibitory 
effects when added to the cells before stimulation than after (Figure 3.13b). 
Even though HB02 and the fractions strongly reduced iNOS mRNA level when 
added after LPS stimulation, this was not reflected on inhibiting NO production. 
Interestingly, the results also show that F7 possess more suppressive effects on 
NO production than other fractions. L-NAME showed consistency in its effect on 
iNOS mRNA level and NO production before and after LPS stimulation. The 
inhibitory effects of HB02, F5, F6 and F10 were comparable to that of L-NAME 
before LPS stimulation but not after LPS stimulation, particularly for HB02 
(p<0.05). These results, therefore, indicate that HB02 and the fractions act 
favourably in regulating iNOS before and after LPS stimulation, but reduce NO 
production more effectively when the cells are treated before LPS stimulation. 
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Figure 3.13: The effect of HB02 and its fractions on iNOS mRNA level and 
NO production. The effect of treating RAW 264.7 cells with HB02 and its 
fractions at 20 μg/mL either before or after stimulation with LPS on the level of 
(a) iNOS mRNA was determined by qRT-PCR (i) Level of iNOS mRNA 
expression when the RAW 264.7 cells were pre-treated with HB02/fractions 30 
minutes before LPS stimulation (ii) Level of iNOS mRNA expression in the 
presence of HB02/fractions added 12 hours after the cells were stimulated with 
LPS. Comparison is relative to untreated LPS-stimulated RAW 264.7 cells 
(control). (b) NO production was determined using the Griess. The results are 
presented as the mean ± SD of at least 3 independent experiments. Statistical 
analysis were carried out using Two-way ANOVA Bonferroni posttest to compare 
the effect of HB02 and its fractions with the effect of L-NAME(LN) at 54 μg/mL,  
denotes * p<0.05. 
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4.5.3 HB02 and its fractions down-regulate iNOS protein levels more 
efficiently when the cells are treated before LPS stimulation. 
 
As shown above, F6 was the most efficient inhibitor of iNOS mRNA level 
whether the cells were treated with the fraction before or after stimulation          
(Figure 3.13a). HB02, F5, F6 and F7 were similarly effective as L-NAME in 
inhibiting NO before LPS stimulation but less effective than L-NAME when used 
after LPS stimulation (Figure 3.13b).  
 
In light of these observations, the effect of HB02 and its fractions on the level of 
iNOS at protein level was evaluated. The level of iNOS protein was assessed 
using Western blotting and results semi-quantified by assessing the intensity of 
the resulting bands relative to an internal standard (β-actin) (Figure 3.14(a)(b)). 
Surprisingly, L-NAME at 54 µg/mL did not affect iNOS protein level despite its 
effect on iNOS mRNA. However, the effect of HB02 and its fractions on iNOS 
protein is consistent with the effect on NO production (Figure 3.13b). There was 
a significant down-regulation of iNOS protein when the cells were pre-treated 
with HB02/its fractions before stimulating the RAW 264.7 cells with LPS. When 
the cells were pre-treated with F5, F6 or F7 the level of iNOS protein level was 
up to seven-folds lower than when the cells were treated with L-NAME       
(Figure 3.14b(i)).  
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In contrast to the strong effects of HB02 and its fractions when added to the 
cells before stimulation, none had a significant down-regulatory effect on iNOS 
protein levels after LPS stimulation, except F7 (Figure 3.14(b)(ii)). These 
findings suggest that whilst HB02 and its fractions had a profound effect on 
suppressing the level of iNOS mRNA they did not have such a strong effect on 
secretion. Surprisingly, however, F7 reduced iNOS protein secretion when 
added before and after LPS stimulation. The level of inhibition of iNOS protein 
secretion with F7 which was much more pronounced than the effect of L-NAME 
(Figure 3.14(a)(b)). Figure 3.14b shows that the inhibitory effect of F7 on iNOS 
protein secretion is about ten-folds higher than L-NAME. This issue, however, 
needs to be further tested. 
 
The results of these experiments show that the suppressive effects of HB02 and 
its fractions on iNOS mRNA level and protein secretion correspond with their 
suppression of NO production when the cells are pre-treated before stimulation. 
In contrast, it appears that HB02 and its fraction reduce mRNA levels but have 
little effects on secretion or the half life of the pre-synthesised iNOS but inhibit 
their enzymatic activity when the cells are treated after stimulation with LPS. 
These experiments were repeated but using higher concentrations of HB02 and 
the fractions (50 μg/mL) to assess whether they could exert toxic effects on the 
cells (Figure 3.15(a)(b)). The results showed that whilst F5, F6 and F7 
significantly inhibited iNOS protein secretion at 50 µg/mL when the cells were 
treated before and after LPS stimulation, that only F5 and F7 had toxicity at this 
concentration. F6 was not toxic as could be seen from the intensity of the           
β-actin bands (Figure 3.15a). 
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Figure 3.14: Western blotting analysis of iNOS protein levels in RAW 264.7 
cells treated with HB02 and its fractions. RAW 264.7 cells were treated with 
20 µg/mL of HB02 or its fractions (lane 3-7) either (i) before or (ii) after 
stimulation with LPS. L-NAME (LN) (lane 8) was used at 54 μg/mL or 200 μM. 
Cells were removed from the wells, washed and lysed with lysis buffer and 
loaded onto the pre-cast NuPAGE gel and separated as described in the 
Methods section. iNOS protein levels were assessed in (a) and in (b) iNOS 
protein levels semi-quantified relative to β-actin using ImageJ. The film was 
scanned and the intensity of the protein band of the treated cells was analysed 
and compared relatively to the negative control (NC)(untreated cell)(lane1) and 
control (stimulated with LPS only)(lane 2). 
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Figure 3.15: Western Blot analysis of iNOS protein levels in RAW 264.7 
cells treated with HB02 or fractions at 50 µg/mL. The experiments were 
carried out as in the legend to Figure 3.14. The effect of 50 µg/mL of HB02 or its 
fractions (lane 3-7) and L-NAME (LN) (lane 8) on iNOS protein secretion 
revealed in (a) and in b) iNOS protein levels were semi-quantified relative to     
β-actin using ImageJ. The film was scanned and the intensity of the protein 
band of the treated cells analysed relative to that of negative control (NC)      
(lane 1) and control (lane 2). 
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4.6 The effect of F6 and compounds 6S and GD on iNOS mRNA and       
NO production.  
 
Results of the experiments described above showed that F6 had significant 
inhibitory effects on iNOS mRNA level and NO production. Furthermore, F6 
effectively reduced iNOS protein secretion. Despite the strong effects, F6 even 
at concentrations of 50 μg/mL did not significantly affect cell viability         
(Figure 3.15(a) (b)).  
 
Therefore, the chemical composition of F6 is determined in order to gain 
insights into the potential anti-inflammatory compounds in ZOR. As described in 
Chapter 2, detailed experiments resulted in the identification and purification of 
two major compounds from F6, 6S and GD. After isolation and characterisation, 
the cytotoxic potential of both compounds on RAW 264.7 cells at concentrations 
of 0.05-20 μg/mL was determined using MTT assay. These studies revealed 
that at these concentrations the macrophage cells line remained >90% viable 
for a 24 hours incubation.  
 
A series of experiments were carried out to determine the anti-inflammatory 
effects of 6S and GD. The two compounds were tested for their inhibitory 
effects on NO production when added before LPS stimulation. These 
experiments showed that the IC50 for 6S and GD were 9.6 ± 2.3 and              
10.4 ± 2.3 μg/mL, respectively (Figure 3.10). Based on the IC50 values 
(approximately 50 μM) obtained, the effect of both compounds at 50 µM  on 
iNOS mRNA expression was determined and compared to L-NAME at 200 µM 
(54 μg/mL).   
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These experiments showed that 6S had a significant inhibitory effect on the 
level of iNOS mRNA whether it was used to treat cells before or after LPS 
stimulation (Figure 3.16a). The inhibitory effects were comparable with the 
effect of L-NAME at a higher concentration. The experiments showed that 6S 
had more potent effects when cultured with the cells before stimulation (Figure 
3.16a (i). GD, unexpectedly, showed no inhibitory effects on iNOS mRNA levels 
when cultured with the cells before LPS stimulation. Indeed, the results showed 
an increase of iNOS mRNA level. In contrast, the level of iNOS mRNA was 
reduced when the cells were treated with GD after LPS stimulation (Figure 
3.16a(ii). These results indicate that the inhibitory effect of GD on NO 
production maybe through affecting iNOS activity rather than its gene 
transcription.  
  
The effect of the both compounds on NO production at 50 μM was also studied.  
Both compounds showed potent suppressive effects on NO production when 
cultured with the cells prior to stimulation with LPS (Figure 3.16b (i)). The 
inhibitory effects of both compounds were about two-fold higher than L-NAME in 
the pre-treatment protocol (p<0.05). Somewhat surprisingly, both 6S and GD 
did not have potent inhibitory effects on NO production when they were used to 
treat the cells after stimulation with LPS (Figure 3.16b (ii)). These findings 
suggest that 6S is more potent in inhibiting NO production by acting mainly at 
iNOS gene transcription. GD, in contrast, appeared to act on the enzymatic 
activity of iNOS but was less effective than expected, possibly, due to the 
relatively high transcription rate of the gene after stimulation of the cells with 
LPS (Figure 3.17b (ii))). 
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Figure 3.16: The effect of 6S and GD on iNOS mRNA levels. RAW 264.7 
cells were cultured as described in the Methods section and either treated with 
6S or GD before or after stimulation with LPS as indicated. Both 6S and GD 
were used at 50 μM. Both were compared to L-NAME at 200 μM. Percent 
reduction in the level of iNOS mRNA were measured relative to the level in 
stimulated but otherwise untreated RAW 264.7 cells (control). The columns 
represent data from 3-4 sets of independent experiments. Statistical analysis 
were carried out using Two-way ANOVA Bonferroni posttest to compare the 
effect of HB02 and its fractions to L-NAME (LN) * denotes p<0.05. 
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4.6.1 6S influences iNOS protein secretion and activity before and after 
LPS stimulation but GD may suppress its enzymatic activity. 
 
To verify the observations of the effects of 6S and GD on iNOS expression and 
activity the level of protein production was analysed by Western blotting. LPS-
stimulated RAW 264.7 cells were treated with the two compounds at 50 μM 
(Figure 3.17). The results showed that 6S reduced the production of iNOS 
protein before and also after LPS stimulation of the cells. This observation is 
consistent with the noted effects of 6S on iNOS mRNA level (Figure 3.17a). In 
contrast, the results showed that GD marginally decrease the level of iNOS 
protein when the cells were treated with the compound before and after LPS 
stimulation (Figure 3.17b (i)), which is similar to the effect of L-NAME (200 μM). 
 
These results indicate that GD does not have a significant effect on iNOS 
mRNA and protein levels but is likely to have an inhibitory effect on its 
enzymatic activity.  In contrast, 6S may have modulating effects on iNOS mRNA 
and protein levels. However, further experiments are required to confirm these 
findings. 
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Figure 3.17: Effects 6S and GD on iNOS protein level. 6S or GD (lane 3/4) 
was added to RAW 264.7 cells either before or after stimulation with LPS. Cells 
treated with L-NAME (at 200 µM) were used as control. Proteins separated by 
electrophoresis were electroblotted onto nitrocellulose membranes and probed 
with conjugated mAb to iNOS and protein levels revealed as described in the 
Methods section. (a) is a photograph of the protein contents in the cell lysate 
from each experiment (b) depicts semi-quantitative levels  of proteins in each 
sample expressed as band intensity relative to the bands representing β-actin in 
each cell sample (i) before  and (ii)after stimulation with LPS. Protein band of 
the treated cells was analysed and compared relatively to the negative control 
(NC)(untreated cell)(lane1) and control (stimulated with LPS only)(lane 2). 
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5 Discussion 
 
5.1 F6 reduces the level of iNOS mRNA and iNOS protein activity. 
 
The experiments described in this chapter show that ZOR modulates NO and 
PGE2 production by activated macrophages. The experiments were carried out 
with a number of objectives in mind. First, to provide experimental evidence that 
ZOR and common ginger ameliorate important pro-inflammatory events 
mediated by macrophages. Second, to provide insights into potential 
mechanisms through which both plants achieve their anti-inflammatory effects. 
Third, isolate and characterise the anti-inflammatory compounds in ZOR. 
  
The results showed that both ZOR and common ginger possessed potent anti-
inflammatory effects comparable with currently-used synthetic pharmaceutical 
compounds (L-NAME, Indomethacin, and dexamethasone). The results also 
provided data on potential methods of extraction of the anti-inflammatory 
compounds from both plants. The results showed that both plant extracts 
efficiently suppressed the production of NO and PGE2 by activated 
macrophages. Further, ZOR inhibited iNOS expression and its enzyme activity. 
Subsequent analyses of ZOR identified compounds with distinct mechanisms of 
action on iNOS expression and/or activity. Further, studies assessed the 
potential beneficial effects of using the extracts for prophylactic and therapeutic 
effects. Fractionation of ZOR identified a number of fractions with therapeutic 
effects amongst which F6 was shown to be the most potent. F6 was, thus, 
shown to suppress NO and PGE2 production with IC50 values lower than HB02. 
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Further, F6 was shown to down regulate iNOS at mRNA level as well as iNOS 
catalytic activity.  
 
Detailed assessment of all 21 fractions obtained for HB02 showed that in 
addition to F6, F7 also displayed potent effects on reducing iNOS mRNA and 
protein secretion. However, in contrast to F6, F7 was more effective in down 
regulating iNOS mRNA levels when the macrophage cell line was treated after 
LPS stimulation. Paradoxically, perhaps, F7 was extremely more effective at 
reducing iNOS protein levels when the cells were treated before and after LPS 
stimulation compared with F6. This finding was in agreement with its effect on 
inhibition of NO production. The somewhat similar effects noted for F6 and F7 
could be attributed to both fractions sharing similar, though not identical 
components. One caveat for suggesting similarities between F6 and F7 (and 
possibly also F5) is that F7 (and F5) have also reduced the level of the control 
housekeeping protein, β-actin which may imply that F7 and F5 are toxic to the 
cells. In contrast, F6 was not noted to be toxic, which supports the notion that 
although F6 and F7 could have similar mechanisms of actions, both also have 
differences in terms of composition or level .of active compounds, 
 
Further studies of F6 showed that it was efficient in down-regulating iNOS levels 
both before and after the cells were stimulated with LPS. Further, it was notable 
that F6 had lower IC50 than L-NAME, the specific inhibitor of NO used in the 
studies as a control. L-NAME is a L-arginine analogue and is a non-selective 
iNOS inhibitor (155). It acts by competing with L-arginine for binding to iNOS. 
Taken together, these data imply that F6 inhibits NO production by acting as an 
iNOS inhibitor.  Although further studies will be required to directly assess the 
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specificity of action of HB02, fractions and compounds, the results suggest that 
they act by influencing iNOS both at transcriptional and post-transcriptional 
levels. 
 
5.2 6S and GD have distinct effects on iNOS but both suppress NO 
production. 
 
To gain insights into mechanisms of the anti-inflammatory effects of ZOR, F6 
was further fractionated and key components were identified. Two major 
compounds, 6-Shogaol (6S) and 1-dehydro-6-gingerdione (GD) were identified 
and their structures were determined (detailed in Chapter 2). Both compounds 
are known and have been identified in common ginger. However, the 
mechanisms of action on inflammatory mechanisms associated with psoriasis 
have not been explored. Moreover, to-date, there are insufficient studies on 
compounds isolated from the oleoresin of ZOR.   
 
To address these issues, the effect of 6S and GD on NO and PGE2 production 
and on iNOS protein and mRNA levels before and after macrophage stimulation 
with LPS were studied. 6S was shown to have a major inhibitory effects on NO 
production, causing >60% reduction in NO production at 50 μM when the     
RAW 264.7 cells were treated with the compound before stimulation with LPS 
(Figure 3.36b). Treatment of the cells with GD also resulted in >60% inhibition 
of NO production. However, the degree of inhibition of NO production was 
significantly less when the compound was added after stimulating the cells. 
Interestingly, however, there was a dichotomy in the effect of both compounds 
on iNOS mRNA levels (Figure 3.16a). 
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Thus, whilst 6S significantly reduced the level of iNOS mRNA level when the 
cells were pre-treated with the compound GD had no inhibitory effects and, 
instead, increased iNOS mRNA level (Figure 3.16a (i)). When the compounds 
were added to the RAW 264.7 cells after stimulation, they both reduced the 
mRNA level of iNOS (Figure 3.16a (ii)). Interestingly, there was no correlation 
between the level of message and the effect on NO production which suggested 
that all of the effect noted for GD on NO production is likely to be due directly to 
affecting the enzymatic activity of the iNOS protein. 6S, in contrast, is likely to 
have reduced NO expression by a combination of its effect on reducing iNOS 
production and an inhibition of its enzymatic activity. However, these questions 
need to be further studied to provide direct experimental evidence regarding the 
exact mechanism of action.  
 
5.3 ZOR’s active compounds display dual inhibitory effects on NO and 
PGE2 production.  
 
As cited earlier, previous studies have suggested that links between the iNOS 
and COX-2 pathways exist. iNOS and its products have been shown to 
influence the COX pathway, particularly, COX-2 activation and PG production 
(140-143, 145). Among the PGs, PGE2 is the most studied for its key role in 
inflammation. With this in mind, it was decided to study the effect of HB02 
fractions and the two active compounds 6S and GD from F6 on PGE2 
production. The effect on PGE2 production by RAW 264.7 cells was studied 
before LPS stimulation.  
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The experiments showed that the fractions, 6S and GD had potent inhibitory 
effects on PGE2 production which were comparable to indomethacin and 
dexamethasone (both at 10 μg/mL) (Figure 3.11). These results are consistent 
with the effects seen for F6 and 6S on iNOS mRNA and protein levels and on 
NO production. Based on the proposed link between the iNOS and COX 
pathways, these results suggest that F6/6S affect both pathways. However, it 
remains unclear whether either F6 or 6S are specific in their action on iNOS 
and/or COX1/2. The anti-inflammatory effects of 6S has been studied before 
and there is evidence to show that 6S has potent inhibitory effects on iNOS and 
COX (121, 149, 156). There is also evidence that  6S down regulates iNOS and 
COX-2 gene expression in macrophages by down regulating of NF-κB 
activation  and through blocking  the activation PI3K/Akt/IκB kinases IKK and 
MAPK (149). The experimental data presented in this chapter are in line with 
these observations and as shown by the ability of 6S to preferentially down 
regulate iNOS mRNA level when the cells were treated before stimulation with 
LPS. GD, in contrast, did not reduce the level of iNOS mRNA and showed 
marginal effect on iNOS protein level when the cells were treated before 
stimulation. However, GD still demonstrated inhibitory effects on NO and PGE2 
production. Thus, this data suggests that GD is most likely to affect the 
enzymatic activity of iNOS possibly by influencing the crosstalk between the 
iNOS and COX pathways (140, 141, 144, 145). Another possibility is that GD 
may have more substantial effects on COX compared with iNOS. Nevertheless, 
this hypothesis needs further studies. 
 
                                                                                                           CHAPTER 3                                                                                                                                                                                                                            
 
 
170 
6 Conclusions 
 
The experiments described in this chapter provide experimental evidence for 
the anti-inflammatory effects of ZOR and has enabled the identification of 
compounds that could mainly underlie these properties. Further, the data 
provide insight into potential mechanisms of action and the beneficial effects of 
this plant in inflammatory conditions including psoriasis.   
 
The murine macrophage cell line RAW 264.7 was selected for the screening 
process as it has been widely used in studies aimed at understanding the role 
of iNOS in inflammation and its role in NO and PGE2 production. This is 
particularly relevant as murine macrophages are known to be better responders 
to LPS stimulation resulting in NO production than human monocytes and 
macrophages (157). Thus, this gives consistency in the evaluation of ZOR’s 
fractions and compounds.  
 
As for the implication of results described in the chapter, it is known that iNOS, 
COX and their products can be modulated through various mechanisms at 
transcriptional, post-transcriptional, translational and post-translational levels 
(158). The results presented in the chapter showed that HB02 and its active 
fractions, particularly F6, have promising effects as potential anti-inflammatory 
agents. This proposition can be justified by the potent inhibitory effects of F6 on 
NO and PGE2 production and by its ability to down regulate iNOS at 
transcriptional and enzymatic levels. In this respect, the results suggest that the 
effect of F6 on iNOS mRNA level can be attributed to the effect of 6S rather 
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than GD. GD, in contrast, appeared to influence iNOS at post-translational level 
by modulating its enzymatic activity although this needs further studies.   
 
Figure 3.18 provides a summary on the potential mechanisms through which 
ZOR extract (HB02), its selected fractions (F5, 6, 7 and 10) and compounds 
from F6 (6S and GD) modulate the production of NO and PGE2. Both 
compounds appear to have dual inhibitory effects on both NO and PGE2, This is 
particularly important in inflammation since both mediators are key inducers of 
the inflammatory cascade in psoriasis. Both NO and PGE2 are also linked to the 
initiation and expansion of Th1 and Th17 lineage cells through by the induction 
of cytokines such as TNFα, IL-23 and IL-12, which are prominent in psoriasis 
pathogenesis. The next stage will, therefore, focus on studying the effect of 
these compounds on the production of IL-12, IL-23 and TNFα by activated 
macrophages. 
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Figure 3.18: A proposed mechanism of ZOR constituents on iNOS and 
COX-2 activities. The cartoon depicts possible mechanisms of ZOR action on                      
inflammation through 6S and GD. 6S acts by reducing iNOS mRNA and protein 
levels resulting in reduced NO and PGE2 production. GD, in contrast, appears 
to act by modulating the enzymatic activities. 
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1 Introduction 
 
1.1  The IL-12 /IL-23 axis of cytokines in inflammation 
 
 Dendritic cells (DCs) and macrophages are important players in the initiation of 
immunity. Both cells function partly by producing IL-12  and IL-23,  that, in turn, 
promote the differentiation of Th1 and Th17, respectively (136). Both immature 
(CD1a+) and mature (CD11c+, DC-LAMP+) DCs are capable of producing IL-12 
and IL-23. Interestingly, both IL-12 and IL-23 have been shown to be expressed 
in dermal DCs at the locality of inflammation. Within the context of psoriasis 
immunopathology, the detection of these two cytokines, and in particular IL-23 , 
is important as Th17 are predominant in psoriatic lesions (159).  The production 
of IL-12 leads to the differentiation of Th0 cells to Th1 cells which produce INFγ, 
a cytokine necessary for innate immunity and also the induction of T-cell 
homing to the skin (Figure 4.1). IL-23, in contrast, is important for the 
differentiation of Th17 cells that produce IL-17. IL-17 induces a chemotactic 
environment for the attraction of PMNs mainly through the production of CXC 
chemokines, such as CXC1 and CXCl5 along with the presence of LTB4. This 
promotes PMNs migration to sites of inflammation and, in chronic inflammation, 
leads to the exacerbation of disease. IL-23 and IL-12 share some common, 
though not identical, biological effects. For example, both activate STAT4, but 
IL-23 also, preferentially induces STAT3. This is demonstrated by the ability of 
IL-23 to weakly induce IFNγ production, whereas IL-12  is a strong inducer of 
IFNγ production (160). Thus, besides strongly activating Th17 cells, IL-23 also 
contributes to the induction of Th1 cells.  
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Various studies have highlighted  the existence of crosstalks between APCs 
and T-cells through the release of inflammatory mediators by APC, particularly 
PGE2, IL-12 and IL-23.  For example, it has been shown that the  IL-23 /IL-17-
axis induces PMN recruitment which is enhanced by the presence of PGE2 
which, in turn, augments the production of IL-23  and  IL-17 but dampens IL-12  
and IFN-γ production (161) (Figure 4.1). This depicts the indirect effect  
prostaglandins have in modulating Th1 and Th17 cell induction and expansion 
by synergising or inhibiting with IL-12  and IL-23 , which are released by 
macrophages. Consequently, this regulates inflammatory cascades promoted 
by Th1 and Th17.  
 
 
Figure 4.1: Crosstalks between the IL-12 and IL-23 axis and inflammatory 
mediators produced by DCs and macrophages. This interaction leads to 
enhanced Th1 and Th17 cell differentiation and expansion. The diagram 
indicates positive (blue arrow), negative (red arrow) and indirect (blue dotted 
arrow) interactions between the inflammatory mediators in the different 
cascades. Adapted and modified from Zakharova et al (2005) and Lemos et al. 
(2009) (161, 162).  
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1.2 The correlation between the IL-12 /IL-23 axis and TNFα 
 
There is evidence that TNFα, which is mainly produced by activated 
macrophages, inhibits Th1 cells by acting as  a negative regulator of IL-12  and 
IFN-γ production. Within this scenario, TNFα would act by limiting the length of 
inflammatory response. TNFα has, thus, been suggested to play an important 
role in the regulation of the  IL-12 /IL-23  axis (162). Numerous studies have 
been carried out to understand the paradoxical roles TNFα plays in immune 
responses, in the sense that it could function both as an inflammatory and also 
anti-inflammatory mediator.  
 
Generally, TNFα is known to play an important role in inducing many 
inflammatory cascades upon infection. Upon LPS stimulation, macrophages 
and DCs are activated through the NF-ĸB transcription factor which leads to the 
production of inflammatory cytokines, including IL-12  (163), IL-23  (164) as well 
as  TNFα (165). TNFα acts in a temporal manner to specifically inhibit IL-12p40 
production by macrophages stimulated with LPS, IFNγ and CpG DNA (162). 
Consequently, inhibition of IL-12p40 reduces IL-12 and IL-23 production by 
macrophage to a similar degree. Therefore, TNFα could act through a negative 
feedback response to regulate Th1 and Th17 induction. This, indeed, has been 
associated with the regulatory role of TNFα during the late stages of infection. 
This may, therefore, explain that despite the beneficial anti-inflammatory effects 
of anti-TNFα therapy (166)  there could be side effects associated with the 
therapy such as cutaneous eruption or psoriaform  rashes in patients diagnosed 
with rheumatoid arthritis, psoriatic arthritis, seronegative spondyloarthropathy, 
and with inflammatory bowel disease  (167, 168). 
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Because of the increased awareness of the central role played by IL-12 and   
IL-23 axis in immune-mediated disease, it has become a therapeutic target in 
recent years. In this context, it has been suggested that the inflammatory 
activity of IL-12 and IL-23 is connected to the presence of the shared p40 
subunit. Regulation of the p40 subunit has been shown to influence IL-12 and 
IL-23 roles in activating the Th1 and Th17 pathways, which are predominant in 
psoriasis. Further, clinical studies have shown that the p40 and IL-23p19 
subunits are promising targets to suppress the pathogenesis of psoriasis. For 
example, treatment with Ustekinumab, a monoclonal antibody with specificity for 
the p40 subunit, results in the resolution of psoriatic lesions in patients (34). 
 
1.3 The p40 subunit of IL-12 and IL-23 as a novel target for the treatment 
of psoriasis 
 
The success of Ustekinumab in the resolution of psoriatic lesions has become a 
benchmark in employing specific and selective targeting of cytokines in 
psoriasis. Ustekinumab binds to, and inhibits the p40 subunit of IL-12 and IL-23. 
Early studies indicate that IL-23 is predominant in psoriasis compared with      
IL-12. Thus, expression of p19 and p40 but not p35 has been shown to 
predominate in psoriatic lesions (169, 170). The important role of      IL-23 has 
also been shown in mice. Intradermal injection of IL-23 into the skin of normal 
mice was shown to result in lesions that closely resemble psoriatic plagues. In 
contrast, injection of IL-12  did not cause psoriasis (171).  
 
In summary, there is good evidence for the involvement of IL-23 in the 
pathogenesis of psoriasis and that targeting of p40 ameliorates psoriasis. This 
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appears to result from down regulation of the activity of Th1 and Th17 lineage 
cells which, in turn, suppress TNFα-induced inflammation and indirectly inhibit 
IL-23-induced PMN migration. Both of the latter events are important in the 
induction of inflammatory cascades that underpin the pathology of psoriasis. 
Thus, understanding and designing new strategies to manipulate the IL-12 and 
IL-23 axis could prove to be highly beneficial in treating patients with psoriasis.  
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2 Objectives 
 
Although ginger has been widely used in traditional medicine, there have been 
few studies aimed at understanding, at the molecular level, how it modulates 
inflammation. Whilst there are some reports on the effect of common ginger and 
its constituents on  leukocyte adhesion and migration (172), iNOS and COX 
(117, 123, 147, 173), limited studies have explored its effects on cytokines such 
as IL-23 , IL-12  or TNF-α. In line with current therapeutic strategies of targeting 
selective inflammatory pathways and molecules, the treatments of psoriasis 
have benefited from the use of biologics such as TNFα antagonists and         
anti-IL-23 Ab. The studies in this chapter, therefore, focus on another side to the 
immune-modulatory effects of ZOR and that is on IL-12, IL-23 and TNFα 
production by macrophages. 
 
These three pro-inflammatory cytokines are implicated in the inflammatory 
cascades that underpin immunopathology of psoriasis and the involvement of 
activated macrophages. In addition, by studying the effect of ZOR, its fractions 
and constituents of these key cytokines, their effects on leukocytes activation 
and recruitment could also be explored. 
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3 Methods 
 
3.1 Samples 
 
ZOR extract (HB02), fractions obtained by VLC fractionation (fractions 5, 6, 7 
&10) and isolated compounds from fraction 6 (6S and GD) were tested at two 
concentrations, 20 μg/mL for the HB02 and fractions and 50 μM for the 
compounds for the effect on the production of key pro-inflammatory cytokines. 
These tested samples were dissolved in DMSO (Sigma) to give a final 
concentration of DMSO in the test solutions of 0.2%. The inhibitory effects of 
the test samples were compared with the anti-inflammatory agent      L-NAME. 
Besides its ability to inhibit NO, L-NAME has been shown to inhibit TNFα  
production from LPS-stimulated macrophages (174). 
 
3.2 Cell cultures and bioassays 
 
All experiments were carried out by methods described in Method 3.3      
(chapter 3) and using the RAW 264.7 cell line. The cell line was treated with 
HB02, the selected VLC fractions and active compounds,  prior to and after 
stimulation of the cells with LPS, as described in the previous chapter. The level 
of mRNA for IL-12 p35, IL-12p40, IL-23p19 and TNFα in the stimulated RAW 
264.7 cells was determined by real-time PCR. The corresponding levels of 
TNFα protein in the collected supernatant were determined using MULTI-
ARRAYTM 96-Well Small Spot ELISA kit.  
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3.3 RT-PCR 
 
RNA was extracted as described in Method 3.6 (Chapter 3). In preliminary 
experiments, the level of TNFα mRNA was also detected in HB02-treated RAW 
264.7 cells before LPS stimulation using conventional PCR (Method 3.7 of 
Chapter 3). The following primers were used for the conventional PCR: 
 
Table 4.1: Summary of PCR primers used. 
Primer Sequence 5’ – 3’ 
GAPDH_for CACCATCTTCCAGGAGCGAGA 
GAPDH_rev ACGGAAGGCCATGCCAGTGA 
TNFα_for CATCTTCTCAAAATTCGAGTGACAA 
TNFα _rev TGGGAGTAGACAAGGTACAACCC 
 
Subsequent studies described in this chapter relied on using real-time PCR to 
accurately quantify the level of gene expression for cytokines of interest 
indicated above. 
 
3.4 Quantification of cytokine mRNA using real-time PCR 
 
Absolute qPCR ROX mixes and pre-designed TAQMAN® probes were used     
(Table 2). The relative quantitative method was used for this set of experiments. 
This method relies on measuring the concentration of mRNA for the gene of 
interest (GOI) in unknown samples relative to mRNA of the reference gene, 
which was GAPDH (Table 2). Level of the reference gene is the baseline for 
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expression of the target gene and is considered a benchmark. The Ct value of 
the target genes was determined and normalized with the Ct values of the 
reference gene to obtain C. Ct values that represent the relative 
quantitative expression level of the target gene. 
 
Table 4.2: Pre-designed primers for real-time PCR. Descriptions of the real-
time PCR primers (TAQMAN gene expression assay pre-designed by Applied 
Biosystems) for mouse pro-inflammatory cytokine genes and house-keeping 
gene (GAPDH) used in the study. The sequences were not available due to 
manufacturer confidentiality. 
Primer Sequence  Amplicon length 
GAPDH TAQMAN assay ID: Mm99999915_g1 
NCBI RefSeq: NM_008084.2 
107 
TNF-α TAQMAN assay ID: Mm99999068_m1 
NCBI RefSeq: NM_013693.2 
63 
IL-12p40 TAQMAN assay ID: Mm00434174_m1* 
NCBI RefSeq: NM_008352.2 
75 
IL-12 p35 TAQMAN assay ID: Mm00434165_m1 
NCBI RefSeq: NM_001159424.1,  
                 NM_008351.2 
68 
IL-23p19 TAQMAN assay ID Mm00518984_m1* 
NCBI RefSeq: NM_031252.2 
61 
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3.5 MULTI-ARRAYTM 96-Well Small Spot assay for cytokine protein 
measurement 
 
This protocol was used to measure the level of TNFα protein produced by 
activated RAW 264.7 cells either with no inhibitors or in the presence of HB02, 
fractions and isolated compounds. The kit was from Meso Scale Discovery 
(MSD; Gaithersburg, MD, USA) and assay was carried out according to the 
manufacturer instructions. The MSD platform is based on the proprietary 
combination of electrochemiluminescence detection and patterned arrays. The 
assay is very sensitive and can simultaneously provide quantitative data on 
single or multiple cytokines using small volumes of supernatant (25 μL). The 
assay has a detection limit 10,000 to 1.2 pg/mL. Briefly, 25 μL of supernatants 
(and recombinant mouse TNFα standard) were incubated for 2 hours on a pre-
designed mouse TNFα 96-well microtiter plate bearing capture antibodies to 
TNFα on the bottom of the wells. After washing, the detection antibody (at 1 
μg/mL) conjugated to the ruthenium-based MSD Sulfo-TAG™ reagent was 
added. Plates were washed and the MSD Read Buffer T (2x) added and results 
read on a Sector Imager (MSD). TNFα concentrations were determined with 
Softmax Pro Version 4.6 software, using a curve fit model (log-log or four-
parameter log-logit) as suggested by the manufacturer.  
  
Prior to the assay, TNFα standards were prepared in DMEM (medium used for 
the samples) from a stock concentration of 1 µg/mL into concentrations of 
10,000, 2500, 625, 256, 39, 9.8, 2.4 and 1.2 pg/mL. Supernatants were tested 
without dilution.  
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3.6 Statistical analysis 
 
Data were analysed using GraphPad Prism software (GraphPad Prism, San 
Diego, California). Means and standard deviation were used to describe 
normally distributed data. The significance of differences between groups was 
assessed using Two-way ANOVA (Bonferroni posttest). Difference of p<0.05 is 
considered significant. 
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4 Results 
 
4.1 The effects of ZOR extract, fractions and compounds on TNFα mRNA 
and protein levels. 
 
Targeting TNFα with biologic antagonists has revolutionized the approach to 
treatment of autoimmune inflammatory disorders, such as psoriasis, rheumatoid 
arthritis and Crohn’s disease. The success of this approach to therapy has 
confirmed the pivotal role of this cytokine in chronic inflammatory condition. For 
this purpose, the effect of ZOR on TNFα production by RAW 264.7 cells both 
before and following stimulation with LPS was studied. 
 
4.1.1 Pre-treatment of RAW 264.7 cells with HB02, or its fractions had no 
suppressive effects on TNFα mRNA level. 
 
The effect of pre-treatment of RAW 264.7 cells with HB02 or its fractions before 
stimulating the cells with LPS was originally studied using conventional PCR. 
HB02 and its selected fractions were all tested at 20 μg/mL prior to LPS 
stimulation. This concentration was chosen based on the average IC50 value in 
the NO inhibition experiments described in Chapter 3. Results of the PCR 
showed that HB02 and its fractions at 20 μg/mL had no, or negligible effects on 
detecting TNFα mRNA in the RAW 264.7 cells (Figure 4.2). Although the data 
showed slight reductions in the intensity of PCR bands representing TNFα 
mRNA for the cells when pre-cultured with the fractions, these results were not 
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reproducible. Therefore, it was decided to establish and use qRT-PCR to 
relatively quantified TNFα level.  
 
 
GAPDH 
TNFα 
 
 1 2 3 4 5 6 7 8 
LPS - + + + + + + + 
Samples - - HB02   F5  F6  F7  F10  LN        
 
Figure 4.2: The effect of pre-treating RAW 264.7 cells with HB02 or its 
fractions on the level of TNFα mRNA using conventional PCR. The cells 
were cultured as described in the Methods and pre-treated with 20 µg/mL of 
HB02 or its fractions 5, 6, 7 or 10 (Lane 3-7) for 30 minutes before the cells 
were stimulated with LPS. The effect of the samples were compared with                   
L-NAME(LN) at 54 μg/mL (lane 8).The treated and stimulated cells were 
incubated for 24 hours and then lysed for RNA extraction.  RNA was extracted 
from the cells and used to reverse transcribe to cDNA which were used for 
conventional PCR. The results were then analysed using a 1%  Agarose gel 
and DNA bands revealed with ethidium bromide.  
 
4.1.2 Real-time PCR reveals that HB02 and its fractions increase the level 
of TNFα mRNA in LPS-stimulated RAW 264.7 cells. 
 
The real-time PCR protocol provided quantitative data showing that pre-
treatment of the RAW 264.7 cells with HB02 and its fractions increased the level 
of mRNA for TNFα. Interestingly, the fractions had differing effects with the 
mRNA level, most enhanced by fraction 10 (Figure 4.3). HB02 and fractions 6 
and 10 added after stimulating the RAW 264.7 cells with LPS also had an 
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enhancing effect on TNFα mRNA level (Figure 4.3ii). Interestingly, fractions 7 
and, to a lesser extent fraction 5 had inhibitory effects on TNFα mRNA when 
they were added to the cells after stimulation with LPS. The data indicated that 
F7 and, to a lesser extent, F5 may contain active compounds that suppress 
TNFα mRNA levels after stimulation. L-NAME, however, did not significantly 
affect TNFα mRNA when added before LPS stimulation. Moreover, it increased 
TNFα mRNA level when added after LPS stimulation. F5 and F7 showed better 
effects than L-NAME on inhibiting TNFα mRNA. In order to validate these data, 
the level of TNFα at protein level was determined. 
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Figure 4.3: The effect of HB02 and fractions (F5, F6, F7 & F10) on the level 
of TNFα mRNA. The level of TNFα mRNA was determined in RAW 264.7 cells 
that were stimulated with LPS. The extract, HB02 and fraction at 20 μg/mL were 
either (i) added to the cells 30 minutes before stimulating the cells with LPS, or 
(ii) added 12 hours after stimulation. The outcomes of the treatment were 
compared with L-NAME (54 μg/mL/ 200 μM) for changes when the cells were 
treated before and after LPS stimulation. Data are presented as the mean ± SD 
of % of TNFα mRNA level relative to control. Statistical comparisons were 
carried out using Two-Way ANOVA (Bonferroni posttest).No significant 
difference was observed between samples in each set of approaches (before or 
after LPS stimulation). 
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4.1.3. 1-dehydro-6-gingerdione (GD) identified in F6 suppresses TNFα 
mRNA level.  
 
The results presented in the previous section showed that F6 increased the 
level of TNFα mRNA. Further, effect of its constituents, 6S and GD (at 50 µM) 
on TNFα mRNA was determined (Figure 4.4). This concentration was chosen 
based on the IC50 of the compounds when tested for NO inhibition. The effect of 
both compounds on TNFα mRNA was compared with that of L-NAME at          
200 µM.   
 
The experiments on TNFα mRNA level showed that GD reduced the level of 
mRNA when the cells were pre-treated with the compound before LPS 
stimulation (Figure 4.4i). 6S, in contrast, increased the level of TNFα mRNA, 
again when the cells were pre-treated. The effect of 6S is, thus, similar to that 
seen for the crude fraction, F6. This finding shows that GD behaves in a 
contradictory manner to both 6S and F6. The findings on the effect of 6S is in 
agreement with previous findings (123) that showed that 6S was unable to 
inhibit TNFα  production and that this relates to the inability of the compound to 
suppress TNFα gene transcription. However, there is a caveat to the study by 
Lantz and colleagues in that their study was based not on purified 6S but on a 
mixture of compounds containing 6S. 
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Figure 4.4: The effect of 6S and GD on the level of TNFα mRNA. The level 
of TNFα mRNA was determined in RAW 264.7 cells that were stimulated with 
LPS. 6S and GD at 50 μM were added to the cells either (i) added 30 minutes 
before stimulation with LPS, or (ii) 12 hours after stimulation. Changes in the 
level of mRNA level were determined using real-time PCR. GD reduced the 
level of TNFα mRNA by about 40% when the cells were pre-cultured with the 
compound before stimulation. Data is in mean ± SD. Statistical comparison 
between all samples was carried out using Two-Way ANOVA (Bonferroni 
posttest) on at least three independent experiments. The outcomes of the 
treatment were compared with L-NAME (200 μM).  
 
As shown earlier, L-NAME did not reduce the level of TNFα mRNA when the 
cells were either treated before stimulation with LPS or added after stimulation. 
In these experiments, 6S and F6 that contains the compound were shown to 
have similar effects to L-NAME. However, no studies are available showing the 
effect of GD on TNFα mRNA. 
                                                                                                           CHAPTER 4                                                                                                                                                                                                                          
 
191 
4.1.4 HB02, tested fractions, 6S and GD have no effect on the level of 
TNFα protein. 
 
To confirm whether any of the tested products of ZOR could or could not affect 
TNFα, their effects on the production of the protein produced by LPS-stimulated 
RAW 264.7 cells was assessed. These experiments also aimed to verify the 
results obtained for their effect on TNFα mRNA levels. The level of TNFα in 
supernatants of the activated RAW 264.7 cells was quantified MSD kit. The 
extract, HB02, tested fractions and compounds 6S and GD were all tested at   
20 μg/mL. The results showed that none of the test samples used had 
significant effects on TNFα protein levels detected in the tested supernatants 
(Figure 4.5). This data confirms the real-time PCR data on the lack of effect on 
TNFα mRNA levels. However, there were slight reductions in the level of TNFα 
protein by the fractions, especially when the test samples were added after the 
cells were stimulated with LPS (Figure 4.5ii). F5, F7 and F10 marginally 
reduced the level of TNFα protein production by activated RAW 264.7 cells by 
1-2% before and after LPS stimulation.  
 
These results, thus, confirm that neither HB02, its fractions nor the two isolated 
compounds are capable of influencing TNFα gene transcription/mRNA stability 
or protein production despite their significant inhibitory effects on iNOS mRNA 
and protein expression. This may suggest that, the test compounds influence 
the activation of different transcription factors or different regulatory pathways. 
Theoretically, this could be due to different turnover rates of the respective 
mRNAs (175). However, the modest ability of F5, F7 and GD in down-regulating 
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TNFα mRNA level after LPS stimulation could be therapeutically relevant as it is 
in line with its inhibitory effect on iNOS.  
 
 
 
Figure 4.5: The effect of HB02, fractions and compounds on TNFα protein 
production. The level of TNFα protein production by RAW 264.7 cells was 
determined using the MULTI-ARRAYTM 96-Well Small Spot MSD kit. HB02, F5-
F10 were tested at 20 µg/mL while 6S and GD were tested at 50 µM. The 
effects were assessed when the cells were either pre-treated with the test 
inhibitors or added after stimulation with LPS. L-NAME was tested at 200 µM. 
No significant differences were observed for the test inhibitors when the cells 
were treated before or after stimulation. The comparison is based on one 
experiment.  
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4.2 The effects of HB02, fractions and active compounds on                    
IL-23p19 mRNA level. 
 
The results presented earlier in this chapter indicated that treatment of the 
macrophage cell line RAW 264.7 with HB02 or with its fractions (except for F5 
and F7) and compounds 6S had either no effect or even increased the level of 
TNFα mRNA. To further explore the effect of ZOR on inflammation, the effect of 
HB02, its fractions and compounds 6S and GD on the level of IL-23p19 mRNA 
was studied.  
 
4.2.1 HB02 and fractions down regulate IL-23p19 mRNA levels. 
 
Experiments revealed that IL-23p19 mRNA level was down-regulated when 
RAW 264.7 cells were pretreated with HB02 and its fractions prior to stimulation 
with LPS (Figure 4.6i). Of the fractions tested, F7 showed the most potent 
inhibitory effect (~60% inhibition). Interestingly, the results showed that pre-
treatment of the cells with L-NAME, increased the level of IL-23p19 mRNA 
levels (Figure 4.6i). This effect is consistent with the noted effect of L-NAME on 
TNFα mRNA level. This finding highlights the fact that ZOR has a wider 
spectrum of anti-inflammatory effects compared with L-NAME (p<0.001). These 
results highlight that the effect HB02/its fractions have on IL-23p19 mRNA may 
be therapeutically beneficial in psoriasis. However, when the extract and 
fractions were tested for their effects on IL-23p19 mRNA after the RAW 264.7 
cells were stimulated with LPS, the opposite affect was observed in that HB02 
and the fractions all enhanced the level of IL-23p19 mRNA to varying degrees 
(Figure 4.6ii).  
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The explanation for this observation is unclear but this could relate to 
differences in the transcription factors, or even components of the same 
transcription factor, involved in steady state induction of IL-23p19 than those 
involved in activated cells and which of these is or is not inhibited by the 
selected ZOR samples. In this respect, it is known that the promoter for IL-
23p19 has a number of sites for NF-κB binding but interestingly it appears that 
the different members of the transcription factor family have different effects on 
the level of IL-23p19 gene transcription. For example, deficiency in NF-κB c-Rel 
protein abolishes p19 production while Rel-A deficiency only partly inhibits the 
production of p19 in macrophages (164). In contrast, deficiency in Rel-B 
enhances p19 production. It could, therefore, be that ZOR inhibits, or promotes 
the binding of the different components of the NF-κB complex, or other 
transcription factors, at each stage of IL-23p19 gene transcription  
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Figure 4.6: The effect of HB02 and its fractions on the level of IL-23p19 
mRNA. The level of IL-23p19 mRNA was determined using real-time PCR. The 
cells were either treated with the test samples 30 minutes before stimulation 
with LPS or treated 12 hours after stimulation. Data are presented as the       
mean ± SD from more than three independent experiments. Statistical 
comparisons between all samples were carried out using Two-Way ANOVA 
(Bonferroni posttest). The outcomes of the treatments were compared with L-
NAME for changes when the cells were treated before and after LPS 
stimulation. All selected ZOR samples showed more potent effects compared 
with L-NAME when added before LPS stimulation (***p<0.001).  
 
4.2.2 The effect of 6S and GD on IL-23p19 mRNA level. 
 
Using the same approach as in the previous section, the effect of 6S and GD on 
IL-23p19 mRNA levels in LPS-stimulated RAW 264.7 cells was then compared. 
The results showed that both 6S and GD reduced the level of IL-23p19 mRNA 
when the RAW 264.7 cells were treated with the compounds before  stimulation 
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(Figure 4.7i). In contrast, treatment of the cells with GD, and to a lesser degree 
6S, increased the level of IL-23p19 mRNA when added after LPS stimulation 
(Figure 4.7ii). L-NAME increased the level of IL-23p19 mRNA irrespective 
whether the cells were treated before stimulation or after. Hence, the inhibitory 
patterns of these compounds are comparable to that of F6 (Figure 4.6). 
 
Figure 4.7: The effect of 6S and GD on the level of IL-23p19 mRNA. The 
level of IL-23p19 mRNA was determined using real-time PCR. The cells were 
either treated with 6S or GD at 50 μM (i) 30 minutes before stimulation with LPS 
or (ii) treated 12 hours after stimulation with LPS. Data are presented as the       
mean ± SD from more than three independent experiments Statistical 
comparisons between all samples were carried out using Two-Way ANOVA 
(Bonferroni posttest). Both compounds showed significant effects than L-NAME 
(p<0.01) when the cells were treated before stimulation.  
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4.3 The effect of HB02, fractions, 6S and GD on IL-12p40 mRNA level. 
 
IL-23 and IL-12 share a common protein subunit, p40 that forms a 
heterodimeric complex with p19 and p35, respectively. The heterodimeric 
complexes are biologically active in the differentiation of Th17 and Th1 cells, 
and important in the pathogenesis of psoriasis. Based on these facts, the next 
set of experiments examined the effect of HB02, its fractions, and 6S and GD 
on the regulation of IL-12/IL-23p40 production by the RAW 264.7 macrophage 
cell line.  
 
4.3.1 The effect of HB02 and fractions on IL-12 /IL-23p40 mRNA levels. 
 
Experiments to assess the effect of HB02 and its fractions were carried out as 
described in the previous section using the RAW 264.7 cells treated either 
before LPS stimulation or after. The results showed that HB02 and its fractions 
significantly reduced the level of IL-12/IL-23p40 mRNA levels when the RAW 
264.7 cells were treated before stimulation with LPS (Figure 4.8i). Interestingly, 
the results showed that HB02 and its tested fraction had more potent inhibitory 
effects on IL-12/23p40 mRNA when the cells were treated after stimulation with 
LPS (Figure 4.8ii). L-NAME also reduced the level of IL-12/IL-23p40 mRNA 
when the cells were added to cells before LPS stimulation but in contrast 
increased the level when added after stimulating the cells with LPS. These data 
suggest that HB02 and its fractions reduce IL-12/IL-23p40 gene transcription 
and/or mRNA stability before and after cell stimulation with LPS. This finding 
may indicate that ZOR could have therapeutic potential in reducing the level of 
IL-12 and IL-23 in pathological conditions including psoriasis. 
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Figure 4.8: The effect of HB02 and its fractions on the level of                    
IL-12 / IL-23p40 mRNA. The level of IL-12 /23p40 mRNA was determined using 
real-time PCR. mRNA levels were determined using LPS-stimulated RAW 
264.7 cells. The cells were either treated with HB02/fractions  (i) 30 minutes 
before stimulation with LPS or treated (ii) 12 hours after stimulation. Data are 
presented as the mean ± SD of IL-12/23p40 mRNA level with the indicated 
treatments.  Statistical comparisons between all samples were carried out using 
Two-Way ANOVA (Bonferroni posttest). Comparisons are based on at least 
three independent experiments. Both treatment approaches reduced                
IL-12 /23p40 mRNA levels and no statistically significant differences between 
the two approaches were noted. All samples showed very significant changes 
compared with L-NAME. The significance is indicated as ***= p<0.001. 
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4.3.2 The effect of 6S  and GD on IL-12 /23p40 mRNA. 
 
In the next stage of this study examined the effect of 6S and GD on                  
IL-12/IL-23p40 mRNA level. Both 6S and GD were tested at 50 μM and 
inhibitory effects compared with L-NAME at 200 μM.  
 
Both 6S and GD consistently showed inhibitory effects on the level of               
IL-12 /23p40 mRNA when the cells were treated before stimulation with LPS 
(Figure 4.9i). The inhibitory effects of both compounds were superior to the 
effect of L-NAME. Interestingly, however, whilst 6S also reduced the level of    
IL-12/23p40 mRNA when the cells were treated after stimulation with LPS, GD 
in contrast increased the level of IL-12 /23p40 mRNA. The inhibitory effect  was 
significant when compared with that of L-NAME (Figure 4.9ii). This may suggest 
that in so far as the effect of suppressing ongoing inflammation in which          
IL-12/IL-23 play a role is concerned, 6S but not GD, has the potential to be used 
as a therapeutic agent. 
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Figure 4.9: The effect of 6S and GD on the level of IL-12/IL-23p40 mRNA. 
The level of IL-12/IL-23p40 mRNA was determined using real-time PCR. The 
effect of treatment with 6S and GD on the level of IL-12/IL-23p40 mRNA was 
determined using LPS-stimulated RAW 264.7 cells. The cells were either 
treated with 6S and GD 30 minutes before stimulation with LPS or treated 12 
hours after stimulation. Statistical comparisons were carried out using Two-Way 
ANOVA (Bonferroni posttest). Data are presented as the mean ± SD of            
% of IL-12 /IL-23p40 mRNA level relative to control. The results for the effect of 
6S vs. GD on IL-12 /IL-23p40 mRNA are based on at least three independent 
experiments. 6S showed very significant inhibition of IL-12/IL-23p40 when 
added after LPS stimulated (p<0.001). 
 
 
 
 
                                                                                                           CHAPTER 4                                                                                                                                                                                                                          
 
201 
4.4 The effects of HB02, fractions, 6S and GD on IL-12p35 mRNA. 
 
In order to determine the spectrum of the effect of HB02, fractions and 
compounds on the two cytokines relevant to psoriasis immunopathogenesis,   
IL-12 and IL-23, experiments were carried out to determine their effect on        
IL-12p35 mRNA level. Besides IL-12/IL-23p40, IL-12 is composed of a 
heterodimer containing IL-12p35. The experiment s to assess the effect of ZOR 
on IL-12, however, were hampered by the finding that LPS stimulation of the 
RAW 264.7 resulted in the production of low and inconsistent levels of             
IL-12 p35 mRNA. In this respect,  there is some evidence that in contrast to     
IL-12p40 and IL-23p19 the induction of IL-12 p35 mRNA requires the activation 
of additional transcription factors to complement LPS stimulation (176). Studies 
have suggested that such transcription factor could be induced by treating 
macrophages with IFNγ (177, 178). Time constraints did not allow for detailed 
assessment of the optimal conditions for using IFNγ in the system to study the 
kinetics of IL-12 p35 production by the RAW 264.7 cells and to assess the effect 
of ZOR.   
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5 Discussion 
 
5.1 ZOR’s extract and active constituents reduce IL-12p40 mRNA level.  
 
There is strong evidence that IL-12 and IL-23 play important roles in the 
pathogenesis of psoriasis. In addition to finding high levels of both cytokines in 
psoriatic skin lesions, recent therapeutic targeting of IL-12 /IL-23p40 has proven 
to be very beneficial. With this in mind, the effect of HB02, its fractions, 6S and 
GD on the IL-12 and IL-23 was studied. The results showed that HB02 and its 
fractions reduced the level of IL-12p40 mRNA whether the RAW 264.7 cells 
were treated before or after stimulation with LPS. Although examining the effect 
of ZOR and its fractions showed they down regulated IL-23p19 mRNA only 
when the cells were treated with HB02 or the fractions before the cells were 
stimulated but not after, their effect on IL-12/IL-23 could be highly relevant 
therapeutically. This is because IL-12/IL-23p40 constituents functionally active 
heterodimeric IL-12 and IL-23 cytokines. This, in turn, implies that HB02 and its 
fraction are capable of indirectly suppressing the differentiation of Th1 and Th17 
lymphocytes. Interestingly, HB02 and its fractions also down-regulated IL-23p19 
mRNA levels which further supports their potential anti-inflammatory effects. 
However, their effect on IL-12p35 could not be determined due to inefficiency of 
LPS in inducing its expression in LPS-activated RAW 264.7 cells (176-178). 
The fact that IL-12p35 is mainly expressed constitutively and not enhanced in 
psoriatic lesions compared with IL-12p40 and IL-23p19 (169, 170), suggested 
that focus should be placed on the effect of the ZOR on IL-23 and Th17 cells. 
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It was interesting to note that among the tested fractions, F7 down-regulated 
TNFα mRNA levels after the cells were stimulated with LPS but had no effects 
on protein levels. This suggests either that the TNFα protein produced after 
stimulation represents pre-synthesised proteins or that the turnover rate of 
production is too strong to be inhibited by F7. Nevertheless, these findings 
suggest that F7 may contain compound/s that modulate the level of TNFα 
mRNA transcription, or stability once transcribed, which could be identified in 
future studies.  
 
Of interest regarding the effect of HB02 fractions was the inability of F6, shown 
in chapter 3 to have the most potent inhibitory effect on NO and PGE2, to 
modulate TNFα levels. This fraction had no effects, or had enhancing effects on 
TNFα mRNA levels. Despite this observation, however, assessing the effects of 
compounds 6S and GD showed that the latter had the ability to reduce the level 
of TNFα mRNA. The fact that 6S resembled F6 in its effect on TNFα mRNA 
may have a stronger influence than GD when in a mixture (in F6). It is 
noteworthy, however, that both 6S and GD up-regulated TNFα mRNA when 
added to the cells after stimulation with LPS and also had little effect on TNFα 
protein production. All these results indicate that, neither HB02, its fractions 
(with the exception of F7) nor compounds; 6S and GD have significant inhibitory 
effects on inflammation mediated by TNFα.  
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5.2 The potential regulatory effects of 6S and GD on Th1/Th17 
differentiation. 
 
There is evidence for a link between the IL-12 /IL-23  axis and TNFα production.     
IL-23 has a central role in the differentiation of Th17 cells. Further, IL-23-
dependent Th17 differentiation is involved in various autoimmune inflammatory 
conditions (179). The presence of IL-23p19 along with IL-17 enhances the 
production of TNFα (180). In turn, TNFα and IL-17  synergistically enhance        
IL-23p19 production (179) and lead to unrelenting progression of inflammation. 
The interaction between IL-23 and TNFα has been suggested by the noted 
effect of Etanercept in patients with RA whereby reduction in TNFα 
consequently leads to a decrease in IL-23  production (181). 
 
One interpretation of these results is that a correlation between the effect of GD 
on TNFα expression when the cells are treated before stimulation and a 
reduction in IL-23p19 mRNA exists. The reduction of about 40% in TNFα mRNA 
(Figure 4.4a) equates with a similar reduction in IL-23p19 mRNA (Figure 4.7i). 
This may suggest that GD acts by directly modulating a common transcriptional 
pathway(s) involved in the production of both IL-23 and TNFα.  
 
The available evidence indicates that LPS-induced TNFα gene transcription is 
mediated by the binding of Egr-1, CRE and NF-κB (κB3/RelA) to promoter 
regions within the gene (165, 182). LPS-induced IL-23p19 gene expression is 
mediated by signaling through the MAPK (ERK, JNK, and p38) pathway leading 
to the activation of NF-κB  (183). Both cytokines are, therefore, induced by 
processes that lead to the activation of NF-κB. This may explain, at least partly, 
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the inhibitory effect of GD on the level of mRNA of both cytokines. A number of 
studies have shown that Rel-A and particularly c-Rel bind to the proximal NF-κB 
site in the promoter region of the IL-23p19 gene (164, 184).  Thus, the 
transcription of TNFα and IL-23p19 genes could be linked to Rel-A binding to 
sites within their promoter regions. Down-regulation of both IL-23p19 mRNA 
and IL-12p40 mRNA by GD and 6S, in contrast, may suggest that the 
transcription of these two genes are connected through c-Rel binding (163). 
 
In contrast to GD, 6S demonstrated similar effects to F6 and HB02. Thus, 6S 
down regulated mRNA levels for both IL-23p19 and IL-12p40 but enhanced 
TNFα mRNA when the cells were treated with 6S before stimulation with LPS. 
After stimulation, 6S reduced the level of IL-12p40 mRNA and, thus, indirectly 
inhibited   IL-12 production. These results may, therefore, suggest that GD has 
advantages over 6S in that the former has the ability to inhibit IL-12 /IL-23 and 
TNFα production when the cells are treated before stimulation. It is not clear at 
this stage, however, whether this would have any beneficial therapeutic 
applications. 
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6 Conclusions 
 
The data presented in this chapter provides an overview for possible 
mechanisms of how ZOR’s extract, fractions and compounds might influence 
inflammation mediated by IL-12 /IL-23 and TNFα (Figure 4.10). The results, 
thus, showed that HB02, its fractions (F5, F6, F7 and F10) and 6S had similar 
effects on IL-12p40 mRNA whether the cells were treated before LPS 
stimulation or after. However, they only had suppressive effects on the level of 
IL-23p19 mRNA when used to treat the cells before stimulation but not after. In 
addition, all except F7 and GD had no effects on the level of TNFα mRNA 
whether the cells were treated before or after stimulation. The exact implication 
of these findings is not available at the stage. However, it is possible that the 
lack of inhibitory effects when the extract, fractions or compounds are added 
after stimulation may relate to the enhanced transcription/turnover rate of the 
genes, or the involvement of additional transcriptional pathways not inhibited by 
the test samples on the cells once stimulated. With this point in mind it may be 
possible to suggest that the ability of F7 to down regulate TNFα mRNA level 
after stimulating the cells may relate to inhibition of signalling 
pathway/transcription factors that are induced after activation but not before.  
 
In contrast to F7, GD was effective in reducing the level of TNFα mRNA level 
before LPS-stimulation of the cells but not after. This, again, may be attributed 
to stronger gene transcription by the same signalling pathway/transcription 
factor or involvement of different ones after activation that is/are not inhibited by 
GD. However, overall these data indicate that ZOR contains compounds that 
target multiple signalling pathways and transcription factors. Some of the 
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findings regarding the effect of HB02, fractions and compounds on the 
cytokines studied in this chapter are consistent with findings by Lantz and 
colleagues who showed that ginger extracts, which contained shogoals and 
gingerols, were unable to reduce TNFα production but potently down-regulated 
COX-2 in LPS-stimulated U937 cells (123). 
 
Figure 4.10: A cartoon depicting proposed mechanisms for the effects of 
ZOR on TNFα, IL-12/IL-23p40 and IL-23p19 mRNA levels before and after 
stimulation of macrophages. The plus (+) and minus (-) signs indicate 
stimulatory and inhibitory effects on the designated cytokine mRNA level, 
respectively.  All ZOR samples regulate IL12/IL23 mRNA level when added 
before LPS stimulation. Of interest, was the ability of F5, F7 and GD in 
regulating TNFα may have a beneficial impact on the treatment of psoriasis. 
The mechanisms outlined indicate that ZOR contains compounds that could 
target multiple signalling pathways and transcription factors involved in 
inflammation. 
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Modulatory effects of ZOR on 
immune cell responses 
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1 Introduction 
 
1.1 The role of leukocytes in psoriasis 
 
In addition to the role Th1 and Th17 T-lymphocytes play in psoriatic 
inflammation, leukocytes such as polymorphonuclear PMNs (PMN) have been 
shown to be involved in the early stages of psoriasis. It is generally thought that 
leukocytes play a key role during the ‘acute’ phase of the inflammatory 
response in psoriasis. This is manifested by the accumulation of PMN and 
parakeratotic hyperkeratosis which is characterised by abnormal keratinisation 
or incomplete formation of keratin in the stratum corneum, loss of granular layer 
and increased cell turnover. The ‘acute’ inflammatory phase is severe and 
resistant to treatment compared with the ‘chronic’ phase inflammation. ‘Acute’ 
and ‘chronic’ inflammations are histological terms to characterise and 
categorise the phenotype of lesions within the same lesional area (185). 
Chronic inflammation is characterised by epidermal hyperplasia and T-
lymphocyte infiltration without the presence of PMNs as seen in plaque 
psoriasis. The characteristics of ‘acute’ inflammation, however, are seen in 
guttate and pustular psoriasis, which are due to viral and bacterial infection. It is 
thought that autoimmune mechanisms trigger the recruitment of PMNs to the  
site of  parakeratosis in the  epidermis to cause the appearance of Munro’s 
microabcesses (subcorneal abcessess) (186). Thus, it is suggested that the 
accumulation of PMNs at the site of inflammation is not a passive event and 
that they act as stimulators of T-cell-mediated immune responses which 
subsequently boost  T-cell-associated-inflammation-sustaining loop through the 
activation of both epidermal keratinocytes and T-cells (185). 
                                                                                                           CHAPTER 5                                                                                                                                                                                               
 
210 
In the initial stages of inflammation, the transmigration of PMNs to sites of 
inflammation is facilitated by the interaction of cellular adhesion and co-
stimulatory signalling molecules. These molecular signals guide the interactions 
between PMNs and activated endothelial cells to enable the former to travel 
through the vascular lining from vessel lumen to inflamed tissues. Cell 
recognition and interaction depend on several adhesion molecules constitutively 
expressed, or induced, on the surface of PMNs and endothelial cells. These 
adhesion molecules are the selectins, the integrins and the immunoglobulin-like 
molecules that operate in a sequential manner (Figure 5.1). The first stage of 
inflammation involves PMN tethering and rolling, and these are facilitated by     
L-selectin, PSGL-1 and E-selectin ligand on the surface of PMNs. They interact 
transiently with their cognate counter-receptor ligands, including GlyCAM-1. 
PSGL-1, hyaluronan, E- and P-selectin, on activated endothelial cells.              
P- selectin/PSGL-1 interaction enables leukocyte rolling, E-selectin controls the 
rolling velocity for binding signal surveillance on the endothelium and               
L-selectin/PSGL-1 enables leukocyte capture on the endothelium. Available 
evidence shows that PSGL-1 mediates rolling and tethering of leukocytes 
through interaction with all three selectins through leukocyte-endothelium and 
leukocyte-leukocyte interactions (187, 188). PSGL-1 directly interacts with         
L-selectin through PMN-PMN interaction. PMN-PMN interaction during free 
flowing allows the PMNs to bind to the adherent PMNs resulting in amplification 
of recruitment rate at the site of inflammation (189). Therefore, selectins and 
their ligands are useful indicators of the initiation stage of inflammatory 
processes.  
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L-selectin (CD62L) is a homing receptor that enables leukocytes to enter 
secondary lymphoid tissues. When L-selectin binds to its cognate ligand on 
activated endothelial cells, leukocyte movement slows down. This enables 
leukocytes to adhere to high endothelial venules and subsequently transverse 
into secondary lymphoid tissues for priming.  During this interaction L-selectin 
will be disengaged, or shed from the cell surface of PMNs upon activation by 
chemokines. Among the selectin family, L-selectin is constitutively expressed on 
all subsets of leukocytes, whilst E- and P-selectin are expressed on activated 
endothelium (134). Previous in vivo studies have shown that the blockade of    
L-selectin reduces PMN accumulation at sites of inflammation in the 
peritoneum, skin and the lung (134). This suggests that L-selectin plays an 
important role in the initiation of inflammation. It mediates the earliest interaction 
between leukocytes and activated vascular endothelium and allows for 
leukocytes rolling in search of inflammatory signals. 
 
In severe psoriasis, decreases in L-selectin expression on monocytes, PMN,   
B-cells and CD4+ T-cells as well as increase of serum L-selectin have been 
observed (190). It has been suggested that L-selectin expression levels on 
some leukocyte subset, particularly CD4+ T-cells corresponds to the severity of 
disease (190). Chemoattractant signaling by chemokines produced upon 
infection/inflammation induce firm adhesion of leukocytes. This is facilitated by 
conformational changes in β2 integrin, such as Lymphocytes function-
associated antigen-1 (LFA-1) and macrophage-1 antigen (Mac-1). LFA-1 is 
comprised of two integrins, CD11a and CD18. CD11a, or integrin-αL (also 
known as ITGAL), is involved in cellular adhesion and costimulatory signaling. 
CD18 integrin is the prime mediator in leukocytes/endothelium interaction (191). 
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Mac-1, which is also known as heterodimeric integrin alpha-M beta-2 (αMβ2) 
molecule (also as complement receptor 3; CR3), is a protein integrin subunit of 
CD18 and CD11b (Integrin-α M or ITGAM). LFA-1 plays an important role in 
firm adhesion whilst Mac-1 is crucial in leukocytes intravascular crawling and 
transmigration to inflamed sites. Mac-1 enables leukocytes to crawl 
perpendicularly against the blood flow, which is an advantage as it allows 
leukocytes to detect endothelial junctions in a short period of time and 
transmigrate through them (192).   
 
These evidence, therefore, indicate that both CD11a and CD11b integrins are 
important markers of leukocyte transmigration. During leukocytes 
transmigration, LFA-1 and Mac-1 interact with receptor ligands, ICAM-1 and/or 
ICAM-2. Both ligands are intracellular adhesion molecules (ICAM) expressed on 
the surface of the endothelial cell. This interaction facilitates recruitment of 
leukocytes to sites of inflammation upon activation by chemokines, such as IL-
8.  IL-8 is known to induce a chemoattractant environment by binding to 
chemokine receptors, such as CXCR-1/CXCR-2. In psoriasis, CXCR-1 is 
expressed on infiltrating cells in the dermal layer of psoriatic skin, whilst CXCR-
2 is expressed on both infiltrating cells and suprabasal layers of psoriatic 
keratinocytes (193). In inflammatory diseases, continuous release of 
inflammatory mediators such as cytokines, chemokines and secondary 
messengers create a chemotactic environment that favours the recruitment of 
more APCs, leukocytes and T-lymphocytes that consequently exacerbate the 
inflammatory response.  
 
/ 
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Figure 5.1: The interaction between leukocytes and endothelial cells 
during transmigration. The adhesive interaction between leukocytes and 
endothelial cells is involved in promoting leukocyte tethering and rolling, 
activation, firm adhesion and transmigration to sites of inflammation. PMN 
tethering, rolling and activation are facilitated by selectins. Integrin, such as 
LFA-1 and Mac-1 take charge for PMN firm adhesion and transmigration. 
Migrated PMNs localise to inflamed tissues and interact with activated antigen 
presenting cells (APCs), which release cytokines and chemokines which, in 
turn, exacerbate the inflammatory response. 
 
1.2 Activation of T-lymphocytes in psoriasis 
 
One of the characteristics of an autoimmune disease is the activation of auto-
reactive T-lymphocytes that is partly mediated by the production of pro-
inflammatory cytokines and chemokines. TNFα, IL-1 and IL-2 are all known 
cytokines that promote T-lymphocyte activation and proliferation. IL-1 is 
secreted by many cells including macrophages, monocytes, T- and B-
lymphocytes, and known for its function as co-stimulator for T-lymphocyte 
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activation. IL-1 induces activated T-lymphocytes to produce IL-2, which 
subsequently induces further T-lymphocyte activation and proliferation. 
According to previous studies, this co-stimulatory role of IL-1 is attributed to two 
complementary effects which are 1) by enhancing IL-2 transcription and 
secretion (194) and 2) by stimulating expression of membrane receptor for IL-2 
(195, 196). Activated T-lymphocytes express activation markers on their surface 
and these include CD25, CD69 and HLA-DR. Generally, after T-cell activation, 
CD69 is the earliest marker to be upregulated followed by CD25 and HLA-DR. 
CD25 is the α subunit of IL-2 receptor (IL-2R), This receptor plays an important 
role in inducing T-cell activation and is critical for the activation of Th1 cells in 
psoriasis. CD69 is a receptor that is transiently expressed after T-cell activation; 
nonetheless, its functional importance in T-lymphocyte activation in psoriasis is 
not entirely clear. 
 
A previous study using flaky skin mice (fn/fn) whose disease resembles 
psoriatic skin showed that high levels of CD69 expression was biased towards 
CD8+ whilst CD25 was dominantly expressed on CD4+ T-lymphocytes (197). In 
patients, this notion is supported by a study showing that CD25 expression is 
prevalent in the epidermal and dermal layer of psoriatic skin as well in the 
circulation whilst CD69 and HLA-DR are significantly increased on circulating   
T-cells (198). Interestingly, a recent study suggested that ligation of CD69 can 
inhibit Th17 differentiation by activating Jak3 signal transducer and STAT5 
(199). This, in turn, prevents STAT3 translocation to the nucleus and blocks 
STAT3-mediated RORγt induction by activating FoxP3 (199). In this context, 
CD69 expression could modulate the Th17 cell expansion, which is pathogenic 
in psoriasis.  
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As cited in chapter 1, Th1 and Th17 have been shown to play significant roles in 
initiating and sustaining inflammation in psoriasis. Besides the described roles 
played by helper T-lymphocytes there is evidence that cytotoxic CD8+ cells also 
produce TNF-α and IFN-γ as well as Th17-related cytokines such IL-17, IL-21 
and IL-22 in psoriatic plaque (200). This highlights the contribution of CD8+ 
subsets in complement with the roles played by helper T-lymphocytes in 
psoriasis. 
 
1.3 Modulation of leukocyte migration and T-lymphocyte activation as 
therapeutic options.  
 
Over the years, therapeutic approaches targeting leukocyte recruitment and 
trafficking by inhibiting expression of selectins, integrins and chemokines has 
been used to treat inflammatory diseases, including psoriasis. Thus far 
Efalizumab has been shown to be effective in treating some psoriatic patients 
by binding to the α-subunit (CD11a) of LFA-1 and inhibiting T-cell activation. 
LFA-1/ICAM  binding has been known to facilitate the activation and migration 
of T-lymphocytes from the circulation into dermal and epidermal layers and, 
consequently, leading to their reactivation (201).    
 
Despite the emergence of effective biologic treatments (described in chapter 1), 
other types of therapy with enhanced efficacy, safety and convenience are 
needed in the treatment of psoriasis. There are studies on potential synthetic 
antagonists that inhibit the interaction between selectins and their carbohydrate 
ligands. Among the successful ones is Efomycine, which mimics the structure of 
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sialyl Lewisx (sLex), which has shown significant beneficial effects in 
experimental psoriasis by acting to impair leukocyte rolling and adhesion (202). 
Designing inhibitors against sLex carbohydrate epitope is based on the fact that 
all the three selectins bind to sLex. Therefore, sLex mimetic behaviour of 
Efomycine enabled it to impair all the three selectins which contribute to its 
higher potency compared with antibody specific to individual selectins (203). 
This implies that sequential inhibition of the selectins is required for profound 
effects against leukocyte transmigration and lymphocytes homing. 
 
Modulation of T-lymphocyte activation and expansion has also been shown to 
be effective in the treatment of psoriasis. This was demonstrated by the 
effectiveness of Daclizumab in resolving psoriatic lesions within six weeks of 
administration in a trial involving 19 psoriatic patients (204). It was, therefore, 
proposed that Daclizumab attenuates CD25, which, in turn, blocks IL-2/IL-2R 
binding and consequently inhibits T-lymphocyte activation.  
 
Recently, it was shown that several phenolic compounds from methanolic 
extracts of Z.officinale (common ginger), which included 6-shogaol, 8-shogaol, 
10 gingerol and dehydro-6-gingerdione had inhibitory effects on T-cell migration 
(172). This study concluded that the compounds inhibited direct binding 
between sICAM and LFA-1 of THP-1 cells (monocytes), whereby, 6-shogaol 
(IC50 =27.1µM) showed most potent activity and better than Lovastatin          
(IC50 =57.2 µM). Furthermore, it was suggested that 6-shogaol and dehydro-6-
gingerdione regulated the late phase of monocyte migration by inhibiting direct 
binding between sVCAM-1 and VLA-4 (172). Thus, these findings indicate that 
both compounds inhibit binding during and after activation of monocytes.  
                                                                                                           CHAPTER 5                                                                                                                                                                                               
 
217 
 
Another study by Nogueira de Melo et al. (2010) demonstrated that the ginger 
essential oil (GEO) causes significant reduction in leukocyte chemotaxis 
towards casein stimuli in an in vitro chemotaxis assay (205). The study 
indicated that direct and systemic effects of the GEO on leukocyte migration as 
an important mechanism of the anti-inflammatory action of ginger (205). 
Moreover, previous studies on the effect of ten commonly used herbs on         
T-lympocytes proliferation indicated that ginger was among the most potent 
immune-suppressors against mitogenic- and allogenic-stimulated-T-lymphocyte 
proliferation in mouse splenocytes (206). Another study using volatile oil of 
Z.officinale Roscoe, showed that it inhibited proliferation of total T-lymphocyte 
and T-helper lymphocytes and suppressed IL-1α production (207). Therefore, in 
general, ginger has the ability to modulate T-lymphocyte activation and 
proliferation. 
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2 Objectives 
 
In the previous chapters the chloroform extract of ZOR (HB02), its fraction 6 
(F6) and the identified compounds (6-shogaol and 1-dehydro-6-gingerdione) 
were shown to have inhibitory effects on NO and PGE2 production as well as  
IL-12/IL-23 axis. In light of these findings, it  was decided to study the regulatory 
effects of HB02, F6 and its compounds on PMN recruitment through the 
endothelium and the expression of adhesion molecules on PMNs in vitro. 
Moreover, the effect of the compounds on CD4+- and CD8+-T-lymphocyte 
activation was explored in preliminary experiments using mouse splenocytes. 
These experiments evaluated the effects of HB02, F6 and compounds on the 
expression of CD25 and CD69 on anti-CD3/CD28-activated-T-lymphocytes. 
The results provide some insight into the mechanisms of ZOR action during the 
early stages of inflammation in psoriasis. The findings could provide a 
foundation for future more detailed studies to understand how ZOR could 
modulate auto-immune mediated inflammation. 
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3 Methods 
3.1 PMN adhesion and migration 
3.1.1 PMN isolation protocol 
 
Peripheral blood from three healthy individuals was collected into 50 mL falcon 
tubes containing sodium citrate at a 1:10 ratio (citrate: blood) and then diluted 
1:1 in RPMI1640 medium. Prior to the PMN isolation process, a mixture of      
3 mL 11191 histopague (Sigma) and 3 mL of 10771 histopague (SIGMA) was 
dispensed and prepared in 15 mL falcon tube. The two histopaque solutions 
make two distinct visible layers. Next, 6 mL of the blood-RPMI1640 mixture 
was layered onto the histopague mixture. The tube containing the mixture was 
then centrifuged at 1337rpm for 30 minutes without the brake being on. Five 
visible layers formed in the blood-histopague mixture after centrifugation 
(Figure 5.2a). The forth layer containing PMNs was extracted out using plastic 
pipette and placed in a new 15 mL falcon tube in a volume of less than 6 mL.  
RPMI1640 was then added to make the volume up to 12 mL and then the 
mixture was inverted to homogeneous. The mixture was centrifuged at       
1500rpm for 15 minutes. The supernatant was decanted and pellet                
re-suspended gently. Contaminating erythrocytes were removed by lysing with 
7.5 mL of ice-cold water and 25 mL of 3.6% NaCl.  This step was carried out 
twice and gently to avoid cell clumping which is an indication of PMN 
activation. The solution was centrifuged for 10 minutes at 1200rpm and 
supernatant removed. The pellet was re-suspended in PBS without calcium 
(containing 0.1% BSA) to a final volume of 2 mL. The number of cells was 
counted using Turk’s solution. 
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3.1.2 Viability assay 
 
To determine the toxicity level of ZOR on isolated PMNs viability. Alamar Blue 
viability assay was carried out. PMNs in the RPMI medium (containing 10% 
FBS, 2 mM L-glutamine, 100 U/mL Penicilin and 100 µg/mL Streptomycin)  
were plated in 96 well plates at a cell density of 2x104 cells/well. The cells were 
left to adhere for 30 minutes before being treated with HB02, F6, 6S or GD at a 
concentration range of 0.5-100 µg/mL. The effect of DMSO was also tested at a 
percentage range of 0.005-5% based on its content in the culture medium. After 
4- and 24-hour incubation at 37ºC, the medium was removed and replaced with 
10% Alamar Blue in fresh medium. The cells were incubated for another            
4 hours at 37ºC and absorbance at 560 and 595nm were measured using a 
microplate reader (TECAN GENios). Cell viability was calculated according to 
supplier’s manual (AbD Serotec) as shown below; 
Cell viability: 
PR( sample)_______ x  100 
 PR (medium control) 
 
PR value for untreated cells (control) or cells treated with ZOR samples was 
calculated as below; 
Percentage reduction (PR) of Alamar Blue: 
 
            (117216 x A1)-(80586 x A2)  x 100 
            (155677x N2)-(14652 x N1 ) 
 
Molar extinction coefficient (E) of oxidized Alamar Blue at 560 nm = 80586 
E of oxidized Alamar Blue at 595 NM = 117216 
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E of reduced Alamar Blue at 560 nm = 155677 
E of reduced Alamar Blue at 599 nm = 14652 
A1 = absorbance of test wells at 560nm  
A2 = absorbance of test wells at 595nm 
N1 = absorbance of negative control (Alamar Blue in media without-cells) at    
560nm  
N2 = absorbance of negative control at 595nm  
 
3.1.3 PMN adhesion and migration study using flow chamber 
 
The migration assay was carried out using a flow chamber assay, developed 
and assisted by members of the Biochemical Pharmacology Department at the 
William Harvey Research Institute (WHRI). Prior to the experiment, a confluent 
human vascular endothelial cell (HUVEC) monolayer (maximum of passage 4) 
was stimulated with 10 ng/mL TNFα for 4 hours. The monolayer was kindly 
prepared and provided by Dr.Dianne Cooper from the Biochemical 
Pharmacology Department.  
 
PMNs at 1x106 cell/mL were incubated with HB02, F6, 6S and GD at 1:6 dilution 
in PBS (supplemented with calcium, magnesium and 0.1% BSA) at 37 °C for 10 
minutes in a water bath. In the preliminary experiments, PMNs were incubated 
with HB02 and F6 at a final concentration of 50 μg/mL. In all subsequent 
experiments, the concentration of HB02, F6, 6S and GD were reduced to        
3.3 μg/mL. The treated PMNs were then perfused over the TNFα-stimulated 
HUVEC monolayers in the flow chamber at a constant rate at 1dyne/cm2 using 
a syringe pump (Figure 5.2b).   
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After 8 minute of perfusion, six random fields were captured for 10s each at 40x 
magnification using JVC TK-C1360B digital colour video camera. The number 
of PMNs captured, rolling and migrating was counted and analysed using 
ImagePro Plus software (Media Cybemetic, Wokingham, Berkshire). The 
number of PMNs was determined as an initial cell capture and then categorised 
as rolling, adhering and migrating. Among the captured PMNs, those which 
have firmly adhered remained stationary for the 10s of observation while others 
rolled or migrated through the endothelial junction. 
 
  
(a)                                                 (b)     
Figure 5.2: The separation and assessment of PMN adherence, rolling and 
migration. (a) PMNs were isolated from the blood of 3 healthy donors (n=3) as 
described in section 3.1.1 and (b) perfused onto TNFα-stimulated HUVEC 
monolayers in the flow chamber under a constant rate of 1 dyne/cm2 using a 
syringe pump. The flow chamber was placed under a microscope with 40x 
magnification. After 8min perfusion, six random fields were recorded for 10s 
each using JVC TK- C1360B digital colour video camera. 
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3.1.4 Expression of adhesion molecules by flow cytometry 
 
Flow cytometry (or FACS) analysis was carried out to determine the effect of 
treatment with HB02, F6, 6S and GD on the expression of CD11b, L-selectin 
(62L) and CXC chemokine receptor-1 (CXCR-1) on PMNs. The assessment 
was carried out with the help of Drs. Dianne Cooper and Lucy Norling from the 
Biochemical Pharmacology Department. In brief, peripheral blood PMNs were 
suspended in PBS (supplemented with calcium and magnesium) containing the 
samples at a final concentration of 50 μg/mL or 3.3 μg/mL, at 37°C for              
10 minutes in a water bath.  The cells were then plated out at a density of 2x105 
cells per well in 96-well plates and incubated with purified mouse mAbs to: 
human L-selectin, human CD11b and CXCR-1 (Table 5.1) for 1 hour on ice. 
The expression of each of the adhesion molecules was recorded and analysed 
with FACSCalibur using CellQuest software (Becton Dickinson, Franklin Lakes, 
NJ).  
 
Table 5.1: Monoclonal antibodies (mAbs) used for assessing the 
expression of adhesion molecules on PMNs.  
Antibody Clone Final Concentration  
CD62L Pe-cy5 DREG56 1:100 
CD11b APC ICRF44 1:100 
CXCR1 FITC 8F1-1.4 1:10 
 
The mAbs used were diluted to final concentration as indicated. All mAbs used 
were from eBioscience. 
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3.2 Activation of T-Lymphocytes 
 
This study was carried out with the kind help of Dr. Fulvio D’Arquisto from the 
Biochemical Pharmacology Department. In brief, 106cells/mL of isolated T-cells 
obtained from splenocytes of normal Balb/c mice aged between 6-8 weeks, 
were cultured and stimulated in 24 well culture plates pre-coated with mAbs 
with specificity for mouse CD3 alone or with CD3 and CD28. Thirty minutes prior 
to stimulation, the cells were treated with 6S or GD at 0.1 µM. Treated and 
untreated cells were cultured for 24 hours in RPMI1640 medium supplemented 
with 10% FCS, 2 mM L-glutamine and 100U/mL gentamycin. Supernatants 
were collected for determination of secreted TNFα and IL-17 levels. 
 
 T-cells treated with 6S or GD were then re-suspended in FACS buffer (PBS 
containing 1% FCS and 0.02% NaN2) and incubated with CD16 FcγR3/CD32 
FcIIR blocking antibody at 4ºC for 30 minutes to prevent non-specific binding of 
the mAbs. To assess expression of CD25 and CD69 on CD4 and CD8, the cells 
were stained with PE and FITC-conjugated mAb, respectively (Table 5.2). The 
stained cells were analysed with FACSCalibur using CellQuest software 
(Becton Dickinson, Franklin Lakes, NJ).  
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Table 5.2: mAbs used for assessing the expression of CD25 and CD69 on 
CD4+ and CD8+ T-lymphocytes.  
Antibody Clone Isotype Final Concentration 
(µg/mL) 
Anti-CD25 FITC PC61.5 Rat IgG1 0.5 
Anti-CD69 PE H1.2F3 Armenian 
hamster IgG 
0.4 
Anti-CD4 PE (L3T4) GK1.5 Rat IgG2b 0.4 
Anti-CD8 PE FITC 53-6.7 RatIgG2a 0.5 
Anti-CD16/32 93 - 0.1 
 
The mAbs used were diluted to final concentration as indicated. All mAbs used 
were from eBioscience. 
 
3.3 Measurement of TNFα and IL-17 levels . 
 
The level of TNFα and IL-17 proteins in culture supernatants was measured 
using Meso Scale MultiarrayTM 96-well kits. The Meso Scale Discovery (MSD; 
Gaithersburg, MD, USA) platform is based on the proprietary combination of 
electrochemiluminescence detection and patterned arrays. Kits used in this 
study are highly sensitive and can simultaneously provide quantitative data on 
multiple cytokines using small volumes of supernatant (25 μl). The assays have 
detection limits of 4000 to 1.2 pg/mL. Briefly, 25 μl of supernatants were added 
to the purchased 96-well microtiter plate coated with capture antibodies to 
mouse TNFα or IL-17 and incubated at room temperature for 2 hours. After 
washing the plate, specific anti-TNFα or anti-IL-17 antibodies (each at 1 μg/mL) 
conjugated with the ruthenium-based MSD Sulfo-TAG™ reagent were added. 
The plates were washed and the MSD Read Buffer T (2x) added and results 
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read on a Sector Imager 6000 incorporating a charge-coupled device (CCD) 
camera. TNFα and IL-17 concentrations were determined with Softmax Pro 
Version 4.6 software, using curve fit models (log-log or four-parameter log-logit) 
as suggested by the manufacturer for the specific cytokine. Concentrations of 
TNFα and IL-17 in the tested supernatants were determined by extrapolation 
from standard curves constructed for the following concentrations for both 
recombinant TNFα and IL-17: 10000, 2500, 625, 156, 39, 9.8 and 2.4 pg/mL. 
 
3.4 Statistical analysis 
 
Data was analysed using GraphPad Prism software (GraphPad Prism, San 
Diego, California). Means and standard deviation were used to describe 
normally distributed data. The significance of differences between groups was 
assessed using Two-way ANOVA (Bonferroni posttest). Difference of p<0.05 is 
considered significant. 
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4 Results 
 
4.1 HB02, F6 and compounds, 6S and GD are non toxic to PMNs at 
concentrations ≤50 μg/mL after 4 hours incubation. 
 
To determine whether the test samples are toxic to the isolated PMNs, viability 
of the cells after incubation with HB02, F6, 6S and GD using AlamarBlue assay 
was determined. The samples were tested using PMNs isolated from three 
individuals and with incubation for 4 and 24 hours (Figure 5.3). Evaluation of 
toxicity level was based on concentrations that result in 50% and 90% PMN 
viability, IC50 and IC90, respectively. 
 
The results showed that more than 80% of the PMN cells were viable after 4 
hours incubation with the test samples at concentrations of ≤50 μg/mL       
(Table 5.3). The IC90 was within the range of 30-50 μg/mL of all samples. 
Incubation of the cells with DMSO resulted in >80% viability at 0.005-5.0% 
DMSO content. This suggests that the ideal concentration of the test samples to 
be studied for PMN migration should be at 50 μg/mL or less. F6 was noted to be 
more toxic than HB02, 6S and GD, with an IC50 of 70±45 μg/mL (Table 5.3). The 
IC50 of HB02, 6S and GD were above 100 μg/mL. 
 
Viability of the PMNs after 24 hours incubation with 50 μg/mL of HB02, F6, 6S 
and GD were also determined. Figure 5.3 shows reduction of 50% viability after 
24 hours incubation relative to 4 hour incubation period. No significant 
differences were observed between culture for 4 and 24 hours for viability of the 
cells with DMSO (Figure 5.3e).   
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Figure 5.3: Effect of HB02, F6, 6S and GD on PMN cell viability. The test 
samples were assessed at the following concentration: 0.5-100 μg/mL for HB02 
and F6 and at  0.5-50 μg/mL for 6S and GD. The effect of DMSO on viability 
was tested at 0.005-5%. Viability was assessed after 4 hours incubation (open 
circles) and 24hours (black squares) incubation at 37ºC. Viability was assessed 
using Alamar Blue assay. Results are in mean ± SD of three independent 
experiments (n=3).  
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Table 5.3: IC50 and IC90 of HB02, F6, 6S and GD on PMN cell viability after 
 4 hours incubation.  
Samples 
Concentration that 
allows 50% cell viability  
(IC50, μg/mL) 
Concentration that allows 
90% cell viability 
(IC90, μg/mL) 
HB02 121± 64 47±33 
F6 70± 45 40.2±47.8 
6-Shogaol (6S) 166±  23 31.4±40.4 
1-dehydro-6-
gingerdione (GD) 
117± 4.2 0.5±41.8 
*Peripheral blood PMNs isolated from three healthy donors.  Data presented in 
mean ± SD.  
 
Based on these data all experiments carried out using PMNs to test the effects 
of HB02, F6, 6S and GD were carried out after an incubation period of 4 hours 
and test samples at ≤50µg/mL of the test samples. 
 
4.2 The effect of HB02, F6, 6S and GD on PMN adhesion and migration. 
 
In view of the inhibitory effects of HB02, F6, 6S and GD reported in this thesis 
on NO production and on the IL-12/IL-23 axis, I studied their effects on PMN 
adhesion onto TNFα-activated HUVEC. For this purpose, I studied PMN 
capture, rolling, adhesion and migration using an in vitro flow chamber assay 
(section 3.1.3). Further, the effect of the test samples on the expression of 
CD62L, CD11b and CXCR-1 on PMNs using FACS (Method 3.1.4) were also 
determined.  
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4.2.1 HB02 and F6 inhibit PMN capture, rolling, adhesion and migration.  
 
The effect of HB02 and F6 on the capture, rolling, adhesion and migration of 
PMN using TNFα-stimulated HUVEC was studied at 50 μg/mL using the flow 
chamber assay. The results showed that HB02 and F6 strongly inhibited the 
capture, rolling and migration of PMNs. HB02 had the strongest inhibitory 
effects on the PMNs. Thus, HB02 inhibited capture by 90.3%, rolling by 57%, 
adhesion and migration by ~100%, relative to control. In contrast, F6 caused 
48% reduction in PMN capture, 80% adhesion and 89% PMN migration. 
Surprisingly, F6 augmented PMN rolling by about two-folds (Figure 5.4b). This 
may suggest that F6 could stimulate margination of PMN rolling, nevertheless, 
F6 strongly inhibited PMN adhesion and migration.  
 
These data suggest that HB02 and F6 inhibit PMN-endothelium interactions 
and, thus, inhibit PMN tethering and transmigration. The higher potency of 
HB02 compared with F6 may be due to the presence of active compounds in 
HB02 which are not present in F6. 
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Figure 5.4: The effect of HB02 and F6 on PMN adhesion and 
transmigration.  HB02 and F6 were tested at 50 μg/mL for their effect on PMN  
a) captured, b) rolling, c) adhesion, and d) migration on TNFα-activated HUVEC 
in flow chambers. The effects of HB02 and F6 were compared to control PMNs 
incubated in PBS (supplemented with calcium and magnesium). The results 
represent one experiment. 
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To further explore how HB02 and F6 influence PMN biology, the effect of both 
test samples on morphological changes on PMNs that could have unfavourable 
effects on endothelial contact, was examined. The results showed that 
incubation of PMNs with HB02 and F6 at 50 µg/mL did not alter nor deform the 
shape of PMNs. Instead the treated PMNs maintained their rounded shape and 
had a tendency for free flowing (Figure 5.5(b)(c)). This observation indicates 
that HB02 and F6 modulate the biology of PMNs to make them less likely to 
adhere and transmigrate rather than impair their biological responses. The 
specific effects, therefore, appear to reduce the interaction between PMNs and 
HUVEC surfaces to promote free flowing and reduce PMN tethering and 
adhesion. The results, thus, eliminate the possibility that the observations are 
due to PMNs morphological defects caused by a toxicity effect. 
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(a) 
 
(b) 
 
(c) 
 
Figure 5.5: Treatment with HB02 and F6 does not alter the morphology of 
PMNs. The morphology of PMNs treated with 50 μg/mL of HB02 or F6 was 
assessed microscopically. The figure shows: a) control PMNs incubated on 
HUVEC cells treated with TNFα; b) PMNs treated with 50 µg/mL HB02; and c) 
PMNs treated with 50 µg/mL F6. No visible morphological changes are seen 
under a microscope with 40x magnification. 
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4.2.2 HB02, F6 and 6S at low concentrations modulate PMN biology.  
 
Due to limitations on the amount of purified 6S and GD and for comparative 
purposes, it was decided to assess the effect of both compounds and HB02 and 
F6 at much lower concentrations (3.3 µg/mL).  These experiments revealed that 
even at these lower concentrations, HB02, F6 and 6S reduced PMN capture, 
rolling, adhesion and migration by up to ~46% relative to control (containing 
0.03% DMSO) (Figure 5.6 a-d). GD, however, augmented PMN adhesion by 
34.2% (Figure 5.6c). It is indicated in Figure 5.7(e) wherein higher margination 
of PMNs in medium containing GD. Nevertheless, GD reduced PMN rolling by 
27.6% and migration by 29.2%. Thus, GD has some inhibitory effect against 
PMN migration suggesting that this compound may act to inhibit the adhesion of 
PMN to HUVEC. 
 
Figure 5.6 shows that F6 and 6S at the lower concentration of 3.3 μg/mL had 
comparable effects on PMN capture, rolling, adhesion and migration, that were 
more effective than HB02 (Figure 5.6). 6S had significant inhibitory effects 
(p<0.05) on PMN capture (~34.2% inhibition), whilst F6 significantly affect PMN 
rolling (44% inhibition) compared to control (Figure 5.6a and b). These data 
may suggest that both F6 and 6S may have inhibitory effects during early 
stages of inflammation through preventing PMN tethering.  
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Figure 5.6: The modulatory effects of low concentrations of HB02, F6, 6S 
and GD on PMN biology. The effect of HB02, F6, 6S and GD relative to control 
(DMSO 0.03%) on PMN biology were tested at 3.3 μg/mL. The effects shown 
are for: a) capture, b) rolling, c) adhesion, and d) migration of PMN using TNFα-
activated HUVEC in flow chambers. The interactions were assessed in six 
random fields from three sets of independent experiments. Statistical 
comparison between the samples and control were crried out using Student         
t-test. * =p<0.05  
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Figure 5.7: The interaction of treated PMNs with HUVEC during perfusion. 
The interaction between PMNs and TNFα-activated HUVEC during the                 
8 minutes perfusion into the flow chamber. Prior to perfusion, the PMNs were 
treated with (a) DMSO control ( at 0.03%), (b) HB02, (c) F6, (d) 6S and (e) GD 
at 3.3 µg/mL, for 10 min. HB02, F6 and 6S reduced PMNs margination and 
recruitment on the endothelial cell, except GD. This observation represents 
three independent experiments. 
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4.3 The effect of HB02 and F6 on L-selectin, CD11b and CXCR-1 
expression. 
 
Results of the previous sections suggested that treatment with HB02, F6, 6S 
and GD specifically modulated PMN biology to restrict migration. To verify these 
data and explore further how these tested ZOR components modulate the 
migration of PMNs, the effect of the test samples on the expression of CD11b 
and L-selectin (CD62L) was examined. The expression of these molecules was 
analysed using flow cytometry as described in method 3.1.4.  
 
4.3.1 HB02 and F6 enhance L-selectin (CD62L) shedding and CD11b 
expression. 
 
Results of the flow cytometry showed that HB02 and F6 both at 50 µg/mL 
caused a dramatic decrease of L-selectin expression (Figure 5.8b) but 
enhanced CD11b expression on PMNs (Figure 5.8c). F6 had a stronger effect 
than HB02 on reducing L-selectin and upregulating CD11b expression. These 
data may suggest that HB02 and F6 enhance PMN activation rather than 
promoting inactivation.  
  
These results suggest that the increased L-selectin shedding and/or decrease 
of L-selectin expression explain the noted reduced rolling of PMNs on the 
HUVEC layer. The increase in CD11b (Mac-1) expression, in contrast, may 
suggest that HB02 and F6 enhance adhesion and, ultimately, transmigration of 
PMNs. However, this is not supported by results of the flow chamber showing 
reduced rolling, adhesion and migration of the treated PMNs (Figure 5.4). The 
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possible reasons for the upregulation of CD11b and implication are not clear 
and further experiments may be necessary. 
 
4.3.2 HB02 and F6 have no significant effects on CXCR-1 expression 
 
The effect of HB02 and F6 on the expression of CXCR-1 was determined 
(Figure 5.8d). CXCR-1 is the receptor for IL-8, a key chemoattractant cytokine 
involved in inflammatory responses (208). The results showed that that both 
HB02 and F6 at 50 µg/mL did not have a significant inhibitory effect on CXCR-1 
expression. This observation may suggest that HB02 and F6 at 50 µg/mL are 
less likely to regulate PMN activation through inhibition of chemoattraction of 
PMNs.  
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Figure 5.8: Flow cytometric analysis of the effect of HB02 and F6 on the expression of CD62L, CD11b and CXCR-1 on PMNs. 
(a) Depicts the FSC/SSC of purified PMNs used in the experiments. Flow cytometry results showing that HB02 and F6 (b) down-
regulated the expression of CD62L (L-selectin), (c) up-regulated CD11b, and d) have negligible effect against CXCR-1 expression on 
PMNs relative to control (CON) treated PMNs (PMNs treated with PBS supplemented with calcium and magnesium. The grey line is 
for staining the PMNs with the isotype control.                   
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4.4 The effects of 6S and GD on CD4+ and CD8+ T-lymphocyte 
responses. 
 
Results presented in the previous chapter highlighted the inhibitory effects of F6 
and 6S on the production of iNOS, IL-12 and IL-23 by activated macrophages. 
However, the overall effects of the two compounds on T-lymphocytes remained 
to be studied. Therefore, experiments were carried out to assess the effects of 
6S and GD on T-cell activation. For this purpose the expression of CD25 and 
CD69, membrane proteins associated with T-lymphocyte activation, were 
assessed following treatment with 6S and GD (Figure 5.9).  
 
4.4.1 6S and GD had no inhibitory effects on CD25 and CD69 expression 
by CD4+ T-lymphocytes.  
 
The effect of 6S and GD on CD25 and CD69 expression was studied at 0.1 µM, 
a concentration that is ten-fold lower than the tested concentration used for the 
PMN adhesion and migration study. The inhibitory effects of 6S and GD was 
tested using primary mouse CD4+ T-lymphocytes isolated from the spleen and 
activated in vitro with anti-CD3/CD28 monoclonal antibodies. Expression of 
CD25 and CD69 was assessed by flow cytometry (Figure 5.9b). The results 
showed that neither 6S nor GD had any inhibitory effects on the expression of 
CD25 and CD69 expression at 0.1 µM (Figure 5.9(b)).  
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4.4.2 GD and 6S reduce CD25 and CD69 expression on activated CD8+                  
T- lymphocytes.  
 
The effect of 6S and GD on anti-CD3/CD28-activated CD8+  T-lymphocytes was 
next examined to complete the overall assessment of the effect on                    
T-lymphocyte responses.  The same approach as described in the previous 
section was used. Expression of CD25 and CD69 was assessed using flow 
cytometry (Figure 5.9c). The results showed that 6S and GD at the low 
concentration of 0.1 μM had marginal suppressive effects on the expression of 
CD25 and CD69 relative to control (Figure 5.9c). This suppressive effect was 
stronger on CD69 than on the expression of CD25. Further, GD had slightly 
more suppressive effects.  
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Figure 5.9: The effect of 6S and GD on the expression of CD25 and CD69 
on activated murine CD4+ and CD8+ T-lymphocytes. One million primary       
T-lymphocytes obtained from the spleen of normal Balb/c mice were stimulated 
with anti-mouse CD3 and anti-mouse CD28.  (a) Shows the gating strategy to 
study the expression of CD25 and CD69 on mouse CD4+ and CD8+                  
T-lymphocytes. The upper panel shows the gating strategy to  identify live cells 
(in gate R1) while the lower panel depicts the gating strategy for identifying       
T-lymphocytes (gate R2). (b) Columns representing the mean fluorescence 
intensity (MFI) values for CD25 (grey columns) and CD69 (black columns) 
expression on CD4+ T-lymphocytes in gate R2. (c) MFI for CD25 and CD69 
expression on CD8+ T-lymphocytes. The cells were treated with either PBS 
(control), 6S or GD. 6S and GD used were tested at 0.1 μM. CD25 and CD69 
expression were determined by flow cytometry (n=1). 
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4.5 6S suppresses IL-17 production by activated CD8+ T-lymphocytes.   
 
Based on the noted effect of GD on CD25 and CD69 expression on CD8+           
T-lymphocytes it was further explored whether the two compounds also 
influence cytokine production by this subset of T-lymphocytes. One further 
reason for measuring the effect of 6S and GD on cytokine production was the 
observation that CD8+ are involved in psoriasis pathogenesis (200). 
 
The results showed that 6S marginally inhibited TNFα (Figure 5.10a) but 
significantly reduced IL-17 (Figure 5.10b) production by 33.2% relative to 
control (p<0.05). In contrast, however, GD did not affect both cytokines. The 
observation that 6S inhibit IL-17 production is consistent with the results 
presented in the chapter 4 wherein HB02, F6 and 6S down-regulated IL-23p19 
mRNA levels. Further, the differential effects of the two compounds on TNFα 
production may also partly explain the previous observation that ZOR extract, 
fractions and compounds enhanced the production of this cytokine. These 
observations, however, need further study. 
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Figure 5.10: The effect of 6S and GD on the production of (a) TNFα and (b) 
IL-17 by activated mouse CD8+ T-lymphocytes. One million primary              
T- lymphocytes obtained from the spleen of normal Balb/c mice were stimulated 
with anti-mouse CD3 and anti-mouse CD28. The cells were either treated with 
6S or GD or non-treated (control). The effect of 6S and GD at 0.1 µM on the 
production of TNFα  and IL-17 by primary CD8+ T-lymphocytes after 24 hours of 
activation with anti-CD3/CD28 was determined using the MESO scale kit.         
(* p<0.05) using paired t-test. Results represent one experiment conducted in 
triplicates. 
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5 Discussion 
 
5.1 HB02, F6 and isolated compounds reduce PMN adhesion and 
migration. 
 
The results presented in this chapter reveal that HB02, F6 and compounds 6S 
and GD modulate margination of PMNs by inhibiting their rolling, adhesion and 
migration through vascular endothelium. The data has shown that the tested 
samples increase L-selectin shedding from the membrane of treated PMNs 
leading to the modulation of their interaction with activated HUVEC. However, 
the results also showed that there was an increase in the expression of CD11b 
on PMNs following treatment with the test samples from ZOR. This implies that 
treatment of PMNs with ZOR test samples resulted in the activation of PMNs 
and that the inhibitory effect on migration is actively induced. However, further 
insights into how HB02, F6, 6S and GD modulate PMN migration further studies 
will be required to fully address this important question.  
 
The available evidence indicates that once PMNs are activated, rolling is 
restricted by L-selectin (CD62L) shedding and that the CD11a/CD18 complex 
and/or LFA-1 will translocate to the endothelial surface via interactions with 
endothelial proteins such as ICAM-1 which then promotes adherence (209). In 
addition to CD11a/CD18, CD11b/CD18 also contributes to PMN adhesion to the 
endothelium by interacting with ICAM-1. Both CD11a and CD11b work together 
and sequentially whereby CD11a/CD18 plays a role in PMN tethering to allow 
CD11b/CD18 to stably bind to the endothelium (210). This, eventually, 
promotes PMN migration.  
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Therefore, given that CD11b was upregulated while L-selectin was down 
regulated on PMNs treated with HB02 and F6 and that there were more free 
flowing PMNs, there is the possibility that inhibition of PMN tethering and 
adhesion is due to orchestrated modulation of PMN functions. Previous studies 
utilising the interaction of PMNs with immobilised fibrinogen/fibrin under flow 
conditions have shown that pre-activated PMNs with lower L-selectin levels had 
impaired abilities to adhere (211). This is demonstrated by the effect of 
leumedins, an anti-inflammatory compounds when pre-incubated with PMNs , 
resulted in  tendency of PMN rolling and reduced adhesion on the endothelial 
under flow (212). This was also reflected in the inhibitory effect of aspirin 
(acetylsalicylic acid or ASA) on T-lympocytes adhesion on activated HUVEC in 
non-static and VLA-4/VCAM-1 independent system (213). It is, therefore, 
possible that the increase in L-selectin shedding and CD11b upregulation by 
HB02 and F6 (Figure 5.8), are due to the promotion of free flowing PMNs during 
PMN-PMN interactions that are facilitated by PSGL-1/L-selectin interaction. Low 
L-selectin expression on pre-activated PMNs resulted in reduced adhesion to 
the HUVEC layer through interaction with P-selectin. The results presented in 
this chapter suggest that HB02 and F6 as well as 6S and GD could influence 
inflammation by weakening the interaction between PMNs and endothelial cells 
through reducing adhesion and, eventually, migration.  
 
PMN activation occurs when these cells are induced by chemoattractant signals 
and PMN/endothelial cell interaction. IL-8 is a known chemokine that 
contributes to PMN activation and migration and IL-8 mRNA is found in freshly 
isolated PMNs. However, whether IL-8 is constitutively expressed or is induced 
by the isolation procedure is still debated (214). The experiments reported in 
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this chapter showed that HB02 and F6 had no significant effects on CXCR-1 
expression. This finding suggests that HB02 and F6 do not influence 
chemoattraction of PMN that is mediated by the IL-8/CXCR-1 axis. However, it 
remains possible that HB02 and F6 may still influence PMN chemoattraction to 
sites of inflammation through another chemokine receptor, CXCR-2, that also 
mediates IL-8 chemoattraction (208), which was not examined in this study. 
Overall, the studies reported in this chapter provide evidence that ZOR contains 
compounds that modulate the early phases of PMN migration and inflammation. 
 
5.2 6S modulates the activity of CD8+ but not CD4+ T-lymphocytes 
 
The expression of CD69 and CD25 on T-cells indicate their activation and 
proliferation in response to inflammatory stimuli. Based on this notion, the effect 
of 6S and GD on the expression of these two membrane proteins in anti-
CD3/CD28-induced CD8+ and CD4+ T lymphocyte activation was studied. The 
experiments revealed that 6S and GD at low concentrations down regulated 
CD25 and CD69 expression on CD8+ but not on CD4+ T-lymphocytes. This 
somewhat unexpected observation is difficult to understand and it remains to 
define mechanisms of action. However, the observation may suggest that both 
compounds could be beneficial therapeutically, as CD8+ has been shown to 
over produce IL-17A and IL-22 in psoriatic skin lesions (215).  
 
As cited earlier, CD8+ T lymphocytes complement the action of Th1 and Th17 in 
response to infections. Further, CD8+ T-lymphocytes produce cytokines such as 
TNFα and IL-17 and can, thus, contribute to inflammation. Therefore, the effect 
of 6S and GD on the production of TNFα and IL-17 by activated CD8+ T 
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lymphocyte was assessed. The results revealed that 6S down-regulated          
IL-17 production and had a marginal inhibitory effect on the production of TNFα. 
Unlike 6S, GD, however, did not affect both TNFα and IL-17 production      
(Figure 5.10). The noted effect of 6S in modulating IL-17 and TNFα production 
by CD8+ T lymphocyte is consistent with its overall anti-inflammatory effects on 
reducing iNOS, PGE2, IL-12 and IL-23 production by activated macrophages. 
However, further studies will be required to assess the broader effects of 6S on 
other mediators of inflammation and range of potential side effects. 
 
The studies reported in this chapter are the first to directly examine the effect of 
ZOR on T-lymphocytes. An earlier study by Tripathi and colleagues showed that 
6-gingerol (6G) selectively down regulated pro-inflammatory cytokines but did 
not affect antigen presenting functions of macrophages such as upregulation of 
MHC-II and co-stimulatory molecules (216). Unlike 6G, the alcoholic ginger 
extract (GE)(1 μl/mL) inhibited macrophage activation and its antigen presenting 
functions which indirectly inhibited T-cell proliferation. GE decreased co-
stimulatory interaction between CD28 on T-lymphocytes and CD80-CD86 
molecules, MHC II and B7 molecule on activated peritoneal macrophages and  
thus, indirectly dampened the activation of CD4+ T-cell proliferation (217). 
Synergistic effects of a mixture of compounds in the GE may, thus, contribute to 
the multi-faceted anti-inflammatory mechanisms.  
 
In comparison to 6G obtained from GE (216), 6S and GD from ZOR did not 
affect the activation of CD4+ T-lymphocytes but, instead, inhibited the activation 
and cytokine production by CD8+ T-cell.  However, direct comparison between 
GE and ZOR is not possible due to variability of the ginger species, composition 
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of the extracts and test systems used in both studies. Nonetheless, the current 
study demonstrates that 6S and GD, which are the dehydrated forms of 6G 
show a tendency to modulate CD8+ whilst 6G influence CD4+ T-cells.  
 
Finally, it would be intriguing to determine how structural differences of gingerol-
related compounds contribute to the activation of different subsets of T-cells. 
Based on data discussed in chapter 2, it is possible to speculate that the 
potency of these compounds could be related to the substitution patterns of the 
hydroxyl and carbonyl moieties on the side chains of the compounds         
(Figure 2.16). Conceivably, this may suggest that compounds which are less 
saturated as indicated by the presence of double bonds (6S and GD), may 
possess higher tendency to inhibit the activation of CD8+ T-lymphocytes while 
6G which is more saturated influences CD4+ T-lymphocytes.  These 
possibilities, however, need to be directly studied. 
 
6 Conclusions 
 
Experiments described in this chapter have shown that HB02, F6 and 6S, 
actively modulate PMN migration by modulating the expression and shedding of 
adhesion molecules. The results showed that treatment of PMNs with HB02, F6 
and 6S prior to their activation and interaction with endothelial cells reduced 
affinity of the adherent PMNs to the endothelial cells and, thus, inhibited PMN 
migration. This assumption is based on the increase of L-selectin shedding and 
CD11b expression on the treated-PMNs despite reduction in capture, rolling, 
adhesion and migration. Furthermore, the data suggests that GD displayed 
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inhibitory effects during PMN/endothelial interactions due to the fact that GD 
increased PMN capture and rolling but inhibited PMN adhesion and migration. 
 
In addition, preliminary study on the regulatory effect of 6S and GD on T-cell 
activation indicates that both compounds may have modulatory effects on CD8+ 
T-lymphocyte activation. Thus, both compounds down-regulated CD25 and 
CD69 expression on CD8+ T-cells at the relatively low concentration of 0.1 μM.  
The effect of 6S on CD8+ T-cells activation is further supported by its ability to 
reduce TNFα and IL-17 production while GD did not affect the production of 
both cytokines.The ability of 6S and GD to modulate PMN recruitment as well 
as CD8+ activation may support the presumption that both compounds could be 
therapeutically beneficial during the early phases of inflammation. Thus far, no 
similar study has been carried out on the effect of crude ZOR extracts, albeit a 
number of in vivo and in vitro studies on leukocyte migration and 
leukocytes/endothelial cell interactions, utilising volatile (205) and non-volatile 
fractions (172) from common ginger, Z.officinale Roscoe have been reported. 
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CHAPTER 6 
 
Modulatory effects of ZOR on 
keratinocytes proliferation 
and skin inflammation 
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1 Introduction 
 
Skin epidermal layer is comprised of 95% differentiating keratinocytes and 5% 
of non-keratinocytes, namely melanocytes, Langerhans and Merkel cells. Skin 
renewal involves stages of epidermal growth and differentiation events. The 
earliest stage involves cell proliferation at the epidermal basal layer resulting in 
the establishment of an extensive network of keratin filaments such as K1 and 
K14. The proliferating cell starts to differentiate as it moves outwards to the 
spinous layer whereby it produces keratins such as K1 and K10, protein 
envelope and membrane-coating granules as part of epidermal building blocks. 
Once it reaches the granular layer, the cell stops differentiating and undergoes 
‘apoptosis-like’ phase, known as terminal differentiation. This forms the cornified 
layer of the stratum corneum, which is depicted as flattened and anucleated 
squames which will eventually slough from the epidermal layer but is 
continuously replaced by new differentiating cells. It is crucial to maintain 
orderly cycle of keratinocytes proliferation and differentiation since keratinocytes 
play an essential role as epidermal barrier in host defence. Formation of a 
strong layer of the stratum corneum provides protection against microorganisms 
as well as maintaining bodily fluid.  
 
In contrast to healthy skin, psoriatic skin is characterised by accelerated and 
vicious cycle of skin renewal. It is depicted by keratinocytes hyper-proliferation 
and abnormal differentiation overlying a skin inflammation reaction. Rapid cell 
proliferation retards complete keratinisation of the epidermis and, thus, results 
in rapid and disorganised stacking of corneocytes. Manifestations of psoriatic 
lesion are facilitated by the crosstalk and instantaneous interactions between 
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activated immune cells such as APCs, cytokine-secreting T-cells, polymorphs 
and hyper-proliferating keratinocytes. Activation of these immune cells is 
stimulated by environmental triggers and genetic defects that lead to secretion 
of an array of cytokines, chemokines and antimicrobial peptides, keratinocytes 
differentiation and migration.   
 
Recent findings by Guilloteau and colleagues (2010) have identified key 
cytokines that are most likely to stimulate formation of psoriatic lesions. 
Combination of IL-17A, OSM, TNFα, IL-22, and IL-1α (M5) has been shown to 
work synergistically in an in vitro inflammatory keratinocyte model which 
resembles features of lesional psoriatic skin (43)(Figure 6.1). This is confirmed 
by the correlation of the transcriptional profiles of inflammation mediators 
present in lesional psoriatic skins compared with the in vitro inflammatory 
keratinocytes model. In comparison to the unstimulated normal human 
epidermal keratinocytes (NHEK), M5-stimulated NHEK had significantly higher 
PMN chemotactic activity and antimicrobial peptides expression for skin innate 
defence (43). This in vitro human model of inflammatory epidermis depicts a 
synergistic effect of Th1, Th17 and Th22 in inducing psoriatic-like characteristic 
in vitro. 
 
It has been widely suggested that Th1 and Th17 T-cell subsets are potent 
mediators of psoriasis pathogenesis. Th1 secretes TNFα while Th17 produces 
IL-17, IL-22 and induces PMN-attracting chemokines (CXC), such as CXCL-1,-5 
and -8 as well as CCL-20 by keratinocytes. TNFα and IL-17 have been reported 
to work synergistically in inducing keratinocytes’ to produce IL-8 (218). 
Furthermore, stimulation by both cytokines also induces many inflammatory 
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products, additively or synergistically, compared with single cytokines in 
keratinocytes (218). Apart from that, IL-1α which plays a major role  in IL-1 
activity in innate immune response, by activating T-cell, macrophages and 
leukocytes function, is predominant in psoriatic keratinocytes (219). This 
creates cytokines milieu that stimulates continuous inflammatory response by 
the keratinocytes.   
 
 Recently, Th22, another subset of T-cells has been described and suggested 
to act in parallel with Th1 and Th17 cells in psoriasis (32). Th22 exclusively 
produced IL-22, which is structurally related to IL-10 as well as IL-19, IL-20,     
IL-24, and IL-26. However, unlike IL-10, IL-22 demonstrates pro-inflammatory 
properties. There is also evidence that IL-22 induces activation of STAT3 in 
keratinocytes and, thus, promotes the generation of cytokines involved in skin 
inflammation (220). Moreover, IL-22 induced the release of IL-20, a downstream 
cytokine produced by the keratinocyte. A large body of evidence indicates that 
IL-22 and IL-20 play key roles in keratinocytes alterations observed in psoriasis 
(221, 222). IL-22 and IL-20 drive keratinocyte hyperplasia by attenuating 
terminal keratinocyte differentiation and down-regulate the production of 
proteins associated with keratinocytes differentiation, including filaggrin, loricrin, 
involucrin, calmodulin-like skin protein (CLSP) and calmodulin-related protein 
NB-1 (220, 223) (Figure 6.1). Furthermore, there is evidence that IL-20 
receptors, IL-20R1 and IL-20R2 protein, are up-regulated in epidermis of 
psoriatic skins compared with healthy skins (224). The upregulation of these 
receptors leads to higher binding of IL-20 to keratinocytes.  
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In addition to these properties associated with IL-22, this cytokine along with 
Oncostatin M (OSM) up-regulates anti-microbial peptides and other 
proinflammatory molecules belonging to the S100 family of calcium-binding 
proteins (42). These include S100A7, S100A8 and S100A9. OSM is a cytokines 
related to the IL-6 family and is mainly produced by activated T-cells, 
monocytes and dendritic cells. These antimicrobial peptides have been shown 
to be extensively expressed in psoriatic keratinocytes but produced in negligible 
amounts in the epidermis of healthy individuals (42). The microbial peptides can 
act as chemokines or induce chemokines stimulating chemotaxis of PMNs, 
monocytes as well as CCR6-expressing Th17 cells that facilitate positive 
feedback loop that exarcebate the inflammation. Therefore, IL-22, IL-17 and 
OSM share similar or overlapping roles in stimulating keratinocytes hyper 
proliferation and inflammatory reactions associated with psoriasis.  
 
Based on these observations most of the above cytokines (IL-17A, OSM, TNFα, 
IL-22, and IL-1α) appear to be inter-related and in combination they provide the 
closest framework of inflammation-mediating molecules in psoriatic skin. Hence, 
these cytokines could be highly useful targets for drug discovery for the 
treatment of skin inflammation. 
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Figure 6.1: Synergistic effects of IL-1α, IL-17A, TNFα, IL-22 and Oncostatin 
M (OSM) in inducing inflammatory cascades in keratinocytes. IL-1α,          
IL-17A and TNFα are involved in the induction of innate immune responses 
whilst IL-22 and OSM induce epidermal differentiation. Over expression of these 
cytokines lead to the up-regulation of chemokines (CXCL1, CXCL8, CCL20)  
and antimicrobial peptides (β-defensin, psoriasin, LL37) by keratinocytes. These 
stimulate chemotactic activities, such as the recruitment of PMNs as well as 
CCR6-expressing Th17 cells that facilitate positive feedback loops. Modified 
from Guilloteau et al. (43). 
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2 Objectives 
 
This chapter explores the effect of HB02, F6 and compounds 6S and GD on 
keratinocyte responses in vitro. The studies are aimed at gaining insights into 
the effect of ZOR on keratinocyte proliferation and differentiation, important 
components of the pathophysiology of psoriasis. In the experiments detailed in 
the chapter I explore an in vitro model of inflammatory epidermis as first 
reported studies by Guilloteau and colleagues (2010). The experiments 
examine the effect of HB02, fraction 6 (F6) and compounds 6S and GD on 
cytokine activated-normal human epidermal keratinocytes (NHEK). Apart from 
observing morphological changes that affect keratinocytes during an 
inflammatory response modelled to reflect psoriasis inflammation, cell 
proliferation and the production of IL-20 and IL-8 cytokines were studied. These 
important cytokines released by activated keratinocytes are known to be 
involved in promoting cell proliferation and inflammation, respectively. The 
overall objectives of the studies described are to assess the effect of ZOR on 
the components of the inflammatory response mediated by keratinocyte.  
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3 Methods 
3.1 Keratinocytes   
 
Two sources of keratinocytes were used in the experiments described here. 
The cells were immortalised human cutaneous keratinocyte, Human Adult low 
Calcium Temperature (HaCaT) cell line and normal human epidermal 
keratinocytes (NHEK) from foreskin. NHEK was obtained from three individuals 
(A-page, SFK1 and SFK2) and cultured from passage 3. Irradiated mouse 
fibroblast-cell line (3T3) was used as feeder cells for culturing the NHEK cells. 
Both the NHEK and 3T3 cells were obtained courtesy of Professors M. Philpott 
and H. Navasaria at the Centre for Cutaneous Research, Blizard Institute, 
Queen Mary University of London. HaCaT was used for assessing the effect of 
selected ZOR consitutents on proliferation whilst NHEK was used to establish a 
psoriatic skin inflammatory model. 
 
3.1.1 Culture conditions of HaCaT keratinocytes cell line 
 
The HaCaT-cell line used in this study was cultured and maintained in DMEM 
medium supplemented with 10% FBS (GIBCO), 100U/mL penicillin and          
100 µg/mL streptomycin and 2 mM L-glutamine. The cells were incubated at 
37ºC with 5% CO2. The cells were sub-cultured when reaching 90% confluence 
by dilution of 1:4 in medium. Confluency of the cell line was calculated to take a 
week-duration, thus, medium was changed once every 3 days in order to 
maintain consistent growth of the cells. The cells were detached from the flask 
surface using 5 mL of trypsin-EDTA with tapping of the flask. The number of 
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cells was counted and viability was assessed using trypan blue and an inverted 
microscope (Nikon TMS).  
 
3.1.2 Culture conditions for NHEK 
 
NHEK cells were obtained from 3 healthy individuals (coded as: A-page, SFK1 
and SFK2) and each at their third passages. The cells were cultured onto 
irradiated 3T3 cells in cell culture medium (DMEM F12) containing RM++ 
supplement (obtained courtesy of Prof. Philpot’s group), 2 mM L-glutamine, 
10% FBS and 100 U/mL penicillin and 100 μg/mL streptomycin. Briefly, 1 x 106 
cells/mL of irradiated 3T3 cells were seeded in T75 flasks and incubated for 1 
hour in 5% CO2 at 37ºC for the cells to attach to the flasks. Once the 3T3 cells 
were attached, 2 x 106 cells/mL of NHEK cells were seeded onto the 3T3 cell 
layer. The cells were incubated in a humidified incubator with 5% CO2 at 37 ºC 
for 1-2 days for NHEK-3T3 cell firm attachment. After two days, the medium 
was changed and the cells were incubated until 70-80% confluence. Prior to 
splitting the NHEK cells, the feeder cell (irradiated 3T3 cells) were first detached 
by washing with PBS and then with 5 mL Versene (EDTA) 0.02%. Next, NHEK 
cells were trypsinised using Trypsin-EDTA and sub-cultured for the next 
passage to be used in assays for determining the effect of ZOR samples on 
proliferation and overall role in inflammation in the test model used.  
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3.2 Preparation of HB02, fractions, 6S and GD compounds for assessing 
their effects on keratinocytes. 
 
Stock concentration of HB02 fractions (F5, 6, 7 and 10 ) and compounds were 
prepared in DMSO at a concentration 10 mg/mL. The samples were then 
diluted in medium (DMEM) to a concentration range of 10-1000 μg/mL for the 
HaCaT proliferation study. For NHEK cell proliferation study, HB02 extract, 
Fraction 6 and compounds 6S and GD were diluted to range of 5-100 μg/mL. 
Cyclosporin A (CsA)(Neoral®) was dissolved in DMSO and diluted in medium to 
a range of concentration of 2-20000 ng/mL. For the study using psoriatic-like 
human model, HB02, F6, 6S and GD were diluted at the concentration of 5, 20 
and 50 μg/mL and CsA at a concentration of 20 ng/mL.  
 
3.3 Proliferation assay 
 
The anti-proliferative effects of extract, fractions and compounds from ZOR on 
HaCaT and NHEK cells were studied using AlamarBlue and MTT assays to 
quantitatively measure proliferation.  
 
3.3.1 AlamarBlue Assay 
 
AlamarBlue assay measures cell proliferation by detecting the REDOX reaction 
in viable cells after 24, 48 and 72 hours. Change of colour of culture medium 
containing the AlamarBlue stain from blue to reddish purple is a measure of cell 
proliferation. Briefly, 1x104 cells/mL were cultured in 12 well plates and 
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incubated for 24 hours at 37ºC in 5% CO2. HB02, fractions were tested at a 
selected range of concentration on cells and incubated for 24, 48 and 72 hours. 
At each time point (24, 48 and 72hours), the medium was replaced with 10% 
AlamarBlue (AbD Serotec) in DMEM and incubated for 4 hours. The colour 
change was measured at 560 nm and 595 nm at each time point using a multi-
well plate reader (TECAN GENios). Cell proliferation was calculated according 
to the manufacturer’s manual as below; 
Cell viability: 
*PR ( sample)_______ x  100 
* PR (medium control) 
 
PR value for untreated cells (control) or cells treated with ZOR samples was 
calculated as below; 
*Percentage reduction (PR) of Alamar Blue: 
            (E2 x A1)-(E1 x A2)  x 100 
            (E3x N2)-(E4 x N1 ) 
 
E1: Molar extinction coefficient (E) of oxidized Alamar Blue at 560 nm = 80586 
E2: Molar extinction coefficient of oxidized Alamarblue at 595 nm = 117216 
E3: Molar extinction coefficient of  reduced Alamarblue at 560 nm = 155677 
E4: Molar extinction coefficient of reduced Alamarblue at 595 nm = 14652 
A1 = absorbance of test wells at 560 nm  
A2 = absorbance of test wells at 595 nm 
N1 = absorbance of negative control (Alamar Blue in media withouT-cells)  
at 560 nm  
N2 = absorbance of negative control at 595 nm  
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3.3.2 MTT Assay 
 
For the tetrazolium-dye (MTT) assay, confluent monolayers of primary cells 
were detached with trypsin and plated out at 2 × 104 cells/well in 96-well flat-
bottom plates. After a 24 hour pre-incubation period, dilutions of test samples 
were added to appropriate wells and plates incubated for 48hr at 37°C in a 
humidified incubator with 5% CO2. Untreated cells were used as control. After 
48 hour incubation, the medium was removed and wells washed with phosphate 
buffered saline (PBS). A 100 μl MTT solution (0.5 mg/mL) (Sigma) in PBS was 
added to each well and the plate further incubated for 3 hour at 37°C. MTT was 
then removed and 100 μl DMSO added to dissolve MTT crystals. The plate was 
shaken for 30 minutes and absorbance measured at 540nm on a multi-well 
plate reader. The percentage of proliferating cells was calculated as the ratio of 
the absorbance readings for the treated cells to that of untreated wells. 
 
3.4 In vitro model of inflammatory epidermis. 
 
NHEK cells were cultured to 80% of confluence in DMEM F12 medium 
supplemented with RM++ growth factor cocktail as described in section 3.1.2.  
DMEM F12 supplemented with RM++ was used only for cell maintenance. For 
this study, complete Epilife medium with HKGS containing final concentration of 
60 μM calcium chloride, 0.2% (v/v) bovine pituitary extract (BPE), 5 µg/mL 
bovine insulin, 0.18 µg/mL hydrocortisone, 5 µg⁄mL bovine transferring and      
0.2 ng/mL human epidermal growth factor, was used. This medium contains 
specific and necessary growth factors for undefined NHEK cell. 1 x 105 
cells/well NHEK cells were seeded into 24 well plates in Epilife medium 
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supplemented with Human Keratinocyte Growth Supplement (HKGS) and 
cultured for 24 hours. The cells were then starved for another 24 hours in Epilife 
medium without HKGS. The purpose of cell starvation is to retard the 
progression of cell proliferation and production of growth factors by the cells. 
After the 24-hour-starvation, the cells were stimulated with, or without, cytokine 
cocktail containing recombinant IL-17A, OSM, TNFα, IL-22, and IL-1α at            
10 ng/mL each and incubated for 6 hours. It is anticipated that after 6 hours 
incubation, gene transcription necessary for secretion of the related cytokines 
has taken place (225). After the 6-hour stimulation period, the cells were treated 
either with F6, 6S or with GD and incubated for another 48 hours and 
supernatants tested for the level of IL-8 and IL-20. The level of IL-8 and IL-20 
was determined using human IL-8 Tissue Culture kit (Mesoscale) and IL-20 
ELISA kit (R & D Systems) respectively.  
 
3.4.1 Measurement of IL-8 level. 
 
The level of IL-8 in culture supernatants was determined using an MSD® 96-
Well MULTI-SPOT kit. The protocol was carried out according to the 
manufacturer’s (MSD®) instructions. The principle of the assay is a sandwich 
immunoassay where a capture antibody is pre-coated onto a single spot in each 
well of a MULTI-SPOT plate. The level of IL-8 in the test supernatant is then 
quantified using a cytokine-specific detection antibody conjugated with MSD 
SULFO-TAGTM reagent.IL-8 standard was diluted in DMEM (medium used for 
the samples) from a stock concentration of 1 μg/mL. The standard was diluted 
to give a range of concentrations of 10,000, 2,500, 625, 256, 39, 9.8 and             
2.4 pg/mL. Test supernatants from the non-treated and treated NHEK cells 
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were tested in undiluted forms. Briefly, 25 μl of supernatant (or recombinant 
human IL-8 standards) were incubated for 2 hours on a pre-designed human   
IL-8  96-well microtiter plate bearing an array of capture antibody with specificity 
to IL-8. After washing unbound supernatant, the detection antibody (at 1 μg/mL) 
conjugated to the ruthenium-based MSD Sulfo-TAG™ reagent was added. The 
plate was then washed with PBST. The MSD Read Buffer T (2x) was added 
and results read on a Sector Imager (MSD). IL-8 concentrations were 
determined with Softmax Pro Version 4.6 software, using a curve fit model (log-
log or four-parameter log-logit) as suggested by the manufacturer.   
 
3.4.2 Measurement of IL-20 level.  
 
The level of IL-20 in culture supernatants was measured using Quantikine® 
ELISA assay kit (R&D Biosystems). The assay was carried out according to the 
manufacturer’s instructions. The assay is, again, based on a sandwich enzyme 
immunoassay principle whereby plates pre-coated with monoclonal antibody 
specific for IL-20 is used to bind IL-20 present in test samples and bound IL-20 
revealed with a conjugated detection antibody. IL-20 standards were prepared 
by diluting a stock solution of 40 ng/mL in Calibrator Diluent RDSP into         
4000 pg/mL which serves as the high standard concentration. This standard 
was further diluted 1:5 serial dilution in Calibrator Diluent RDSP until the 
concentration of 62.5 pg/mL. The diluents served as zero concentration              
(0 pg/mL). Samples or supernatants collected from treated NHEK cells were 
tested without dilution. One hundred μl of diluent RD1W were added to each 
well of the 96-well assay plate followed by 100 μl of the standards, control or 
test samples and plate incubated for 2 hours at room temperature (RT). The 
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mixture was then aspirated and washed 4 times with ~400μl wash buffer using 
a squirt bottle. After the last wash, the plate was blotted dry on clean paper 
towel. Two hundred μl of enzyme-linked polyclonal antibody specific for IL-20 
were added to each well and incubated for a further 2 hours at RT. The plate 
was washed again for 4 times as before to remove any unbound conjugate. 
Two hundred μl of substrate solution was added and plate was incubated for 30 
minutes at RT in the dark. Finally, 50 μl of stop solution was added and colour 
change from blue to yellow was measured. The optical density of each well was 
determined at 450 nm and corrected at 560 nm using multi-well plate reader 
(TECAN). The data was plotted and analysed using Transform Linear 
regression of GraphPad Prism to determine the concentration of IL-20 in the 
supernatants. 
 
3.5 Statistical analysis 
 
Data analysed using GraphPad Prism software (GraphPad Prism, San Diego, 
California). Means and standard deviation were used to describe normally 
distributed data. The significance of differences between groups was assessed 
using One-way ANOVA (Tukey’s test). Difference of p<0.05 is considered 
significant. 
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4 Results 
4.1  The effect of ZOR test samples on HaCaT cell proliferation. 
 
During the early stages of the experiments, the anti-proliferative effects of F5, 
F6, F7 and F10 on HaCaT-cells at concentrations of 10-1000 μg/mL was  
assessed. The anti-proliferative effect of the fractions on HaCaT was assessed 
after incubation for 24, 48 and 72hr. The fractions were evaluated and ranked 
based on their potency in inhibiting HaCaT proliferation.  
 
The results showed that F5, F6 and F7 reduced proliferation in a time- and 
dose-dependent manner (Figures 6.2a-c). For instance, at 50 μg/mL, F6 
inhibited HaCaT proliferation by 23.4 ± 11.2% after 24 hours, 27.1 ± 10.6% after 
48 hours and by 50.2 ± 2.5% after 72 hours. All three fractions showed 
comparable inhibitory activity at the concentrations of more than 50 μg/mL. 
However, F10 did not have a significant inhibitory effect on proliferation at the 
lower concentrations of 10 and 50 μg/mL. Because the fractions demonstrated 
similar anti-proliferative effects at 50 μg/mL, the comparative activity and 
potency of the fractions could be best distinguished at the lower concentrations 
of 10 μg/mL. Figure 6.2 shows that after all incubation periods and at 10 μg/mL, 
F6 was the strongest inhibitor of HaCaT proliferation. F6 at a concentration of 
10 μg/mL inhibited HaCaT proliferation by 20.7 ± 12.0% after 24 hours, 21.2 ± 
8.7% after 48 hours and 32.2 ± 8.8% after 72 hours. Although, at higher than10 
μg/mL concentrations F5 and F7 had similar inhibitory effect to F6, the latter 
remained the most consistent and, apparently, potent inhibitor of HaCaT 
proliferation. F10, in contrast, had the lowest anti-proliferative effects inhibitory.  
 
                                                                                                           CHAPTER 6                                                                                                                                                                                                                           
 
267 
 
Figure 6.2: The anti-proliferative effects of HB02 fractions on HaCaT cells . 
The HB02 fractions F5, F6, F7 and F10 were tested for their efficiency on 
inhibiting HaCaT-cell proliferation at the indicated concentrations (X-axis) after 
incubating the cells with the fractions for: a) 24hr; b) 48hr; and c) 72hr. Treated 
and non-treated cells were stained with AlamarBlue solution after 24, 48 and 
72hr, and incubated for 4hr at 37ºC. Absorbances were measured at 560nm 
and 595nm (reference) using multiwell plate reader (TECAN) and proliferation 
calculated according to the formula described in section 3.1.2 of the methods. 
Data presented in mean ± SD of % cell proliferation. 
                                                                                                           CHAPTER 6                                                                                                                                                                                                                           
 
268 
4.2  The effect of HB02, F6, 6S and GD on NHEK cell proliferation  
 
The anti-proliferation study using HaCaT-cells showed that F6 was the most 
potent fraction at inhibiting keratinocyte cell line proliferation. To further verify 
the anti-proliferative effect of F6 and also assess which of its two major 
components 6S and GD contributed mostly to anti-proliferation their effects on 
normal human epidermal keratinocytes (NHEK) at a narrow concentration range 
of 5-100 μg/mL and after incubation for 48 hours were tested. The inhibitory 
effects of HB02, F6, 6S and GD were tested in comparison with Ciclosporin A 
(CsA) at a concentration range of 2-20000 ng/mL. CsA was chosen as a 
positive control based on its potent inhibitory effect on keratinocytes 
proliferation and chemotactic activity as reported (226, 227) and for its use in 
treating psoriasis (27, 28, 71, 228).  
 
Figure 6.3 showed the effect of HB02, F6, 6S and GD on NHEK cell 
proliferation after 48 hours incubation. Figure 6.3a showed that at the lowest 
concentration of 5 μg/mL, HB02, F6 and GD in fact enhanced cell proliferation. 
GD, in particular, increased cell proliferation by approximately 62%, followed by 
HB02 by 35% and F6 by 8%. 6S, on the other hand, reduced proliferation by 
14% relative to untreated cells. However, at higher concentrations, 15 μg/mL 
and onwards, F6 and 6S dramatically inhibited NHEK proliferation by more than 
80%. In comparison to F6, 6S showed a robust anti-proliferative effect by 94% 
at 15 μg/mL and by 100% at 50 μg/mL. In comparison, F6 inhibited proliferation 
by 70% (Figure 6.3a) at 15 μg/mL and 88% at 50 μg/mL. HB02 and particularly, 
GD were less effective in inhibiting NHEK proliferation.  
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 Overall the results showed that 6S, F6, HB02 and GD at concentrations of      
7.7±3.6 μg/mL, 14.6±7.3 μg/mL, 32.8±16.3 μg/mL and 42.2±14.7 μg/mL, 
respectively, inhibited 50% of NHEK proliferation. 6S was the most efficacious 
anti-proliferative or with highest cytoxicity effect, followed by F6, HB02 and GD. 
It was observed that CsA was unable to inhibit more than 50% proliferation at 
concentrations lower than 20000 ng/mL (20 μg/mL) (Figure 6.3 b).  
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Figure 6.3: The anti-proliferative effects of HB02, F6, 6S and GD on NHEK 
cells. NHEK cells were obtained from foreskin of three healthy individual         
(A-page, SFK1 and SFK2).  The figures show cell proliferation after 48 hours 
incubation with: a) HB02, F6, 6S and GD at a range of concentrations 5-100  
μg/mL; b) Ciclosporin A (CsA) at 2-2000 ng/mL. NHEK cell proliferation in the 
presence of test samples is presented in comparison with the proliferation in the 
absence of the samples as indicated by the dotted line and considered as 
100%. After 48 hours, proliferation of treated and non-treated cells was 
determined using MTT assay as described in method 3.3.2. Percentage 
proliferation was calculated as the ratio of proliferation obtained for the treated 
cells to untreated cells. Data was presented as the mean ± SD based on three 
independent experiments (n=3).   
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4.3 The effect of ZOR on inflammatory epidermis using an in vitro model.  
 
The previous sections have assessed the effect of ZOR extract, fractions and 
isolated compounds on various general inflammatory pathways of psoriatic 
pathology. Within the context of the effect of ZOR on psoriasis it was important 
to study the direct effects of the ZOR derivatives on a model as directly relevant 
to psoriasis as possible. For this aim to be achieved, an in vitro model of 
inflammatory epidermis modified from a protocol by Guilloteau and colleagues 
(43) was established. The protocol is based on using NHEK cells and 
stimulated with a cocktail of pro-inflammatory cytokines. NHEK were obtained 
from the foreskin of three healthy individuals (A-page, SFK1 and SFK2) and 
stimulated with a combination of IL-17A, OSM, TNFα, IL-22, and IL-1α at 10 
ng/mL. Once established, the stimulated NHEK cell cultures were treated with 
HB02, F6, 6S and GD at concentrations of 5, 20 and 50 μg/mL and the effects 
of the test compounds on morphology of the NHEK cells and cytokine 
production were examined. The test concentrations of HB02, F6, 6S and GD 
were chosen based on the effective concentration in inhibiting NHEK cell 
proliferation from the previous sections. CsA was tested at the concentration of 
20 ng/mL.  
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4.3.1 Changes of the NHEK cell phenotype. 
 
Studies of NHEK phenotype changes and of proliferation were based on the 
appearance of NHEK cells under the microscope. Stimulated cells are 
presented as polygonal-shaped cells with distinctive nuclei (Figures 6.4a-d). 
Figures 6.5 and 6.6 depict SFK1 cells which were stimulated with the 
inflammatory cocktail of cytokines (CT) and then treated with HB02, F6, 6S and 
GD at 20 and 50 μg/mL, respectively. Figure 6.7 depicts A-page cells which 
were CT-stimulated and treated with HB02, F6, 6S and GD at 5 μg/mL.  
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(a) Control 
 
(b) Stimulated with cytokines 
cocktail (CT) 
 
 
(c) CT + CsA (20 ng/mL) 
 
Figure 6.4:  The morphology of NHEK cells following stimulation.  NHEK 
cells were obtained from individual SFK . The cells microscopic pictures depict 
the cells were either: (a) unstimulated and untreated (Control); (b) stimulated 
with CT (containing 10 ng/mL of each IL-17A, OSM, TNFα, IL-22, and IL-1α); 
and (c) CT-stimulated and treated with  Ciclosporin A (CsA) at 20 ng/mL 
(positive control). The shown morphology is representative of three independent 
experiments. Prior to treatment, NHEK cells were seeded in 24 well plates in 
Epilife medium with HKGS for 24 hours then starved for another 24 hours in 
Epilife without HKGS. After starvation, the cells were stimulated with CT and 
incubated for 6hr before treatment with HB02, F6, 6S, GD or CsA. Changes in 
cell morphology were monitored at 40x magnification under microscope and 
captured using JVC TK-C1360B digital colour video camera. 
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The results showed that the NHEK cells from individual SFK1 which were 
stimulated with CT and then treated with HB02, F6, 6S and GD at 50 μg/mL 
shrank and became less confluent (Figure 6.5) compared with control (compare 
Figure 6.4a with 6.4b). The phenotype changes were similar to the appearance 
of cells undergoing apoptosis. Visually, apoptotic bodies are characterised by a 
condensed and ‘invaginated’ cell membrane. The number of cells in was 
reduced by treatment with HB02, F6, 6S and GD at 50 μg/mL compared with 
untreated cells, cells stimulated with the CT, and CT-stimulated and treated with 
CsA (Figure 6.4c). This may correlate to the strong anti-proliferative or 
cytotoxicty effect of these samples, particularly F6 and 6S at this concentration 
on unstimulated NHEK (Figure 6.3a). 
 
 Even at the concentration of 20 μg/mL, similar phenotype changes were 
observed and reduction in cell proliferation was also observed after treatment 
with HB02, F6 and 6S (Figure 6.6) and to a lesser extent with GD. F6 and 6S 
had more potent effects compared with HB02 and GD. Treatment with F6 and 
6S at 20 and 50 μg/mL resulted in a dramatic reduction of NHEK proliferation. 
GD, however, did not appear to affect cell morphology at 20 μg/mL. The 
morphology and cell density were comparable to cells which were only 
stimulated with CT (Figure 6.4b). These results, therefore, confirm that GD was 
less affective in regulating keratinocytes proliferation compared with HB02, F6 
and 6S at this concentration. This corresponds to the least anti-proliferative or 
cytotoxicity effect of GD on unstimulated NHEK (Figure 6.3) 
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(a) CT + HB02 (50 μg/mL) 
 
 
(b) CT + F6 (50 μg/mL) 
 
 
(c) CT + 6S (50 μg/mL) 
 
 
(d) CT + GD (50 μg/mL) 
 
Figure 6.5:  Phenotype changes in NHEK cells treated with selected ZOR 
samples (HB02, F6, 6S and GD) at 50 μg/mL. Changes in NHEK cell 
phenotype were assessed microscopically. The cells were stimulated with the 
cytokines cocktail (CT) and treated with either: (a) HB02; (b) F6; (c) 6S; or  (d) 
GD at 50 μg/mL for 48 hours. Significant phenotypic changes are noted in the 
cells indicating that the Selected ZOR compositions inhibited proliferation at     
50 μg/mL and may also result in apoptosis. Cell morphology was assessed at 
40x magnification and captured using JVC TK-C1360B digital colour video 
camera.  
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(a) CT + HB02 (20 μg/mL) 
 
(b) CT+ F6 (20 μg/mL) 
 
 
(c) CT + 6S (20 μg/mL) 
 
 
(d) CT + GD (20 μg/mL) 
 
Figure 6.6:  Phenotype modulation of NHEK cells treated with selected 
ZOR samples (HB02, F6, 6S and GD) at 20 μg/mL. Changes in the NHEK 
cells were assessed as described in the legend to Figure 6.5 after stimulation 
with the CT and treatment with (a) HB02 (b) F6 (c) 6S and (d) GD at 20 μg/mL 
for 48 hours. The figure indicates that F6 and 6S and, to a lesser extent, HB02, 
reduced cell proliferation whereas GD did not neither did the latter affect 
morphology of the cells.  
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Figure 6.7 shows the effect of HB02, F6, 6S and GD at the lower concentration 
of 5 μg/mL on the NHEK cells (from donor A-page). The figure shows no 
significant changes in the morphology of the cells in the treated cells compared 
with untreated cells. Although, it was noted that the cells were less ‘polygonal’ 
than the untreated cells. (Figure 6.4b). These results indicate that treatment of 
the NHEK cells with the ZOR test samples at 5 μg/mL is unlikely to influence 
proliferation of the keratinocytes significantly. However, it is necessary to point 
out that this presumption is based on one dimensional analysis and hence may 
not be unequivocal evidence for lack of effect on cell differentiation at this 
concentration.  
 
To further explore the potential of ZOR to influence keratinocyte biology and 
contribution to inflammation, the effect of HB02, F6, 6S and GD on the 
production of IL-20 by the activated NHEK was studied. IL-20 is known to have 
a role in inducing keratinocyte hyperproliferation and contribute to inflammation 
in psoriasis 
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(a) Ct + HB02 (5 μg/mL) 
 
 
(b) CT + F6 (5 μg/mL) 
 
 
(f)CT + 6S (5 μg/mL) 
 
(g) CT + GD (5 μg/mL) 
 
Figure 6.7: Lack of phenotype changes in NHEK cells treated with 
selected ZOR samples, HB02, F6, 6S and GD, at 5μg/mL. Treatment of CT-
stimulated NHEK cells with (a) HB02; (b) F6; (c) 6S and (d) GD at 5 μg/mL for 
48 hours had no noticeable effects on the morphology of the cells. 
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4.3.2 The effect of ZOR on the production of IL-8 and IL-20 by activated 
keratinocytes. 
 
IL-8 and IL-20 are important cytokines involved in inflammation and keratinocyte 
hyperproliferation associated with psoriasis (221, 229). Subsequent to exploring 
the effect of the most relevant ZOR constituent/s on NHEK morphology and 
proliferation, the effect of HB02, F6, 6S and GD on the production of IL-8 and 
IL-20 was examined. The production of both cytokines was determined in the 
supernatant of cells stimulated with CT and treated with HB02, F6, 6S and GD 
at the concentration of 5 and 20 μg/mL. 
   
4.3.3 The effect of HB02, F6, 6S and GD on IL-20 production by 
keratinocytes.  
 
IL-20 has been shown to be involved in keratinocyte hyperproliferation and the 
alteration of terminal differentiation process in psoriatic skin (221, 229). By 
assessing the effect of selected ZOR composition (HB02, F6, 6S and GD) on 
IL-20 production, it would be possible to confirm their potential therapeutic 
effects on keratinocytes proliferation and differentiation.  
 
The experiments showed that the test samples at the lowest concentration of     
5 μg/mL weakly inhibited IL-20 production (<4% inhibition) (Figure 6.8). This 
observation is consistent with the lack of effect of the ZOR samples on the 
morphology of the activated NHEK cells (Figure 6.7). However, when HB02, F6, 
6S and GD were tested at 20μg/mL they significantly down-regulated IL-20 
production (90.8±6.0%, 99.9±0.3%, 99.4±0.5% and 88.9±7.0%, respectively). 
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The inhibitory effects were significantly higher than seen with CsA at 20 ng/mL 
(p<0.01).  
 
These data are, again, consistent with the potent anti-proliferative effects of 
HB02, F6 and 6S on the NHEK cells (Figure 6.3a and Figure 6.6). However, 
despite this concordance in the effect of the test compounds on IL-20 
production and on proliferation and morphology, it remains to be established 
whether these effects are connected at the molecular level. This would require 
further detailed investigation which was beyond these studies, due to time 
limitations. 
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Figure 6.8: The effect of HB02, F6, 6S and GD on IL-20 production by 
activated keratinocytes. The samples were assessed for their inhibitory 
effects on IL-20 production by NHEK cells stimulated with the cytokine cocktail 
(CT) containing IL-17A, OSM, TNFα, IL-22, and IL-1α, each at 10 ng/mL. HB02, 
F6, 6S and GD were tested at two concentrations 5 and 20 μg/mL and the 
results analysed using One-way ANOVA (for comparison of the effect of the 
samples to CsA (20 ng/mL). HB02, F6, 6S and GD all significantly inhibited      
IL-20 production when tested at of 20 μg/mL compared with Ciclosporin A (CsA) 
at 20 ng/mL (p<0.001). Values are presented as the mean ± SD on three 
independent experiments. 
 
4.3.4 The effect of HB02, F6, 6S and GD on IL-8 production by 
keratinocytes. 6S down-regulates IL-8 secretion. 
 
IL-8 is a key chemoattractant cytokines in inflammatory responses and is known 
to be involved in psoriasis. In order to assess the therapeutic efficacy of ZOR in 
treating psoriasis, the effect of HB02, F6, 6S and GD on IL-8 by the activated 
NHEK cells, was studied. As in studying the effect of the test compounds on    
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IL-20 production, their effects on IL-8 production at both 5 and 20 μg/mL, were 
tested.  
 
Figure 6.9 shows that relative to the control, all test samples increased rather 
than decreased IL-8 production at 5 μg/mL of concentration. F6 and 6S in 
particular significantly enhanced IL-8 production by the activated NHEK cells. 
This increase, however, was inconsistent as depicted by high SEM values.  
 
At the higher concentration of 20 μg/mL, HB02, F6 and GD increased IL-8 
expression. However, 6S reduced IL-8 production by 68.0 ± 17.0% relative to 
the control. This inhibition was statistically significant when compared with CsA 
at 20 ng/mL (p<0.05). 
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Figure 6.9: The effect of HB02, F6, 6S and GD on IL-8 production by 
activated keratinocytes. The effect of HB02, F6, 6S and GD on IL-8 
production by NHEK was studied by ELISA. The NHEK cells were stimulated 
with the cytokine cocktail (CT) then cultured either with or without HB02, F6, 6S, 
GD or CsA at the indicated concentrations. One-way ANOVA (Tukey’s test) 
analysis was used to compare the effect of the test samples relative to that 
obtained with the control (CT). No significant differences were observed for the 
samples at 5 and 20 μg/mL relative to control (CT) or CsA (20 ng/mL) except for 
6S at the concentration of 20 μg/mL (p<0.01). Values are presented as the 
mean ± SE on three independent experiments. 
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Table 6.1: Summary of the effects of HB02, F6, 6S and GD on NHEK 
proliferation and cytokine production.  
Samples % change in 
proliferation of 
unstimulated 
NHEK cells 
Phenotypic 
changes in 
stimulated 
NHEK 
% change in IL-20 
production 
% change in IL-8 
production  
HB02 16.7±32.5 (-) Yes 90.8±6.0 (-)  61.7± 101.7 (+) 
F6 98.3±8.2 (-) Yes 99.9±0.3 (-) 46.6± 112.0 (+) 
6S 103.5±5.5 (-) Yes 99.4±0.5 (-) 67.6 ± 17.0  (-) 
GD 23.9±31.7 (-) No 88.9±7.0 (-) 26.7 ± 62.6  (+) 
 (-) indicates inhibition/reduction while (+) indicates increase/enhancement. 
 
Table 6.1 summarises the overall effects of HB02, F6, 6S and GD at 20 μg/mL 
on NHEK cells that have been reported in this chapter. The anti-proliferative 
effects were tested using unstimulated NHEK cells while the effect on 
morphology and IL-8 and IL-20 production was assessed on CT-stimulated 
NHEK cells. All samples at this concentration reduced proliferation of             
un-stimulated NHEK cells and reduced IL-20 production by CT-stimulated 
NHEK. It is interesting to note that only 6S reduced IL-20 and IL-8 production in 
NHEK and also reduced cell proliferation. Furthermore, 6S had a superior effect 
on IL-8 and IL-20 production compared with CsA. However, given that CsA was 
tested at a concentration of 1000 times lower than 6S (Figure 6.8 and 6.9), it 
could, if tested at 20 μg/mL, promote equal or better effect than 6S. This 
hypothesis, however, need further studies. In the aspect of cytotoxicity, it is 
worth-noting that HB02 and GD which were less toxic toward normal 
unstimulated cell, showed potent inhibitory effect on IL-2 production by CT-
stimulated cells. Hence, this issue needs further studies. 
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5 Discussion 
 
5.1 HB02, F6 and 6S induce apoptosis-like morphology in keratinocytes  
 activated with a cocktail of pro-inflammatory cytokines.  
 
The experiments described in this chapter show that HB02, F6, and 6S when 
used at high concentrations (≥20μg/mL) inhibited NHEK cell proliferation   
(Figure 6.3), and caused NHEK morphological changes similar to cells 
undergoing apoptosis (Figure 6.6) and reduced IL-20 production in activated 
NHEK    (Figure 6.8). 6S, in addition to causing all these changes in activated 
NHEK cells, also reduced IL-8 production (Figure 6.9). 
 
Changes in the morphology of stimulated NHEK cells after treatment with         
20 and 50 μg/mL of HB02, F6, 6S and GD suggest that cells may be 
undergoing apoptosis with structures resembling apoptotic bodies in the treated 
cells (Figure 6.5 and 6.6). Thus, there is the appearance of condensed 
cytoplasms, dismantled cytoskeleton, invaginated cell membranes and 
rounding-up cells, which are some of the characteristics of apoptotic cells (230, 
231). HB02 induced less apoptotic morphology than F6 and 6S. Cells treated 
with GD, however, did not display apoptotic features at the lower concentration 
of 20 μg/mL, but rather the cells resembled healthy, elongated and proliferating 
cells.  
 
Generally, apoptosis and terminal differentiation in the skin cells are defined as 
cell death, however, based on cell nomenclature,  both can be distinguished by 
different molecular and metabolic pathway (230). Apoptosis is an accelerated 
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process of cell death that begins with induced or involuntary disruption of cell 
proliferation at the basal layer that caused cessation of organelle functions. 
Consequently, this leads to organelles’ degradation, by which cell membranes 
are invaginated, and the cytoskeleton dismantled, attracting macrophage to 
phagocytose the cells. Terminal differentiation of the cells, on the other hand, is 
a constitutive process of skin renewal. Cell proliferation begins at the basal 
layer, followed by stages of differentiation in the suprabasal and granular layer. 
Finally, this resorts to terminal differentiation, or cornification that forms the 
corneocytes of stratum corneum. Unlike apoptotic cells, the cornecytes, or dead 
skin cells are sloughed instead of being phagocytosed (230).  
 
Based on visual observation of the cells, as sampled in Figure 6.6, it is possible 
to propose that HB02, F6 and 6S induce apoptosis in stimulated NHEK cells. 
This appears to be indirectly supported by the potent anti-proliferative effect of 
these 3 test samples on unstimulated NHEK. However, this was not 
demonstrated for GD. Nevertheless, the fact that GD strongly reduced IL-20 
production at 20 μg/mL is intriguing. Of further interest is that GD demonstrated 
anti-proliferative effects on unstimulated NHEK but seemed not to affect the 
survival and differentiation of stimulated cells. These observations may suggest 
that GD could help maintain skin homeostasis if used therapeutically. In 
contrast, the robust effects of HB02, F6 and 6S had on NHEK cell proliferation, 
may be beneficial for therapeutic effects on hyperproliferating cells in psoriatic 
lesions. In order to determine whether any of the test samples induce apoptosis 
or cause cornification of keratinocytes it would be necessary to study the 
expression of proliferation- and differentiation-associated proteins as well as 
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related metabolic changes. Such experiments were not possible due to time 
constraints.  
 
5.2 6S modulates IL-20 and IL-8 production in CT activated 
keratinocytes. 
 
Experiments carried out to assess the effect of the ZOR derivatives tested in 
this chapter revealed that HB02, F6, 6S and GD had paradoxical effects on the 
production of two key cytokines. Thus, whereas HB02, F6, 6S and GD all 
inhibited IL-20 production to varying degrees, only 6S had suppressive effects 
on IL-8 production. For these experiments, CsA was used as a positive control 
based on the fact that CsA has been shown to influence the expression of 
genes associated with inflammation. Indeed, CsA has been used in the 
treatment of psoriatic patients and it has been shown to influence signalling 
pathways mediated by a number of cytokines including IL-1, IL-12, IL-23, IL-20, 
IL-17, IL-22, CCL20, TNFα, IFNα and CXCL9 (232).  
 
The results also showed that GD and 6S displayed rather different mechanisms 
of action in influencing cell proliferation and inflammation in the in vitro model of 
inflammatory epidermis. At 20 μg/mL, the activity of both compounds was 
different in that 6S reduced the production of both IL-8 and IL-20, whereas GD 
enhanced the production of IL-8.  
 
Interestingly, the study showed that CsA at 20 ng/mL did not reduce IL-8 
production despite its effect on IL-20. This observation is in agreement with 
previous studies showing that CsA did not inhibit IL-8 production by cytokine-
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stimulated keratinocytes (233). This was attributed due to the fact that the effect 
of CsA on keratinocytes cytokine production is indirect and reflect the effect of 
CsA on the immune system (233). This may suggest that evaluating the effect 
of CsA, as well as HB02, F6 and GD on IL-8 production in cytokine-stimulated 
keratinocytes is insufficient to provide a conclusive view on how these could 
influence psoriatic inflammation. Thus, an inclusive approach involving the 
effect of these test samples on other immune cells including T-cell, B cells and 
macrophages would be necessary. Nevertheless, the approach used in these 
studies has provided relevant information that could be used to construct a 
tentative outline for how these test samples could modulate inflammation 
relevant to psoriasis. In this respect, the ability of 6S to reduce IL-8 production 
by activated keratinocytes is intriguing and suggest that 6S could also modulate 
the production of other chemotactic factors associated with the induction of IL-8 
such as anti-microbial peptides, as suggested by Guillteau and colleagues (43).  
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6 Conclusions 
 
The experiments described in this chapter have shown that 6S is highly 
effective in modulating keratinocyte proliferation as well as inhibiting the 
production IL-20 and IL-8 by cytokine-activated keratinocytes. These activities 
were significantly more effective than seen for HB02, F6 and GD. The ability of 
6S to inhibit cell proliferation may partly be due to its potent effect on IL-20 
expression. However, whether this could result in apoptosis of the cells or 
promote the terminal differentiation of keratinocytes is to be established. These 
observations appear to suggest that ZOR derived compounds could have 
therapeutic benefits in treating psoriasis provided that potential side effects are 
adequately assessed. However, the safe application of ZOR derived 
compounds, most likely including 6S, would require further testing in vitro and in 
vivo using relevant animal models.  
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CHAPTER 7 
 
General Discussion 
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1 Summary of the findings 
 
Psoriasis is an autoimmune skin disease triggered by a combination of genetics 
and environmental factors leading to the induction of various inflammatory 
pathways. Numerous therapeutic approaches are used to treat patients with 
psoriasis ranging from the use of UV light for treatment, to a range of 
pharmaceutical drugs to biologics. Thus far, no specific treatment that embarks 
consistent efficacy in all patients has been discovered. This is due to variability 
in environmental triggers and the nature of immune effector mechanisms 
triggered in different patients subgroups or individual patients (234, 235). The 
aim of this thesis was to identify potential mechanisms of action of extract and 
compounds from a ginger species known as Halia bara or  Z.officinale  Roscoe 
var. rubrum (ZOR), known to have therapeutic benefits in inflammatory 
diseases. This study encompasses a detailed assessment of ZOR extracts and 
derived compounds on activated macrophages, leukocytes and keratinocytes, 
all of which are known to be key players in psoriasis as well as most 
autoimmune diseases. Bearing in mind the complexity of the cytokines network 
in psoriasis, it is hypothesised that the outcomes of this study will provide a 
framework of potential mechanisms of action of ZOR against inflammatory 
cascades in psoriasis. Furthermore, it was hoped that the study could identify 
active compounds in ZOR that exert modulating effects on key cytokines 
involved in inflammatory cascades in most chronic conditions. 
 
 
 
                                                                                                           CHAPTER 7                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
 
292 
1.1 The effect of ZOR on macrophages. 
 
The first stage of this study involved investigating the anti-inflammatory effects 
of ZOR extracts, fractions and isolated compounds on activated macrophages. 
This was carried out by assessing the inhibitory effects of these ZOR samples 
on the production of a number of key pro-inflammatory mediators produced by 
LPS-activated macrophages that include NO, PGE2, TNFα, IL-12/IL-23p40 and 
IL-23p19 (Table 7.1). There is good evidence from different investigators for the 
involvement of all of these pro-inflammatory mediators in the pathogenesis of 
psoriasis. The mediators are transcribed when the relevant transcription factors 
are activated by LPS interaction with a multitude of receptors (TLR4), co-
receptors (CD14, MD-2) and messenger proteins and signaling molecules  
(LBP, IRAK, TRAF) in macrophages (236). These interactions activate a 
number of signalling pathways such as NF-κB, ERK, JNK and p38 MAP kinase 
resulting in production of cytokines, which, however, beyond the scope of this 
thesis. 
 
In the preliminary experiments, it was substantiated that ZOR extracts potently 
inhibited NO and PGE2 production by activated macrophages (the RAW264.7 
cell line). In this respect, the results showed that the chloroform extract from 
ZOR; HB02 was the most potent among extracts obtained using different 
solvent, in inhibiting both NO and PGE2 production when added to 
macrophages before LPS stimulation. Furthermore, the fractions (F5, F6, F7 
and F10) extracted from HB02 were more efficacious than L-NAME in inhibiting 
NO production. In addition, these fractions were comparable to dexamethasone 
and indomethacin in their ability to inhibit PGE2 production. These findings are 
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in agreement with previous studies on the inhibitory effects of red ginger on the 
production of NO and PGE2 (147). These results also highlighted the 
relationship between the NO and COX pathways (140, 141, 145).  
 
To elaborate on how ZOR affected the NO pathway, the effect of HB02 and its 
fractions on INOS mRNA and protein levels when added to macrophages at two 
time points: before and after LPS stimulation of the RAW264.7 cell line, was 
determined. HB02 and its fractions reduced iNOS mRNA levels both when 
added before and after LPS stimulation. Among the fractions, fraction 6 (F6) 
and F7 showed the strongest effects on reducing iNOS mRNA levels when 
added to macrophage before and after LPS stimulation. Culture of the 
macrophages with F7 caused a dramatic reduction in iNOS protein levels that 
was significantly more pronounced compared with the other fractions. However, 
F7 was also cytotoxic to macrophages at high concentrations (≥50µg/mL). F6, 
in contrast, was less effective than F7 but had not cytotoxic effects on the 
RAW264.7 cell line. F6 suppressed iNOS mRNA and protein levels at high 
concentration while sustaining cell viability. Based on this observation, F6 was 
identified as the potential fraction for further characterisation. 
 
These studies were followed by series of purification processes that resulted in 
the identification of the main components of F6. Extensive characterisation of 
the components revealed that these were 6-shogaol (6S) and 1-dehydro-6-
gingerdione (GD). Both compounds are derivatives of gingerol, a phenolic 
compound commonly present in fresh ginger (97), wherein both 6S and GD are 
the dehydrated form of gingerol. Referring to them as gingerol-related 
compounds, both exhibit ‘druggable’ structures with the presence of hydroxyl 
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and carbonyl moieties on their side chains (Figure 2.17). These structures are 
among the characteristics of a drug-like compound as proposed by Lipinski’s 
Rules of five (133).  
 
Based on these findings, the contribution of these two compounds to the 
biological effects of F6 on iNOS mRNA and protein levels was investigated. 6S 
showed similar effects to F6 in reducing iNOS mRNA level. In contrast, GD 
showed a tendency towards reducing the enzymatic activity of iNOS. Hence, 
the effect of F6 on iNOS mRNA levels may be attributed to 6S rather than GD. 
Interestingly, however, neither compound had a significant effect of iNOS 
protein level or NO production when added after macrophage activation. F7, in 
contrast, had a profound inhibitory effect of on iNOS protein level but limited 
effects on NO production. Suffice is to say, these results suggest that HB02 
contains compounds that preferably act in a prophylactic manner before 
inflammation initiated by activated macrophage. 
 
The effect of HB02, F6 and 6S on TNFα production was unexpected that all 
enhanced TNFα production both when added before or after LPS stimulation. 
This observation is inconsistent with other studies in which common ginger 
extracts were shown to suppress TNFα production by LPS-stimulated 
macrophages (217)  and synoviocytes (148). According to Frondoza et al 
(2004), a ginger extract containing hydroxyl-methoxy-phenyl compounds 
suppress NF-κB activation and induce IκB-α, resulting in the inhibition of TNFα 
production and inactivation of COX-2 in synoviocytes. However, it remains 
unclear to which extent this disagreement between the effects of ZOR and 
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common ginger is due to variation in the compositions of the extracts and to 
differences in the experimental protocols. 
 
There is currently no data on to how HB02, F6 and 6S enhance TNFα 
production by LPS-stimulated RAW264.7 cells. However, it is possible that 6S, 
or other as yet unidentified compounds, could be activating a pathway that 
leads to TNFα production. In this respect, there is evidence that the production 
of TNFα in LPS-stimulated macrophages is influenced by  the activation of ERK, 
JNK (236) and MAPK/p38 (237). There is also evidence that the process is 
facilitated by specific receptor-associated proteins such as TNFα receptor-
associated factor-6 (TRAF6) and IL-1 receptor-associated kinase (IRAK) (236).  
 
Paradoxically, the results showed that GD reduced TNFα mRNA levels when 
added to the cells before LPS stimulation. This finding could relate to the ability 
of this compound to reduce TNFα gene transcription by suppressing TLR4 
signalling, or by activating IRAK. Further, there is evidence that activation of 
IRAK-M and AKT, that function in negative feedback, repress TLR4 signaling 
and modulate TNFα release (238). Nonetheless, this hypothesis needs to be 
further studied. However, it is unclear why F6 did not show similar inhibitory 
effects on reducing TNFα mRNA whilst GD did. One hypothesis is that the 
effect of GD might be masked by a bystander effect from other compounds 
present in F6. 
 
Alternatively, F5 and F7 may affect posttranscriptional events that regulate 
TNFα mRNA levels. Modulation at posttranscriptional level may involve various 
complex events such maintaining RNA stability, translation initiation, transcript 
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distribution and regulation of 3’ ARE (AU-rich element) of TNFα mRNA (236, 
239). This observation, remain to be clarified by future study. Bearing in mind 
the pleiotropic effects of TNFα in promoting and inhibiting inflammation, it is 
noteworthy that the differential effects of components of ZOR on TNFα 
expression might embody the multi-targeting ability of ZOR components before, 
during and after transcription of TNFα.  
 
Experiments to assess the effects of ZOR on the IL-12/IL-23 axis showed that 
the ZOR samples strongly suppressed IL-12p40 and IL-23p19 mRNA levels 
when added to the macrophages before LPS stimulation. In addition, HB02, F6 
and 6S, but not GD, also inhibited IL-12p40 production when added to the 
macrophages after LPS stimulation. This observation could be relevant to 
psoriasis since IL-12 and IL-23 in key cytokines in the differentiation Th1 and 
Th17 cells, respectively (25, 160, 240). These findings, therefore, suggest that 
HB02, F6 and 6S could modulate the generation of Th1 and Th17 T-cell 
functions. These findings are important since IL-23 is established as one of the 
prime inflammatory mediators in psoriasis (169, 170) and targeting p40 subunit 
has been used for the treatment of psoriasis (34). These results could, thus, 
suggest that ZOR and, particularly F6 and its compounds, could strongly 
modulate macrophage responses during inflammation. 
 
1.2 The effect of ZOR on leukocyte migration and T-lymphocyte  
 activation. 
 
A key feature of chronic diseases is the continuous migration of immune cells 
such macrophages and polymorphs (PMN) into sites of disease under the 
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influence of a chemotactic environment resulting in inflammation. Therefore, the 
next phase involved examining the effect of HB02, F6, 6S and GD on PMN 
adhesion and migration using TNFα-stimulated human endothelial cells 
(HUVEC) in vitro. Examination of PMN adhesion and migration under the 
microscope showed that all tested ZOR samples reduced adhesion and 
migration at low concentrations. Concurrent flow cytometric analyses for the 
expression of adhesion molecules showed that treatment with the ZOR samples 
enhanced L-selectin (CD62L) shedding and CD11b expression by activated 
PMNs. The increase in CD11b expression and L-selectin shedding was 
unexpected and may suggest that the effect of ZOR on PMNs is complex but 
that it ultimately leads to reduced cell migration to site of inflammation. 
 
Results of testing HB02, F6, 6S and GD for their effect on PMN migration 
showed that 6S had the most potent inhibiting effects on PMN adhesion but that 
GD had little effects. Instead, treatment of PMNs with GD promoted margination 
of PMNs on endothelial cells but inhibited adhesion and migration through 
endothelial cells. These results suggest that 6S and GD have different, but 
possibly, complimentary modes of action on PMN migration. 
 
In addition to the effects previously shown for the tested ZOR samples in 
modulating iNOS and IL-12/IL-23 by activated macrophages, these results 
highlight their modulatory effects on the response of PMNs to inflammation. 
This property could be important since PMN activation is linked to the balance 
of interaction between iNOS, IL-12/IL-23 and PGE2 (161, 241). Therefore, 
although these observations are based on limited assay systems (macrophages 
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and PMNs), it is sufficient to indicate that the tested ZOR samples possess 
important anti-inflammatory properties. 
 
In light of these observations, the effects of 6S and GD on the activation of 
helper CD4+ and cytotoxic CD8+ T-lymphocytes were studied. Primary               
T-lymphocytes were obtained from the spleen of healthy 8-12 week old mice. 
The effect of 6S and GD on inflammatory responses of isolated T-lymphocytes 
was studied following activation of the cells with antibodies to mouse CD3 and 
CD28. The results revealed that neither 6S nor GD had significant effects on the 
activation of mouse CD4+ T-lymphocytes. In contrast, the two compounds 
showed inhibitory effects on the activation of CD8+ T-lymphocytes. This was 
indicated by the reduction in the level of expression of the activation markers 
CD25 and CD69 on CD8+ T-lymphocytes. Based on these rather unexpected 
findings, the effect of 6S and GD on the level of TNFα and IL-17 produced by 
this T-lymphocyte subset was studied. The results showed that 6S reduced the 
production of both cytokines by CD8+ T-lymphocytes. These results, thus, 
further highlight the potential of 6S in regulating activation of CD8+                    
T-lymphocytes. However, further studies would be required to verify these 
results and determine the potential relevance to treatment for patients with 
psoriasis. 
 
1.3 The effect of ZOR on keratinocytes. 
 
In view of the diverse and, at times, paradoxical anti-inflammatory effects 
observed for HB02, F6, 6S and GD on macrophages, PMNs and T-lymphocytes 
it was necessary to also assess their effects on keratinocytes. Abnormally 
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activated keratinocytes play a key role in sustaining the inflammatory response 
in psoriasis through proliferation and the production of pro-inflammatory 
cytokines and chemokines (219). Therefore, the effect of the ZOR samples on 
keratinocytes in an in vitro model of inflammatory epidermis was studied. The 
model has been published and has been shown to closely resemble cellular and 
molecular profiles of psoriatic skins (43). In this model, human primary 
keratinocytes are stimulated with IL-17, IL-22, TNFα, IL-1β and OSM                 
(a member of IL-6 family), all established key cytokines in psoriasis 
pathogenesis (42, 43, 218, 220, 242). The effect of the ZOR samples on 
keratinocyte proliferation and cytokine/chemokine production in this system 
were then investigated. Cytokines studied included IL-20, which is known to 
promote cell hyperproliferation in psoriasis (224) and IL-8 that plays a important 
role in inflammatory responses, particularly as a chemoattractant (243). IL-20 is 
produced exclusively by keratinocytes in response to Th22 and Th17-related 
cytokines (221) and is expressed on the entire layer of the epidermal 
keratinocytes in patients with psoriasis (224). IL-8 production by keratinocytes is 
triggered by the synergistic effect of TNFα and  IL-17 (218).  
 
The results revealed that 6S had a profound effect on inhibiting IL-20 and IL-8 
production by activated keratinocytes. This effect was significantly more 
pronounced compared with the effect seen for HB02, F6 and GD. The effect 
observed for 6S was also higher than seen for the positive control CsA. In view 
of the reported increase in IL-20 production and its role in keratinocyte 
proliferation (224), it is possible that the ability of 6S to inhibit keratinocyte 
proliferation may partly due to its potent inhibitory effect on IL-20 production.  
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It was previously suggested that IL-20 triggers CD8+ T-cell to induce 
keratinocyte growth factor (KGF) production that facilitates cell 
hyperproliferation in psoriatic skins (224 405). It was, thus, interesting to note 
that 6S was also shown to inhibit murine CD8+ T- lymphocytes activation and 
reduce TNFα and IL-17 by this T- lymphocyte subset. These results, therefore 
suggest that 6S could have therapeutic benefits in treating cutaneous 
inflammations associated with IL-20 production and CD8+ T- lymphocytes 
activation. This beneficial therapeutic effect would further be bolstered by the 
ability of 6S to strongly inhibit IL-8 production. A previous study proposed that 
IL-8 production is primarily localised to the suprabasal layer of the psoriatic 
epidermis, suggestive of the role IL-8 plays in keratinocyte differentiation rather 
than proliferation (244).  
 
6S also promoted changes in the phenotype of activated keratinocytes 
suggestive of inducing apoptosis in these cells. This effect was also noted for 
HB02 and F6 and, thus, highlights the potential of ZOR in psoriasis. GD, in 
contrast, did not affect the phenotype of the keratinocytes nor had an effect on 
IL-8 production despite its effect on IL-20 production.  
2 Conclusions 
 
Results of experiments detailed in this thesis have shown that ZOR extract, 
fractions and two identified compounds have modulatory effects on a range of 
pro-inflammatory pathways including the production of cytokines, cell migration 
and proliferation. Interestingly, however, the study also revealed that the two 
identified and fully characterised from one of the most relevant ZOR fractions, 
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6S and GD displayed differential effects on activated macrophage, PMNs,        
T-lymphocytes and keratinocytes (Table 7.1). Overall, the data presented 
provide a detailed insight into the multi-target effects of 6S and its modulatory 
effects on inflammatory responses mediated by immune cells and by 
keratinocytes. Furthermore, the similarities between the biological effects 
revealed for 6S and, the rather unrefined HB02 and F6, highlights the influence 
of 6S on the activity of the HB02 and, by inference, ZOR. It was interesting to 
note, however, that in contrast to 6S, GD had limited anti-inflammatory effects 
with its key notable effect in reducing the level of TNFα mRNA. Interestingly, 6S 
was unable to reduce the level of TNFα mRNA. In terms of function-structural 
relationships, it is tempting to speculate that these differences might be due to 
structural differences between 6S and GD. The two compounds are 
differentiated by the presence of an enolic-hydroxyl moeity at C-5 on the side 
chain of GD which is absent in 6S. Instead, at the same position in 6S, there is 
a double bond. These observations raise issues as to whether it would be 
preferable to use the compounds individually or in combination. However, 
further detailed studies are required as these questions were beyond the scope 
of this study.  
 
Overall, the study provides a new overview of potential mechanisms of action of 
ZOR in modulating inflammatory cascades, potentially relevant to psoriasis. 
However, further studies exploring the effect of ZOR on the interaction between 
immune cells and keratinocytes in an in vivo model system of psoriasis would 
be required before the potential therapeutic efficacy of ZOR in psoriasis could 
be substantiated. 
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3 Potential implication for the use of ZOR in a therapeutic strategy for  
       psoriasis. 
 
Although extensive studies on the molecular and cellular pathogenic 
mechanisms involved in psoriasis have been carried out, the etiology and key 
pathogenic mechanism(s) that sustains the disease remains in debate. 
Nevertheless, knowledge and understanding key pathogenic aspects of the 
disease has led to emergence of broader therapeutic approaches for treatment. 
This study has examined the potential of naturally-occurring active compounds 
in Z.officinale Roscoe var. rubrum (ZOR) to be used as anti-psoriatic agents. 
Thus, the study shows that active compounds isolated from ZOR; 6-Shogaol 
(6S) and 1-dehydro-6-gingerdione (GD) have the ability to regulate important 
cytokine networks and inflammatory pathways relevant to psoriasis. 
 
Overall, both compounds, albeit at different doses, possess complimentary 
effects in regulating the production of NO and PGE2, reduce the level of           
IL-12p40 and IL-23p19 mRNA, inhibit PMN migration, reduce the activation of 
CD8+ T-cells and  inhibit IL-20 production by keratinocytes. The evidence 
provided in the study, thus, suggests that the compounds could work 
synergistically to modulate a range of inflammatory pathways in psoriatic 
plaques. Thus, further work that arises from this study is to identify the 
mechanistic interaction of both compounds in modulating the inflammatory 
events mentioned above. 
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The study has also revealed a number of interesting mechanisms through which 
6S and GD could influence inflammation. Thus, the results have suggested that 
the suppressive effects of the two compounds on NO and PGE2 production may 
indirectly reduce IL-12/IL-23 mRNA expression by macrophages. The reduction 
in IL-12 and IL-23 levels, in turn, will reduce the activation and differentiation of 
Th1 and Th17 which have been shown to be important for the development of 
psoriasis. Further, the ability of the two compounds to inhibit PMN migration 
indicates that the compounds would have strong anti-inflammatory effects 
during the initiation of inflammation. Furthermore, since both compounds 
preferably affected CD8+ T-cells as compared with CD4+ T-cells, it is likely that 
the compounds would modulate inflammation at the cutaneous level. Because 
CD8+ T-cells are mainly found in the epidermal layer in psoriatic skin (30), this 
may suggest that the two compounds may suppress the inflammatory response 
locally. Thus, this may be beneficial for cutaneous therapeutic treatment on 
psoriatic lesion.In addition, reduction in IL-17 production by CD8+ T-cell, 
although marginal, suggests that the compound have the potential to regulate 
Tc17, or IL-17 producing CD8+ T-cells. Based on studies conducted elsewhere, 
the role of Tc17 resembles that of Th17 cells (245, 246). However, this 
hypothesis needs to be directly examined in experiments in which this T-cells 
subset is directly studied.  
 
In addition to the inhibitory effects of 6S and GD on immune cells, the two 
compounds also modulated IL-20 production by keratinocytes. IL-20 is a 
member of the IL-10 family of cytokines and was recently shown to be involved 
in inflammation and bone resorption in patients with inflammatory conditions 
(247). In addition to the relevance of this observation to the pathogenesis of 
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psoriasis, the data suggest that the compounds could have therapeutic benefits 
in psoriatic arthritis which is associated with joint damage and bone loss. 
However, further studies will be required to test this possibility. 
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Table 7.1 : Summary of the effects of ZOR’s extract (HB02), fractions (F5-10) and compounds (6S and GD) on inflammatory  
                  responses produced by activated macrophages, PMNs, T-lymphocytes and keratinocytes.  
      
              Down-regulated/inhibited         Up-regulated/increased       No effect        Not studied 
 *CsA was tested at 20 ng/mL                                 
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Table 1: Selected plants for preliminary anti-inflammatory screening  
Plants Anti-inflammatory properties 
 
Mangifera indica  
 
Common name:  
Mango, Mangga 
 
 
VIMANG®, a Cuban standard aqueous extract from the stem 
bark of Mangifera indica consisting of 10% Mangiferin 
demonstrated good antioxidant and anti-inflammatory 
activities. The extract was shown to have the ability to inhibit 
both cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) 
pathways by inhibiting arachidonic acid metabolites such as 
PGs and LTs in animal models (248). It also reduced serum 
levels of TNFα and human synovial secretory phospholipase 
(PL)A2 (248). sPLA2 plays a significant role in initiating the 
production of arachidonic acid from cell membrane 
phospholipids. Thus, inhibiting sPLA2 could lead to the 
inhibition of both COX and LOX pathways. Therefore, the 
extract might have the potential to possess inhibitory effects 
on the pathogenesis of psoriasis. 
 
Ipomoea batatas  
 
Common name: 
Sweet potato, Ubi 
biru 
 
 
It is a type of sweet potato with blue colour rhizome/root 
content. Upon fermentation, it produces polyphenolate which 
is mainly a caffeoylquinic acid derivative with potent 
antioxidant effects. This derivative exhibits radical 
scavenging activity, and has inhibitory effects on 
mutagenesis, cancer, diabetes, bacterial and viral infections, 
inflammation, and also inhibits melanin (249). 
 
Crinum asiaticum 
  
Common Name: 
Crinum lily, 
Tembaga suasa 
 
 
Crinum asiaticum leaves are usually used by Malay 
traditional medicine practitioners for the treatment of 
fractured bones. The leaves are wrapped around fractured 
areas to reduce swelling. The active constituents isolated 
from Crinum asiaticum L var. japonicum include: crinamine, 
lycorine, norgalanthamine and epinorgalanthamine. Crinum 
was found to inhibit hypoxia inducible factor-1 (HIF-1) which 
functions in activating the transcription of genes involved in 
angiogenesis, cell survival and glucose metabolism in 
cancerous cells (250). 
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Pandanus 
amaryllifolius  
 
Common name : 
Screwpine, 
Pandan 
 
Pandanus amaryllifolious is a pandanus species with 
scented leaves widely found in Southeast Asia. Studies 
have been carried out to identify the active compounds 
within the root and leaves. The aroma from the leaves is due 
to the presence of 2-acetyl-1-pyroline. Several alkaloids with 
pyroline-derived structures have been identified in the 
leaves using acid-base extraction. These alkaloids are 
pandanamine and pandamerilactones. Although the active 
constituents of the plant from different locations might vary, 
the majority of the alkaloids have at least one                    
α,β-unsaturated γ-lactone ring derived from pandanamine 
(251). Subsequently, a lectin designated Pandanin was 
identified using saline extraction of fresh leaves. It is an 
unglycosylated protein with a molecular mass of 8.0 kDa 
with 50-60% homology to those of mannose-specific lectin. 
Pandanin exhibits hemagglutinating activity against rabbit 
erythrocytes and anti-viral activities towards human viruses 
such as herpes simplex virus type-1 (HSV-1) and influenza 
virus (HIN1) (252). 
Zingiber officinale  
Roscoe  var. 
rubrum  
 
Common name: 
Ginger Sp., Halia 
Bara 
 
Zingiber officinale Roscoe var. rubrum originated from 
Zingiberaceae family is native to Southeast Asia. 
Traditionally, in Malaysia, it is used as one of the ingredients 
in postnatal treatment of wound healing. To date, the plant 
has not been studied for its anti-inflammatory activity, 
although many other species of Zingiberaceae family are 
known to possess such activities.  The major active 
constituent of the plant is geraniol with 28.4% recovery in 
the essential oil of Zingiber officinale Roscoe  var. rubrum 
(253).  The major compound of the Zingiberaceae family, 
Zingiberene is present at ~3-17%.   
 
Artocarpus 
heterophyllus  
 
Common name: 
Jackfruit, Nangka 
Artocarpus heterophyllus is an edible fruit widely distribution 
in South and Southeast Asia, New Guinea and Southern 
Pacific. Studies were carried out to identify the active 
constituents of the plant in the leaves, bark and the fruit of 
jackfruit. Several flavonoids have been identified and 
isolated and shown to possess good antioxidant and anti 
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 inflammatory activities. The most potent is artocarpanone 
which exhibits significant effects on NO production and 
iNOS protein expression in macrophages, RAW 264.7 cells 
(254). The inhibitory effect of artocarpone on NO production 
in LPS-activated macrophage line RAW was due to the 
suppression of iNOS protein expression. A phenolic 
compound derived from the fruit extract, artocarpesin was 
also found to have the potential to suppress NO and  PGE2 
production by down regulating the expression of iNOS and 
COX-2 protein (255). Studies have shown that iNOS and 
COX-2 were found to be up regulated in psoriatic lesion 
(31), therefore, these plant actives might have the potential 
as an anti-psoriatic agent. 
Morinda citrifolia  
 
Common name: 
Mengkudu, Noni, 
Indian Mulberry 
 
 
 
Many studies have been done on the active constituents of 
the leaves, bark and fruit of Morinda citrifolia in terms of their 
chemical characteristics and potential bioactivity.  It is a 
native common name of the plant in Malaysia has been 
used in traditional medicine to treat diabetes. The leaves 
taste bitter and are normally eaten as vegetable side dishes 
with rice. The leaves were shown to contain flavonol 
glycoside that has good antioxidant properties. The 
inhibitory activities of the extract against LOX and COX 
might signify its potential as an inhibitor of psoriasis 
pathogenesis 
Artocarpus altilis  
 
Common name: 
Breadfruit, Sukun 
 
 
 
 
The plant is originally from Southeast Asia, has spread to 
pacific islands which have a tropical climate. In Malaysia and 
Indonesia, the plant is known as Sukun, or breadfruit due to 
the structure of the fruit which is spongy bread-like structure. 
Artocarpus atilis is in the family of Moraceae and Order of 
Rosales. It can grow to a height of 30 meters and produce 
up to 200 fruits per year. The fruits have a high content of 
carbohydrates and are eaten as delicacies in form of chips. 
The leaves are usually used as animal feed. In Indonesia, 
the leaves are used for the treatment of liver cirrhosis, 
hypertension and diabetes.Various studies have shown that 
flavonoids as well as triterpenes that are extracted from the 
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leaves possess good antioxidant, anti-platelet aggregation, 
cytotoxicity and anti-inflammatory activities.  Yu Wang et al. 
(2007) elucidated that the geranyl flavonoid of Artocarpus 
atilis  has potential as an anti-cancer agent. 
Piper 
sarmentosum  
 
Common name: 
Wild betel, Pokok 
Kadok 
 
 
 
Originated in Asia; China, India and Southeast Asia, Piper 
sarmentosum is from the family of Piperaceae. It is used as 
a food additive or flavouring and in folk medicine. Within the 
region of the Malay and Indonesian archipelago, the roots 
and leaves of the plant are used to treat toothache, fungi 
dermatitis, coughing, asthma and pleurisy. Previous studies 
have shown that the plant has larvacide and adulticide 
activity on mosquitoes (256) as well as antimalarial activity   
(257). Studies indicate that a compound from flavonoid 
group Narigenin is extractable from the leaves and that this 
possesses good antioxidant and superoxide scavenging 
activity (258). These findings, therefore, suggest that the 
plant has an inhibitory effect on many inflammatory 
pathways.  
 
Tinospora crispa   
 
Common Name: 
Bakawali, Patawali 
 
 
Tinospora crispa is a wild-type plant species widely 
distributed in the primary rainforest throughout Philipines, 
Indonesia, Malaysia, Thailand and Vietnam, in tropical and 
subtropical regions of India and  some parts of the Far East. 
It is the origin of the family of Menispermaceae. The plant is 
usually used in the Malay traditional medicine for the 
treatment of diabetes and hypertension. In the Philippines, 
the plant is used to treat chronic rheumatism and malarial 
fever. In India, The plant is used as a tonic, antiperiodic and 
diuretic agent. The plant was first studied by westerners at 
the beginning of the 20th century and recognised that the 
plant contained alkaloids and bitter glucosides.  More recent 
studies have identified the active constituents and their 
bioactivity properties. Basically, the bitter taste is due to the 
presence of alkaloids, and some alkaloids have been 
identified; columbine (whole plant), picroretine (leaves), 
tinosporidine and  tinosporine. In addition, the stem was 
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found to contain glucosides such as berberine, triterpenes, 
cycloeucalenol, cycloeucalenone  and  flavonoids; flavone 
O-glycoside and others.  Studies have confirmed that 
Tinospora crispa has antidiabetic (259), antioxidant (260) 
and anti-inflammatory (261) properties . 
Archidendron 
bubalinum 
 
Common name: 
Kerdas 
 
Archidendron bubalinum originated from the Leguminosae 
family and is found in Southeast Asia. It is a small to 
medium-sized plant which grows to a fairly large tree of up 
to 42 m tall. The seeds’ features are ellipsoid, flattened, 
without pleurogram and possess a pungent smell and bitter 
taste. The seeds are used as food additives and flavouring 
in Malay food, but could also be eaten raw. Traditionally, the 
seeds are used as a diuretic and also as a medicine for 
diabetes. To date, no study has been carried out to identify 
the active medicinal compound, or compounds in the seeds 
as well as the bioactivity of such compound(s).   
Marantha 
arundinancea 
 
Common name : 
Arrowroot, Ubi 
bemban 
Marantha arundinancea is a herbal plant about 0.5-1 meter 
tall with starchy rhizomes.  It is a beet species from the 
Marantaceae family and is traditionally used as disinfectant 
and antidote to poisons. There is very little scientific 
information on the plant 
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Table 2: Levels of evidence, evaluating quality of studies on drugs.  
 
Level of Evidence 
(LOE) 
Description 
A Highest level with randomised, controlled clinical and 
cohort studies 
B Conclusive retrospective, or analytical cohort studies, 
research results, case control studies from level A 
C Case report or follow up studies from B 
 
D Expert opinion without scientific background, pure 
laboratory research or mechanism of action. 
 
Reference: OCEBM Levels of Evidence Working Group*. "The Oxford 2011 
Levels of Evidence". Oxford  Centre for Evidence-Based Medicine. 
(Adapted from http://www.cebm.net/index.aspx?o=5653) 
 
 
 
 
 
APPENDICES 
 
336 
 
 
Figure 1: 1H NMR spectrum of 6-shogaol dissolved in chloroform-D (CDCl3), 500 MHz. 
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Figure 2 : The 13C NMR spectrum of 6-shogaol dissolved in CDCl3, 125 MHz. 
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Figure 3: NMR DEPT-135 spectrum of  6-shogaol dissolved in CDCl3, 125 MHz. 
 
 
 
 
APPENDICES 
 
339 
 
 
Figure 4: COSY 2D-NMR spectrum of 6-shogaol dissolved in CDCl3. 
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Figure 5: HMQC 2D-NMR spectrum of 6-shogaol dissolved in CDCl3. 
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Figure 6: HMBC 2D-NMR spectrum of 6-shogaol dissolved in CDCl3.
 
 
 
 
APPENDICES 
 
342 
 
 
4000 6003500 3000 2500 2000 1500 1000
cm-1
101
90
91
92
93
94
95
96
97
98
99
100
101
%
T
2963.8cm-1
2933.1cm-1
2858.6cm-1
2368cm-1
1697.6cm-1
1671.3cm-1
1631.8cm-1
1518cm-1
1465.3cm-1
1434.7cm-1
1373.3cm-1
1277cm-1
1237.5cm-1
1040.3cm-1
1158.6cm-1
1123.6cm-1
987.76cm-1
799.36cm-1
650.39cm-1
3410.7cm-1
825.64cm-1
 
 
Figure 7: Infrared spectrum of 6-shogaol. 
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Figure 8: UV Spectrum of 6-shogaol. 
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Figure 9: 1H NMR spectrum of 1-dehydro-6-gingerdione dissolved in CDCl3, 500 MHz. 
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Figure 10: 1H NMR spectrum of 1-dehydro-6-gingerdione dissolved in solvent mixture of CDCl3 and methanol-D4,  
500 MHz 
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Figure 11: The 13C NMR spectrum of 1-dehydro-6-gingerdione dissolved in CDCl3, 125 Mhz. 
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Figure 12: NMR DEPT-135 of 1-dehydro-6-gingerdione dissolved in CDCl3, 125 MHz 
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Figure 13: COSY 2D-NMR spectrum of 1-dehydro-6-gingerdione dissolved in CDCl3. 
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Figure 14: HMQC 2D- NMR spectrum of 1-dehydro-6-gingerdione dissolved in CDCl3. 
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Figure15: HMBC 2D-NMR of 1-dehydro-6-gingerdione dissolved in CDCl3 
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Figure 16: Infrared spectrum for 1-dehydro-6-gingerdione . 
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Figure 17: UV spectrum of 1-dehydro-6-gingerdione 
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Figure 18: Accurate mass spectrum of 1-dehydro-6-gingerdione 
